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Summary
Whilst cognitive enhancement was present in literature of the general public as well as
in research as I commenced my Ph.D. in 2010, there was not an abundance of data re-
lating to the use of such cognitive enhancers (CE). The authors of the memorandum on
cognitive enhancement in ‘Gehirn & Geist’, a journal for the general public, mentioned
in November 2009 an absence of surveys [1]. Such data could be seen as fostering the
debate in society and are in line with the requests of Forlini and Racine after conduct-
ing an analysis of English newspaper articels about the non-medical use of Ritalin R©[2].
Until then, no data regarding the use of CE concerning Switzerland existed, with only
one survey published in Germany in February of 2009 [3].
The goal of my Ph.D. was to evaluate data regarding the attitudes and handling of CE
in Switzerland. I developed and evaluated an online survey among students of the Uni-
versity of Zurich (Chapter 2). I received completed questionnaires from 1765 students
and compared the answers of users and non-users with a focus on their characteristics
and attitudes. In order to evaluate the attitudes of physicians, a paper-and-pencil survey
was developed by others whereas I conducted the pre-tests and the survey and evaluated
the data (Chapter 3). From the pre-defined sample of 1600 Swiss practicing physicians,
379 physicians completed the questionnaire (response rate 24.7%), which addressed their
familiarities with requests for CE and their willingness to prescribe such products.
With these data I want to contribute to an evidence based policy debate in Switzerland.
Furthermore, I assume that such data will lead to a more balanced media presentation
of CE usage and a better-informed public debate. Instead of contributing to what has
been called a media hype [4], the data from the students could help to understand why
some students are taking CE and others not, as well as where they obtain it from. On
the other hand, knowledge of how often physicians in Switzerland received requests for
such CE and how they deal with it will give another perspective on the prevalence of
the usage of CE in Switzerland. Both questionnaires contained questions relating to
ethical aspects of CE. An additional project within my Ph.D. was more theoretical in
nature and was designed to critically investigate the claim that increased productivity
is a benefit of cognitive enhancers (Chapter 5).
In summary, this work provides insights into the attitudes of students as well as physi-
cians in Switzerland when it comes to the usage of cognitive enhancement, including
ethical aspects of such usage. Moreover, there was also an additional focus on the desire
for increased work productivity in the discussion regarding cognitive enhancement.
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1 Introduction
1.1 Cognitive Enhancement
Cognitive enhancement is a well-known field in bioethics. Indeed, different definitions
exist when it comes to this term, one of which is provided in a frequently cited paper by
Greely et al., where cognitive enhancement is described as the usage of medications to
treat psychiatric and neurological conditions for improving the performance of a healthy
person [5]. I will use this definition in the following work, but will add ‘for improving
directly the cognitive performance of a healthy person’. The term ’directly’ was added
for excluding products that e.g. calm down and therefore indirectly enhance cognition.
Improving cognitive performance stands for the improvement of the short- and long-
term memory as well as effects on the executive functioning [6]. The latter stands for ‘a
cognitive system that controls and manages other cognitive processes and is involved in
planning, cognitive flexibility, abstract thinking and inhibiting inappropriate actions’ [6].
Taken together, my definition of cognitive enhancement is the following: The usage of
medications used to treat psychiatric and neurological conditions with a view to directly
improving cognitive performance and in turn improving short- and long-term memory
as well as effects on the executive functioning of a healthy person.
Another common term often used in place of ‘cognitive enhancement’ is ‘neuro - en-
hancement’. In this work, I will only utilise the term ‘cognitive enhancement’ due to the
fact that ‘cognition’ is a narrower term than the word ‘neuro’; the latter of which stands
for anything concerning nerves including cognitive and mood enhancement. The reason
behind my preference of such a narrow term will be explained in the following sections
on cognitive enhancers.
A search for publications on the topic of ‘cognitive enhancement’, yielded 8998 papers.
These were found on ‘web of knowledge’ based on Web of Science R©, BIOSIS Previews R©,
MEDLINE R©, Zoological Record R©and Journal Citation Reports R©[7]. With regard to the
topics ‘cognitive enhancement’ and ‘ethics’, 111 publications appeared with a maximum
in 2009 of 18 publications and a range from 1992-2013. This data shows that there is
an active and on-going discussion in the academic field concerning the topic of cognitive
enhancement.
Publications around cognitive enhancement are not at all restricted to the academic
field. A basic search in the German and English press revealed 1195 publications starting
from 2003 until today (Search terms were: braindoping, ‘hirndoping’, neuroenhancement
or cognitive enhancement; database LexisNexis, 14. August 2013). Such publications
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in the media were analysed by Partridge et al. The authors analysed English print
newspaper articles from 1st January 2008. to 31st December 2010 and concluded that
the possible benefits of using drugs for cognitive enhancement are more often mentioned
in the 142 analysed articles than the potential risk and side effects. In addition, the
main source of these articles, which claim that cognitive enhancement is common and
widespread, provides a weak support for such statements [4]. The authors asked jour-
nalists as well as researchers for caution concerning the presentation of the non-medical
use of drugs for cognitive enhancement. The data of Partridge et al. were in line
with previous analyses of English newspaper articles concerning the non-medical use of
Ritalin R©from 1st January 2000 - 14th November 2006 [2]. The authors concluded that
the beneficial effects of Ritalin R©were generally portrayed enthusiastically, although there
was far from an abundance of information regarding associated risks. The authors also
analysed the ethical and social issues presented in the media. They concluded that even
though some arguments were mentioned in the media, it is important to foster better
informed public debates [2].
1.2 Cognitive Enhancers
Exactly what constitutes a cognitive enhancer differs in the literature. Such an existence
of different definitions can also be observed in the surveys regarding the use of CE where
various reference products were included (see section 1.6 on ‘state of research’). Fo¨rstl
defined CE as, among others tea, red wine and sugar [8]. However, the definitions are,
for the most part, narrower than this. Lieb defined CE as the misuse of drugs, which
were developed as treatments for specific illnesses and which were only available on
prescription [9, p. 21]. Such a definition excludes luxury food like chocolate, caffeine,
nicotine as well as drugs such as cocaine, which have not been developed as treatments
against an illness. Drugs included in this definition were Ritalin R©, Adderall R©, modafinil,
antidementia drugs and antidepressants.
In the two surveys conducted for my Ph.D., I used a rather narrow definition in order
to ensure that the participants had the same or very similar products in mind while
answering the questions. This helps to make the answers comparable. For the sur-
vey among students, I used the definition: ‘Products for increasing your concentration
and/or alertness as a healthy person’ and included the products Ritalin R©, Adderall R©and
Modasomil R©. Additionally, I included a list of products for Ritalin R©called Concerta R©,
Daytrana R©, Metadate R©, Equasym R©and Medikinet R©whilst for Modasomil R©, I included
the products Provigil R©, Vigil R©and modafinil (fore more information Section ‘2.2 Pub-
lication’). The main reasons behind this selection were that these three products have
been declared as the most common CE [e.g. 5] and are also used as reference products
in other empirical surveys. For the survey among physicians, a definition of ‘neuroen-
hancement’ was given, including the products methylphenidate (Ritalin R©), modafinil
(Modasomil R©), antidepressants and antidementia drugs. I will now present a short
overview of the most common CE, namely Ritalin R©, Adderall R©and modafinil.
2
1.2.1 Ritalin R©and Adderall R©
Ritalin R©(methylphenidate) and Adderall R©(mixed amphetamine salts) are drugs which
were developed for the treatment of attention deficit hyperactivity disorder (ADHD) [5].
Methylphenidate and amphetamines increase the level of the neurotransmitters nora-
drenaline and dopamine, both of which are involved in controlling alertness, concentra-
tion and attention [9, p. 66]. Methylphenidate increases the levels of these neurotrans-
mitters by blocking the receptor for a reuptake into the cell. As a result, Ritalin R©can
only lead to increased concentration of these neurotransmitters if the cells are already in
an activated state having released neurotransmitters. On the contrary, amphetamines
can also increase neurotransmitter concentration if the cells are in an inactive state. One
assumes that amphetamines directly increase the release of the neurotransmitters nora-
drenaline and dopamine whilst also blocking the receptors which play an important role
in carrying information regarding the release of neurotransmitters back to the cell [9, p.
72]. Structurally related with amphetamines are the addictive drugs ‘Ice’ and Cristal-
meth’. These drugs consist of metamphetamine, which is essentially D-amphetamine
with an additional methyle-group [9, p. 66]. Another structurally related drug is ‘ec-
stasy’ (methylendioxy-metamphetamine=MDMA).
In ADHD patients, Ritalin R©and Adderall R©lead to a decrease in hyperactivity, inat-
tention and impulsivity [10]. Reports about healthy people taking Ritalin R©are docu-
mented in different Swiss and other countries newspapers and magazines (e.g. ‘Das
Magazin’, 2009; ‘The New Yorker’, 2009; ‘Time’, 2009; ‘NZZ Folio’, 2010; ‘The New
York Times’, 2012 [11, 12, 13, 14, 15]. Indeed, people who conducted self-experiments
reported increased energy levels and concentration. Some reports also mentioned side
effects including, among others, sleep problems.
Studies about the effectiveness of methylphenidate in healthy people were analysed
by Repantis et al. [16]. They analysed 19 publications, which were chosen due to the
methodological approach (on healthy probands and randomised control trials) and the
relevance of the results. The authors concluded that Ritalin R©had a significant positive
effect on memory. No consistent evidence was found for attention, mood and executive
functions. With regard to wakefulness, it was not possible to perform any statistical
analysis due to the lack of baseline measurements in these studies (meaning that the
effect of CE was only compared with the effects of the placebo). The effect on memory
was seen in single dose studies. Indeed, there was an insufficient number of studies with
repeated drug doses, thus meaning that statistical analyses could not be conducted.
Studies examining effects on sleep-deprived probands were analysed but not comparable.
One of these studies concluded a negative effect on the self-reporting, with people rating
their performance better than it actually was [16]. These results from the meta-analysis
of Repanits et al. were in line with the conclusion drawn from a previous meta-analysis
of the empirical evidence of Ritalin R©as a CE [17]. The author of that meta-analysis
concluded that neither drug efficacy nor the benefit-to-risk balance provided evidence
that Ritalin R©is a suitable CE.
A very common side effect Ritalin R©in healthy people was increased heart rate, which
was reported in 13 of 14 analysed studies reporting side effects [18]. An increase in blood
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pressure was not consistently found. Other reported side effects were headache, anxiety,
nervousness, dizziness, drowsiness and insomnia [18]. Taken together, Ritalin R©has an
effect on memory, although until know no effects on e.g. wakefulness and attention
could be proven in a meta analysis of studies in healthy people, even though such effects
were described in self-experiments.
With regard to Adderall R©, no meta studies exist to the best of my knowledge. Ilieva
et al. conducted a powered double-blind cross-over placebo controlled trial on a stan-
dard dose of Adderall R©among a sample of 24 female and 22 male probands all of whom
were healthy and young (age 21-30) [19]. The authors concluded that Adderall R©had no
medium or high effect on any of the 13 measures for cognition ability including memory,
inhibitory control, convergent creativity, intelligence and scholastic achievement. Some
small effects were found for tests relating to word recall, convergent creativity and non-
verbal intelligence among lower ability participants. Another finding was that the users
may perceive the drug as enhancing their cognition [19].
Following a much smaller meta-analysis of twelve studies, of which six studies where
about Ritalin R©and six about amphetamines like Adderall R©, Lieb concludes that these
substances increase attention in healthy probands and decrease reaction time. He also
reported that studies on sleep-deprived probands with amphetamines showed increase
effects on reaction time [9]. Observed side effects in each of these six studies are sum-
marised in another paper [20]. For Ritalin R©and amphetamines, observed side effects in
healthy probands included tachicardia, hypertonia, uneasiness and concentration dif-
ficulties (>10% of the probands reported them). More than 1% of them mentioned
headaches, dizziness, gastrointestinal problems and others. The authors stated that a
risk of addiction exists, although it would be higher if the substance was injected or
sniffed [20].
Interestingly, these effects of Ritalin R©and amphetamines shown in studies on healthy
probands are lower than the reported effects in self-experiments. Possible explanations
are forwarded by Eckhardt et al., who propose that the situation under laboratory
conditions cannot equate to real-life situations. Additionally, the placebo effect could
have led to a subjective over-estimation of the effects [21]. Irena Ilieva and colleagues
conducted a closer examination of this discrepancy after concluding in their study that
the cognitive benefits of Adderall R©are only modest [19]. The authors came up with three
possible suggestions: 1) that users may have a small cognitive advantage which is useful,
2) that individual differences may lead to sizable cognitive advantages for some users, or,
the focus of their paper, 3) that users may gain a non-cognitive advantage which helps
them to perform better in school or on the job [22]. Such a non-cognitive advantage
would be motivational instead of purely cognitive.
An analysis of data from a Swiss insurance Helsana-group revealed that the purchase of
methylphenidate as well as the amount increased continuously over the years spanning
2006 to 2009 [23]. In 2006, 3300 of 20’000 insured people received methylphenidate
(=0.26%), which increased to 5100 of 28’900 in 2009 (=0.37%). In 30% of cases these
people received methylphenidate from a physician whilst in 70% of cases they sourced
it from a pharmacy or on prescription [23].
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In summary, an effect on memory in healthy people could be proven for Ritalin R©and
ambiguous data exists concerning effects on attention [16, 9]. It was found that Adderall R©
could have some small effects for tests regarding word recall, convergent creativity and
nonverbal intelligence among lower ability participants [19].
1.2.2 Modafinil
The third CE one often referred to in the literature is modafinil. Brand names of
this psychotropic drug include Provigil R©and Nuvigil R©in the US, Vigil R©in Germany and
Modasomil R©in Switzerland and Austria. Modafinil was developed for the treatment of
exhaustion caused by narcolepsy, sleep apnoea or sleep disorders due to shift work [5].
Indeed, Provigil R©, manufactured by the company ‘Cephalon’ passed the one billion US-
dollar mark in 2008. That was the year when the ‘Food and Drug Administration’ (FDA)
imposed a fine on ‘Cephalon’ of 425 million US dollars. The FDA called ‘Cephalon’
to account for advertising Provigil and other drugs outside the approved usage [24].
The chief motive for using modafinil outside the approved usage is the overcoming of
exhaustion and jetlag [25].
Whilst the mechanism behind the effect of modafinil is not yet fully understood, it
could be shown that modafinil has direct and indirect effects on various neurotransmitter-
systems [10]. In more detail, interferences of modafinil with the neurotransmitters hypo-
cretin, histamine, gamma-aminobutyric acid (GABA), glutamate and norepinephrine
have been found [26]. Modafinil is involved in modulating orexin, which regulates wake-
fulness and blocks a dopamine transporter leading to increased dopamine levels [26].
Minzenberg and Carter accomplished a meta analysis in 2008. The authors concluded
that there is increasing evidence that modafinil can improve cognitive functions like
working and episodic memory [27]. Furthermore, they wrote that modafinil increases
alertness and decreases feelings of exhaustion. In their publication on methylphenidate,
Repantis et al. also investigated surveys relating to modafinil [16]. They analysed 31
publications, which where equivalent to the selection of studies on methylphenidate cho-
sen by the methodological approach (on healthy probands and randomised control trials)
and the relevance of the results. They concluded that modafinil improves attention for
well-rested people. For such well-rested individuals, the positive effects on wakefulness,
memory and executive functions were significantly higher than when placebo was given.
However, repeated doses of modafinil could not prevent the negative effect of a longer pe-
riod of sleep deprivation on cognitive performance, even though maintaining wakefulness
and possibly even leading to overconfidence concerning ones own cognitive performance
[16].
These effects are of significant interest to the army. According to publications released
by the Defence Medical Supplies Agency, the British army has bought more than 24’000
tablets of Provigil since 1998 [28]. No recent data on this topic was found.
Side effects of modafinil included primarily headaches, dizziness, gastrointestinal com-
plaints (e.g. nausea, abdominal pain, dry mouth), increased diuresis, palpitations, ner-
vousness, restlessness, sleep disturbances and insomnia, the latter of which was par-
ticularly common in studies with non-sleep deprived individuals [16]. In their paper,
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Esposito et al. summarised that modafinil might lead to fewer side effects compared
to other drugs such as amphetamines and methylphenidate. Modafinil also has an ad-
vantage over the likes of methylphenidate with regard to addiction. Indeed, the latter
is unstable when heated and can therefore not be injected intravenously [29]. However,
Roberto Esposito and his colleagues also highlighted that this assumption concerning
side effects could be false due to recent findings which prove the strong effect had by
modafinil on the dopaminergic system [26]. Why this could be is explained in the next
section.
In general, some researchers have claimed that CE have similar effects to those of
coffee e.g [9]. However, this has been refuted by Andreas Heinz and his colleagues [29].
Unlike psychostimulants and other drugs, coffee maintains a dopamine release in the
prefrontal cortex but not in the ventral striatum. Modafinil on the other hand leads to
a release of dopamine in the ventral striatum, which is a core area of the reward system.
Indeed, modern addiction theories see the dopaminergic neurotransmitter system as
playing a key role [29]. All of the known substances with addiction potential lead to an
increase of dopamine in the so-called reward system [29]. Drugs such as amphetamine,
cocaine, methylphenidate and modafinil maintain a release of dopamine of approximately
175% to 1000%, where the references are triggers of the dopamine release by food,
sex and human communication of around 50% to 100% [29]. Next to the differences
pertaining to the number of triggered releases of dopamine exist differences concerning
habituation. Repeated environmental stimuli lead rapidly to habituation. In contrast,
drug usage leads consistently to an increase in the release of dopamine. This results in a
counter-regulatory neuroadaptive process like e.g. the reduction of dopamine receptors.
Therefore, repeated drug use, which leads to a reduction in response after environmental
stimuli, maintains an increase in the desire for further drug consumption and away
from goal-directed behaviour like ‘food, sex or communication’ [29]. CE, which should
per definition modulate learning and memory performance, necessarily affect dopamine
neurotransmitters due to the fact that basic learning mechanisms are driven by reward
and punishment and therefore by the reward system [29]. Additionally, the dopamine
function in the ventral striatum is directly linked to the fluid IQ about problem solving
and flexible behaviour adjustment [29]. Due to these aspects, the authors doubt that
there will ever be a CE which has effects on memory and learning without the potential
for addiction.
1.2.3 Further CE
Other groups of CE, which are mentioned in literature next to methylphenidate, am-
phetamines and modafinil, include antidementia drugs and antidepressants [e.g. 9]. For
each of these two classes of drugs I will present a short overview regarding their possible
effects as CE and observed side effects.
A meta review on the effects of antidementia drugs, e.g. the acetylcholinesterase in-
hibitors (the substances donepezil, galantamine and rivastigmine) and memantine was
conducted [16]. The analysis of 20 studies revealed that the current research neither sup-
ports nor opposes the use of antidementia drugs as CE. These drugs were well tolerated
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in most of the trials. Observed side effects for acetylcholinesterase inhibitors in these
studies were benign and lead only in a few cases of dropouts. Such side effects included
mainly gastrointestinal complaints as well as headaches, dizziness, nightmare and in-
somnia. The studies included in this review on memantine did not mention side effects
with the exception of one study mentioning drowsiness. With regard to memantine, Lieb
mentioned side effects of increased blood pressure, headaches, dizziness, sleepiness and
constipation, which were very common (>10%) or common (1-10%) [9]. However, due to
the fact that the authors cited the Medicines Compendium, these side effects are most
probably only seen in sick people using memantine for a treatment [9, 20, p. 78]. In most
of the analysed studies of the meta review the drugs were well tolerated [16]. Benign side
effects were observed in the repeated trials of acetylcholinesterase inhibitors including
gastrointestinal complaints as well as headaches, dizziness, somnolence, nightmares and
insomnia [16].
A systematic review and analysis of the effects of antidepressants (in detail the sub-
stances paroxetine, citalopram, reboxetine, fluoxetine, sertraline, fluvoxamine, moclobe-
mide, bupropion, venlafaxine, escitalopram and duloxetine) as a CE as well as a emo-
tional enhancer was conducted by Dimitris Repantis and colleagues [30]. The conclusion
was very similar to that pertaining to antidementia drugs: The 65 included studies did
not provide evidence for or against any effect in healthy people. The authors even con-
cluded that these studies were inept when it came to answering this question, most likely
because most of them were not designed to answer questions regarding CE. Side effects
reported in the analysed papers of that systematic review were mostly benign. They
were usually observed after the initial administration and normally wore off with con-
tinued intake [30]. The most common side effects included gastrointestinal complaints,
sleep disturbance, restlessness, tremor, headache, dizziness, fatigue and drowsiness [30].
Taken together, the studies relating to antidementia drugs and antidepressants do not
provide evidence for or against any effect in healthy people.
1.2.4 Non-Pharmaceutical Products and Methods
Such non-pharmacological products and methods would not be included in the definition
above of CE nor in the definition about cognitive enhancement. The most commonly
used definition of cognitive enhancement specifies that it must be a medication. However,
broader definitions of CE do include such non-pharmacological products and methods.
I will discuss here the products coffee, energy drinks, sugar and nicotine as well as the
methods physical exercise, sleep, meditation, mnemomic strategies, computer training,
brain stimulation and possible further products [18, 20]. This selection is not seen as
exclusive for non-pharmaceutical products and methods as CE but includes the main
products and methods mentioned in the literature.
Caffeine is an adenosine receptor antagonist and reduces inhibition of neural firing
[18]. Effects include elevated mood, increased alertness and better attention. Caffeine
tolerance can occur most likely in heavy coffee drinkers. Withdrawal of caffeine can
lead to headaches, increased subjectively perceived stress and reduced alertness and
fatigue. However, these withdrawal effects are manly caused by psychological rather
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than pharmacological factors [18]. Energy drinks are another source of caffeine and it
has been suggested that such drinks enhance physical and cognitive performance [31].
These drinks contain 40-250mg of caffeine (a cup of coffee contains around 40-120mg
[21]), and often also taurine, guarana`, ginseng, glucuronolactone, B-vitamins, and other
compounds [31]. A literature search on Pubmed, Psych Info and Google Scholar led
the authors to the conclusion that there is an overwhelming lack of evidence that the
other components of energy drinks other than caffeine and, to a lesser degree, glucose
and guarana`, have any enhancement effect [31]. Another suggestion is that the effects of
energy drinks are based on the combination of caffeine with sugar [21].
Sugar improves attention, response speed and working memory. Specifically, the most
noticeable effects were found on the declarative memory [18]. A systematic review of the
effects of chocolate on cognitive function and mood included 10 studies [32]. The analysis
revealed that five out of eight studies on effects on mood showed a positive effect on mood
state or an attenuation of negative mood. Three out of eight studies concerning effects
on cognitive function showed clear evidence for cognitive enhancement by the chocolate
components cocoa flavanols and methylxantines such as caffeine and theobromine. Taken
together, the positive effects of having a coffee and a chocolate bar when feeling tired
and/or unfocussed has been proven by many studies. Another option would be to go for
a run, have a nap or smoke a cigarette.
Physical activity has beneficial effects on brain function and cognition, whilst sleep
enhances cognitive capacities, specifically memory and creativity [18]. Many anecdotal
reports exist on this subject, e.g. Friedrich August Kekule´ who claimed that he discov-
ered the ring shape of the benzene molecule after having dreamt of a snake seizing its
own tail [33]. Studies could replicate such enhancing effects of sleep on creativity [18].
The effects of nicotine have been investigated in many studies [34]. Positive effects on
attention, working memory and complex task performance have been found in satiated
smokers as well as in non-smokers [34]. However, many people are aware of the severe
side effects of smoking, which could even increase since the EU parliament decided re-
cently to increase the warning notices and include pictures of side effects on the packages
of cigarettes.
Meditation should be practiced for a while if it is to improved sustained attention
abilities. However, even if one is a beginner, positive effects were seen on attention [18].
A recent meta analysis found that the strongest effects related to changes in emotionality
and relationship issues, as well as medium effects on attention and smaller effects on
memory and other cognitive capacities [35].
Mnemonics is seen as denoting internal cognitive strategies with the goal of enhancing
memory [18]. A famous example is the method of loci, which was performed by the
ancient Greek and Roman orator. Information items are visualised at salient points along
a route, which is then mentally walked through in order to retrieve the information [18].
The more complex the memorised information, the stronger the effects of such methods.
Games and computerised training are promising methods when it comes to cognitive
enhancement. Effects on processing speed and perception were observed as were smaller
effects on different memory domains [18].
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Electrical brain stimulation can be non-invasive, including transcranial direct current
stimulation (tDCS) and transcranical magnetic stimulation (TMS) or invasive, includ-
ing deep brain stimulation (DBS) or direct vagus nerve stimulation (dVNS). These four
techniques use electrical impulses to make neurons either less excitable by hyperpolar-
isation or more excitable by depolarisation [18]. The results of various studies lead to
the assumption that tDCS, TMS and dVNS can enhance the memory encoding. DBS
on the other hand can directly affect the modulation of memory systems [18].
Possible further products for enhancing memory CE could target the specific and until
now not completely understood mechanism underlying memory formation. The goal
would be to enhance neuroplasticity by targeting glutamate receptors for the induction of
long-term potentiation or to increase the amount of CREB, a protein which strengthens
the synapses and is thus involved in long-term memory consolidation [6]. Such products
would be ampakines modulating glutamate receptors or the CREB activators. It has
been shown that the enhancement of CREB function leads, in some regions of the brain,
to positive effects on memory, anxiety and depression. However, in other brain areas
it has had opposite effects, such as increasing fear, anxiety, depression as well as drug
addiction [6].
Taken together, various products and methods can improve the cognitive performance
of healthy people. Whilst these products and methods are not included in the definition
of cognitive enhancement provided in Section 1.1, which focusses on medications used
to treat psychiatric and neurological conditions, they are included in wider definitions
of this term.
1.2.5 Products for other Enhancements
The authors of the TA-Swiss report (Centre for Technology Assessment) have differen-
tiated between cognitive and emotional enhancement [21]. Emotional enhancement is
defined as products for coping with stress [21]. This group consists of antidepressants,
betablockers, sleeping pills and suppressants, oxytocin and illicit drugs such as ecstasy
and cocaine. The term ‘directly’ was used in the definition of CE for excluding these
products above. Most of these products will indirectly influence the cognitive perfor-
mance by reducing the feeling of stress.
Another term, and one used more often in the literature is mood enhancement (ME)
[e.g. 6]. However, such a distinction between CE and ME is not as sharp as it seems
here, where products could lead to e.g. an increase in spirit as well as alertness and to a
better attention. I will now provide a more detailed explanation of the possible effects of
mood enhancers including antidepressants, betablockers, sleeping pills and suppressants,
oxytocin and illicit drugs like ecstasy and cocaine.
As mentioned above, Repantis et al. concluded that there are is scientific evidence
relating to the cognitive or mood enhancing effect of antidepressants in healthy people
[30].
Betablockers are a drug used to tackle irregular heart rate and anxiety states [36].
The off-labelled usage of this drug is against stage fright or generally in acute stress
situations [21]. Clinical evidence does exist regarding the positive effects of small doses
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of betablockers on stage fright [37]. Another field in which betablockers could work as
ME is in the inhibition or eradication of non-conscious negative emotional memories [38].
Betablockers could work as a treatment against post-traumatic stress disorder (PTSD)
but also as a ME e.g. shortly after or even before (e.g. to soldiers) a most probably
traumatic situation [38].
Sleeping pills and suppressants are anxiolytic, sleep-inducing, calmative and muscle
relaxing [21]. Such pills could again be used indirectly as CE in order to cope better
with pressure [21].
The neuropeptide oxytocin mediates pro-social behaviour such as pair bonding and
maternal care, although more research is needed in order to understand the effects of
oxytocin on human social behaviour [6]. Whilst I will not go into details regarding the
illicit drugs, one major and obvious point is that they have a high addiction potential.
Other products mentioned by the authors of the TA-Swiss report as enhancers against
stress are Adaptogenes like Ginkgo biloba as well as alcohol. Gingko biloba is used by
healthy people to tackle cognitive decline related to age [39] even though no clinical
evidence has been found for such effects, independent of a single dose or repeated usage
[39]. Alcohol is not a good CE at all, and leads to impairments in psychomotor and
cognitive tasks e.g. slowing reaction times, impairing memory formation and increasing
errors [40]. With this said however, it can be used as a EC [21]. This could lead to
an elevated mood and an anxiolytic effect [21]. On the other hand, the consumption of
ethanol could lead to riskier behaviour whereby people may overestimate their ability
and act more on short-term consequences than long-term consequences [40].
The aforementioned products, which could be used for other forms of enhancement
are not included in the definition of cognitive enhancement given in Section 1.1. Indeed,
I focus in the surveys on products which directly improve the cognitive performance
in healthy people, with a view to improving the short- and long-term memory as well
as effects on executive functions such as planning, cognitive flexibility and abstract
thinking. However, even when focussing only on products to enhance cognitive functions
it is important to ask what exactly we want to enhance, as I will do in the following
section.
1.3 What Do We Want to Enhance
The pharmaceuticals which have an effect on CE are Ritalin R©, Adderall R©and Modafinil.
These drugs, as well as other non-pharmaceutical products and methods with an effect on
cognitive performance, are listed in table 1.1. The products which serve other enhance-
ment purposes were not included, with a focus instead placed on cognitive enhancement.
The effects differ considerably when it comes to the functions which the substances
enhance (Table 1.1). Thus, the question is; what do these substances enhance? As
mentioned at the beginning of this chapter when defining cognitive enhancement, De
Jongh et al. define cognition in relation to CE as the following: The improvement of the
short- and long-term memory as well as effects on the executive functioning [6]. The latter
represents “a cognitive system that controls and manages other cognitive processes and is
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Table 1.1.: Substances with an effect on cognitive performance.
Substance Positive effects
Ritalin R© Memory, perhaps: Concentration, mood and executive functions
Adderall R© Word recall, convergent creativity, nonverbal intelligence
Modafinil Working and episodic memory, increase alertness, improves atten-
tion
Caffeine Mood, alertness, attention
Sugar Attention, response speed, working and declarative memory
Nicotine Attention, working memory, complex task performance
Physical activity Brain function, cognition
Sleep Memory, creativity
Meditation Attention abilities, changes in emotionality and relationship issues
Mnemonics Declarative memory
Games and computer-
ized training
Perhaps: processing speed and perception, memory
tDCS, TMS, dVNS Memory encoding
DBS Modulation of memory systems
involved in planning, cognitive flexibility, abstract thinking and inhibiting inappropriate
actions” [6].
When looking at the general term ‘enhancement, opposite effects can both be seen
as enhancement. An example of this is the formation of memory - where the strength-
ening of such formation was seen as part of cognitive enhancement and the intake of
e.g. betablockers before building traumatic memories as mood enhancement. This is
neither ambiguous nor contradictory due to the fact that enhancing performance, which
is the broad definition of enhancement [5], can be case-to-case dependent, but in some
situations it involves a strengthening and in others a reduction of the memory formation.
Important aspects when talking about the improvement of cognitive performance is
to address certain side effects including a decrease in the function of other brain regions.
The conclusion that Adderall R©can only increase concentration at the expense of decreas-
ing creativity has been disproven [41] and even a small positive effect of Adderall R©on
convergent creativity has been found [19]. But other side effects could include trade-offs
between the enhancement of cognition versus mood. For example, MDMA, alcohol or
some antidepressants can lead to cognitive-impairment effects [6]. On the other hand,
antidepressants as well as moderate consumption of alcohol lead to indirect positive ef-
fects on cognition by reducing anxiety and stress. Reinoud de Jongh and his colleagues
concluded that ‘the enhancement of mood does not necessarily have to be accompanied
by cognitive impairment’ [6]. The same is also a true case for the converse situation,
meaning that the enhancement of cognition does not have to have negative effects on
mood. Following one particular study, it has been suggested that modafinil has gen-
eral mood-elevating effects but can also increase negative affects such as anxiety [42].
In general, de Jongh et al. concluded that there is no evidence for a trade-off between
cognition and mood, but that one does exist between different cognitive domains e.g.
long-term memory (LTM) and working memory, consolidation of LTM and modifying
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memories, cognitive stability and capacity to flexibly alter behaviour [6].
Taken together, the effects can vary and depend on our understanding of the improve-
ment of cognitive performance. Secondly, no trade off after the usage of CE between
cognition and creativity nor cognition and mood was found, although trade-offs concern-
ing different cognitive domains can exist.
1.4 Ethics and Empirical Data
Empirical data can play an important role in ethics. According to Pascal Borry and his
colleagues, such data can contribute to each step of ethical reflection: To the description
of the moral question, to the assessment of the moral question and to the evaluation of the
decision-making [43]. During the first step, which involves a description, empirical data
can help to answer the essential ‘what, why, how, who, where and when’ questions [44].
If these reality-revealing questions are not answered, the risk remains that a judgment is
only based on a partial reality [43]. The second step involves an assessment of the moral
questions which exists regarding the integration of principles, norms, virtues and values
in the specific case, and again, empirical data can help to assess them. The last step is
the evaluation; something which is often neglected by the authors. Here empirical data
can reveal unforeseen consequences or effects of the decision [43].
The authors highlighted that empirical data can never directly lead to answers regard-
ing the way we ought to be [43]. Such is-ought fallacies is defined by Rob de Vries and
Bert Gordijn by referring to David Hume that a set of descriptive premises alone cannot
lead to a moral conclusion [45]. Such an is-ought fallacy in the example of cognitive
enhancement according to the thee steps of ethical reflection [43] would be the moral
conclusion that CE should be allowed: because many students are taking CE (step one);
because many students believe that such CE would lead to a better life by leading to
more leisure time (step two), or because such products lead to a better life for students
by leading to more leisure time (step three). Empirical data can only contribute to
ethical clarification and decision processes. Such contribution means that descriptive
premises can be part of the set of premises leading to a moral conclusion, if at least
one of the premises is not based on empirical findings and therefore normative instead
of descriptive [46]. Additionally to the is-ought fallacy, there are two additional fallacies
respectively theses called the naturalistic fallacy and the fact-value distinction regard-
ing the use of empirical data in ethics [45]. The naturalistic fallacy goes back to G. E.
Moore and stands for the fallacy of identifying the notion ’good’ with natural or meta-
physical predicates. The fact-value distinction is according to Rob de Vries and Bert
Gordijn more a certain meta-ethical view than a fallacy or a problem. Such a fact-value
distinction could only than lead to a problem in empirical ethics if it is mandatory to
reject the fact-value distinction to engage in this field of ethics [45]. Such a rejection
would be needed if it is necessary to claim that at least some statements or concepts
are irreducibly both evaluative and descriptive, if it presupposed a realistic analysis of
moral discourse or if it necessary assumed that scientific facts presuppose values [45].
The authors conclude that none of these three necessities are presupposed in empirical
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ethics and therefore that empirical ethics as a discipline does not have to take sides in
this meta-ethical debate [45].
The classical epistemology of moral philosophy focused on how individuals acquiring
and justifying reliable moral knowledge. The social epistemology favoured by many
feminist and other nonmainstream ethical approaches turn away from such a focus on
the individual [47, p. 44f]. Instead on applying a so called ’theoretical-juridical template’
by Margaret Urban Walker in moral philosophical analysis [48, p. 7], where the focus is on
individuals but also being impersonal, disembodied and rationalist, one has to integrate
in the analysis additional data that are used to make moral judgements. According to
Margaret U. Walker, moral life is not a project of individuals doing more or less rational
choices. Instead, she sees morality as a collaborative social practice through which
relationships, responsibilities and commitments are acknowledged and constructed by
people [47, p. 46]. In such an ’expressive-collaborative’ model moral life is represented
as interpersonal and the focus is shifted from action guides to values and practices
leading to moral principles [47, p. 46]. Margaret U. Walker is making two points about
moral epistemology as summarized by Jackie Leach Scully [47, p. 47]. First, if the social,
cultural and economic situation influences the moral judgements of individuals, than it
is important that we systematically analyse in ethics what people really do in certain
situation and what their reasons for their acts and choices are [47, p. 47]. Secondly, it
is important to note that we as researcher are influenced by the situation we are in as
well. Any ethical reflection is inescapably along a specific line of sight determined by
the identity of the knower. This is even more important because until recently, most
people working in moral philosophy were part of a subgroup of being male, well educated,
mostly white, from Judeo-Christian cultural backgrounds and mostly not disabled [47,
p. 47].
The empirical turn in ethics is based on an increased acceptance of contextuality and
greater questioning of the epistemological uniqueness of moral knowledge [47, p. 45].
Empirical ethics is therefore not just a support of normative ethics, but important in
itself to understand the ethical actors.
1.5 Ethical Considerations
I will now provide a very brief summary of the ethical considerations in the field of
enhancement. Human enhancement and cognitive enhancement constitute elements of a
well-discussed field in ethics so I will limit myself presenting the main field of arguments.
The main fields of ethical consideration were put forth by Martha J. Farah and col-
leagues almost ten years ago [49]. They mentioned four topics, namely safety concerning
the tolerable risk when taken by healthy people, the social pressure to enhance, distribu-
tive justice when talking about access to CE, and personhood and intangible values, re-
spectively what it means to be a person and the value of achievement [49]. The authors
also mentioned ethical issues, which are important for enhancement but which are not
restricted to the field like research ethics and ‘neurocorrection’ in classrooms, prisons
and other places [49]. A recent paper addressing arguments in the field of enhancement
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listed some additional arguments [50]. One of these arguments pertained to the reduc-
tion of valuable human diversity when being able to control how we are along with the
lack of imagination regarding how various we could be [51]. Douglas also mentioned the
argument first raised by Little in 1998 [52] of undesirable social norms in relation to
cosmetic surgeries; an argument later adapted by Schermer to the field of CE. The main
premise of the argument is that certain norms may be undesirable, including adapting
workers ‘to the demands of employers in society’ [53]. This argument is discussed in more
details in Chapter 5 on cognitive enhancement and productivity.
Conserning these ethical considerations, the high number of people being part in the
debate on human enhancement position themselves mostly between the two extreme
poles of the so called transhumanists resepectively bioconservatives [e.g. 6]. The trans-
humanists see enhancement as something good or even as a moral duty [e.g. 54, 55]. In
contrast, the bioconservatives fear that, through enhancement technologies, we may lose
what it means to be human [e.g. 56, 57].
1.6 State of Research
The present section will provide an overview of the current state of research, with a
summary of the quantitative surveys among students and others. The research objective
was to evaluate the percentage of users in a sample. The subsections were grouped
according to the publications until autumn 2010 when I began my Ph.D. and afterwards
until the autumn of 2013. The third subjection (1.6.3) relates to quantitative surveys
among physicians, which pertain primarily to their attitudes and handling of CE. The
surveys in the following three subsections about the usage of CE are presented in Table
1.2 (p. 21). Table 1.3 (p. 23) contains the surveys about the handling of CE by
physicians.
1.6.1 State of Research until 2010
McCabe et al. published the first well-known and broad survey concerning cognitive en-
hancers [58]. Participants of a pen-and-pencil survey included 10’904 randomly selected
students from 119 colleges or universities in 39 US states of in 2001. The analysis of
the representative sample (response rate 52%) showed that 6.9% of these participants
have had taken Ritalin R©and/or Adderall R©at least once for nonmedical reasons [58]. The
past year prevalence was at 4.1% whilst the past month prevalence was 2.1%. Nonmed-
ical use was higher among students who were male, white, members of fraternities and
sororities and those who had lower mark averages. Students who had taken Ritalin R©or
Adderall R©for nonmedical use were also more likely to have consumed alcohol, cigarettes,
marijuana, ecstasy and cocaine than non-users. Higher rates for users were found among
colleges with increased competitive admission standards [58].
Another survey from this group was completed in 2005 among 4589 college students
[59]. Although this online survey was not representative of the US student population
the sample was randomly selected with a response rate of 66%. In total, 8.3% of the
students reported illicit use of prescription stimulants. Around three-quarters of the
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students had used Adderall R©or generic or similar medicaments during the last year
whilst almost one fourth of them had used Ritalin R©or generic medicaments. A higher
rate of illicit prescription stimulant use was found for Hispanic and Caucasian students
compared to Asians and African-Americans. The most common reasons to take such
drugs as CE were to help with concentration, to help study and to increase alertness.
In 2007, Sahakian and Morein-Zamir asked the readers in their commentary in the
scientific journal ‘Nature’ if they could imagine increasing their brainpower through
the use of drugs [10]. On account of the high number of comments by readers, ‘Na-
ture’ launched an online survey concerning the usage of methylphenidate (Ritalin R©),
modafinil (Provigil R©) and betablockers [25]. A total of 1400 ‘Nature’-readers from 60
different countries responded to the online survey. It is important to note here that this
sample was not randomly selected. The analysis of the data revealed that one out of five
participants had taken one of these drugs for non-medical reasons in order to enhance
their focus, concentration or memory [25]. The most common CE here was Ritalin R©(62%
of the users of this sample). 44% of the users of CE took modafinil and 15% betablock-
ers. Therefore, some of the respondents hade taken more than one of these three CE. In
addition, 80 participants specified other drugs which they had taken as CE. Most com-
mon among these was Adderall R©, whilst others reported various alternative medicines
such as Ginkgo biloba and omega-3 fatty acids [25]. Roughly half of the users reported
unpleasant side effects including headaches, jitteriness, anxiety and sleeplessness. One-
third accessed the drugs via the Internet, slightly more than half via prescription (52%)
and the remaining participants obtained the drugs from pharmacies [25].
A systematic review regarding the misuse of ADHD medication was published in 2008
[60]. PubMed was searched using the key words ‘misuse’, ‘diversion’, ‘stimulants’, ‘illicit
use’, and ‘ADHD medications’ from 1995 to 2006. Studies examining other psychos-
timulant misuse or abuse were not included. The authors analysed 21 studies among a
total of 113’145 study participants. Nineteen studies were surveys, whilst the other two
involved an interview and a chart review respectively. The review revealed that past
year nonprescribed stimulant use ranged from 5-9% in grade and high school age chil-
dren. In college-age individuals, this range was 5%-35%. Data pertaining the included
studies suggested that students who were white, members of fraternities or sororities,
individuals with lower grades, use of immediate-release compared to extended-release
preparation, and students who report ADHD symptoms are at higher risk of misusing
as well as diverting such products. Lifetime rates of diversion of students with stimu-
lant prescriptions ranged from 16%-19%. The reported reasons for taking such products
included, to concentrate, to improve alertness, to get high or to experiment [60].
The first German survey concerning CE was an online questionnaire conducted by the
‘Deutsche Angestellten-Krankenkasse’ (German health insurance for employees) among
3017 German employees between 20 and 50 years in 2008 [3]. Indeed, 5% of the respon-
dents admitted that they had taken drugs as a healthy person in order to increase their
achievement or complacency. Less than 2.5% of all the participants were taking such
drugs continuously. Four out of ten of these continuous users were consuming it a few
times per week or even on a daily basis (less than 1% of the 3000 employees). More-
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over, 44% of the users had taken drugs to tackle anxiety, nervousness and discomposure,
followed by drugs against depression (35%). Drugs against ADHD were taken by 13%
of participants. For around 45% of the users it was possible to source the drugs from
a pharmacy without the need for a prescription. This showed that many of the users
were referring to products, which were available without any prescription. 12% of them
bought it via Internet pharmacies whilst 14% sourced it from a pharmacy or a physician
on prescription. Slightly more than one fifth of these 3000 employees (21.4%) received a
recommendation to take such drugs without any therapy. Such recommendations were
mostly formulated from direct social environments like families or friends. Around half
of the participants (49.9%) held the view that the usage of such drugs without any
therapeutic necessity is aligned with risks which overrule the benefits.
These surveys represented the current state of research when I started my Ph.D. in
2010. Since then, various CE surveys have been published. I will summarise the major
ones (exclusion was when less than 500 people were participating) according to the
profession of the participants, the country of origin and the year of data collection.
These surveys were found by a search logarithm which I started on ‘PubMed’ in 2010:
”neuroenhancement” (All Fields) OR ”neuroenhancements” (All Fields) OR ”cognitive
enhancement” (All Fields) OR ”neuro enhancement” (All Fields) OR ”pharmacological
enhancement” OR ”pharmacological neuroenhancement”. In addition, I also regularly
checked researchers in the field of surveys on CE and looked at the references of literature
in the field.
1.6.2 Surveys after 2010 - Students
Germany
A paper-and-pencil survey concerning the knowledge and handling of CEs was con-
ducted in Germany in 2009/2010 [61]. The CEs were methylphenidate (Ritalin R©, Con-
certa R©) amphetamines (Adderall R©) and Modafinil and were defined as non-medical use
of prescription stimulants. In addition to this, the authors asked about the prevalence
of the use of illicit stimulants exclusively for cognitive enhancement including ecstasy,
cocaine and amphetamines. The participants included 1035 pupils (18-21 years old) and
512 university students (on average 24 years old). The analysis of the data showed that
1.3% of the participants had taken at least one of the prescription stimulants for non-
medical reasons (0.8% of the pupils and 1.6% of the students). More of the participants
had had experiences with the illicit stimulants as CE: The lifetime prevalence was 2.6%
(2.4% of the pupils and 2.9% of the students). One third of the pupils had heard about
the possibility of increasing cognitive abilities through the use of prescription stimulants
and almost two thirds of them concerned illicit stimulants. Slightly less than two thirds
of the students knew that each of the two categories could be used as CE.
A longitudinal survey was completed in Germany in 2010 [62]. 11’000 students were
randomly selected from four previously randomly selected German Universities. At t1
5882 students responded (response rate 53.5%) of which 69.1% participated at t2. The
lifetime prevalence of using prescription medicine in order to enhance cognitive efficiency
without any medical necessity was 4.6%. A comparison of the two investigations involv-
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ing the same participants at different time points revealed that an increased cognitive
test anxiety increased the prevalence of medication use. Cognitive test anxiety was mea-
sured by three items on students worries: Thinking about the consequences of failing,
worrying about one’s results and thinking about what will happen if one does not do
well.
Another cross-sectional, online study which took place in 2010/2011 and surveyed
8000 German students, was directly concerned with stress compensation and improved
performance [63]. The sample was weighted according to gender, the school, the subject,
the semester and the county for being representative. The response rate was 25%, and
the data showed that 12% of the students had taken one or more substances to deal
with the requirements of studying. With regard to the stimulants methylphenidate,
modafinil, cocaine, amphetamines, MDMA (ecstasy), betablockers or cannabis, 5% of
these students confessed to having taken at least one. In 55% of the cases the substance
was taken for the preparation of an exam and in 45% it was taken in exam situations.
When comparing the users of such substances and non-users, differences were found in
relation to the confidence of one’s future. Indeed, students who were confident about
their future were more likely to be non-users than users.
At around the same time in 2010/2011 another online survey was conducted at a Ger-
man University among 1324 participants [64]. The students were non-randomly selected.
Of these students, 7% had used CE at least once during their life in order to improve
cognitive performance or mood. In this instance, CE stood for prescription products like
e.g. Ritalin R©, modafinil, Adderall R©and Prozac R©, and the illicit drugs cocaine, heroine
and ecstasy. Users were more likely to see CE as more beneficial and less harmful when
compared to nonusers. The users also had more experience with lifestyle drugs compared
to the nonusers, although no difference was found due to alcohol consumption. The main
motives behind the use of CE were to manage a high level of stress and a large academic
workload.
In addition, and again during the same time period, another online survey was con-
ducted about CE on a non-randomly selected sample in Germany [65]. In total, 1053
students from a University in Berlin participated, with 2% admitting to having taken
Ritalin R©to enhance the study performance and 0.6% admitting to having taken modafinil.
Overall, 1-13% of these students admitted to having taken medical (e.g. among oth-
ers Ritalin R©, Adderall R©, Prozac R©) or non-medical substances (cocaine, Ginkgo biloba,
cannabis, caffeine pills) in order to enhance study performance. The most commonly
cited reasons were to support concentration, to relax and to increase alertness.
Using the randomised response technique (RRT; for more information please read the
discussion section of ‘2.2 Publication’) a paper-and-pencil survey among 2569 students in
Germany was conducted (no information about the year in which data was collected, but
published in 2013) [66]. The percentage of participants found to have an estimated 12-
months’ prevalence of using cognitive enhancing drugs (stimulant drugs, caffeine tablets,
cocaine, methyl-phenidate, and mephedrone) was 20%.
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USA
2732 medical students participated in an online survey in the US (more precised in
the greater Chicago area) in 2011 [67]. Overall, 18% of these medical students had
used prescription stimulants at least once in their lifetime. Most often the preferred
psychostimulants were amphetamine salts (Adderall R©) or methylphenidate (Ritalin R©,
Concerta R©, Metadate R©, Methylin R©). Such usage correlated with the use of drugs like
ecstasy and having male gender. In most cases the students confessed to having received
the drug from a friend or relative (48.5%), followed by receiving it from a psychiatrist
(24.2%) or a classmate (23.7%). Reasons for this usage were most often for ‘help me
to study’ (65.2%), followed by ‘help me concentrate’ (61.6%), ‘stay awake’ (36.4%) and
‘increase my alertness’ (35.4%). ‘Treat my ADHD’ was also mentioned by 24.2% of the
students. Therefore, students taking it to combat an illness were included in the 18% of
the users from this study.
A systematic review on publications between 1990 and 2012 regarding the use of
methyl-phenidate among medical students was accomplished [68]. The search languages
were English, Portuguese, and Spanish, whilst nine articles were included. A prevalence
lifetime use of methylphenidate as NE was 8.3% to 9%.
In the year 2007, or before (no information about the year of data collection, but
publication date was August 2007), four online surveys were conducted among under-
graduates (not mentioned from which University, but authors from the USA) [69]. These
surveys did not investigate the prevalence rate, but instead focussed on the concerns in-
fluencing the willingness to use CE. Studies one and two, with samples comprising 357
and 266 undergraduates respectively, examined the association between the effect of
one’s self-identity and the willingness to use CE. The authors concluded that people are
less willing to enhance traits which are believed to affect the self (e.g. motivation and
self-comfort) in contrast with traits, which have less of an effect on the self (e.g. memory
ability, concentration) [69]. The third study, in which 359 undergraduates participated,
again pertained to the willingness to enhance, although it also focussed on the desire
to ban legal access to CE. Indeed, the willingness to enhance was again influenced by
concerns about altering the fundamental self. On the other hand, the desire to ban
legal access to CE was determined by moral concerns. Interestingly, this willingness to
enhance was not associated with the desire to ban legal access to CE [69]. The fourth
study surveyed 500 participants aged 18 to 45 years. The results suggest that advertisers
can reduce their concerns about self-identity influencing the willingness to use CE by
pointing out that CE are enabling rather than altering self-identity [69].
UK
In the UK, only non-peer-reviewed publications on surveys were found. One such anony-
mous online survey was conducted by ‘Newsnight’ and ‘New Scientist’ among readers in
November 2011. Of the 761 participants, 38% answered that they have taken CE. Such
CE included Ritalin R©, Adderall R©and modafinil. The survey, which was mentioned by
the authors, is not representative of society [70]. ‘The Guardian’ and ‘Mixmag’ (a dance
music and clubbing magazine) conducted another survey [71]. Of the 15’000 people in
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the UK and in the USA, 15% answered that they hade taken an unknown white powder
in the past 12 months. A third of them admitted that it was supplied by someone who
they did not trust [71]. This survey was not about CE, but about the willingness of
taking a drug with unknown side effects.
Switzerland
Up until very recently, no peer-reviewed survey among students had been published. It
is in light of this that I will summarise here additional surveys about CE which have been
conducted in Switzerland. Indeed, in 2008 a paper-and-pencil survey was accomplished
in the example city Kreuzlingen for the German speaking part of Switzerland. Its aim
was to answer the question of what society thinks of CE [72]. Two paper-and-paper
questionnaires were established on action and political aspects respectively. The two
main goals were to answer whether or not a person would like to take a CE him- or
herself and whether CE should be allowed or forbidden for others. The questionnaire on
political aspects contained an additional six reasons and ten concerns about CE. These
concerns and reasons were established due to literature, media and open interviews
accomplished by the author [72]. Around 2/3 of the 291 participants stated that they
would certainly not or probably not take CE even if no side effects at all would appear
(response rate: 14.6%). In addition, 1/5 of the participants would certainly or probably
take CE whereas all others were unsure. The questionnaire on political aspects revealed
that almost 2/3 would forbid it and approximately 1/4 would allow it. The other 11% were
undecided (response rate: 11.5%). The three most common concerns were that these
products represent an unnatural interference with the body, that one’s own gut feelings
tell oneself to keep away from such products, and that one would change and no longer
be oneself. The three most common reasons for using CE were to learn more quickly, use
them for prevention of age-related problems, and to regain lost mental vigour. Taken
together, most of the participants would not take such a CE even if no side effects would
appear and would forbid such CE in a society.
One non-representative online survey among Students of the University of St. Gallen
(HSG) was conducted by authors of the magazine among the students of the HSG [73].
Of the 1025 participants, 3.1% answered that they were using Ritalin R©in order to en-
hance performance.
On the same day as our study, a survey was published concerning the usage of cogni-
tive enhancers among students in Switzerland [74]. 6275 students of the ETH in Zurich,
the University of Zurich and the University of Basel completed an online survey out
of 28’118 contacted students (response rate: 22.3%). Neuroenhancement was defined
as the usage of prescription drugs or the usage of drugs of abuse including alcohol and
cannabis in order to enhance cognitive function. The category of ‘prescription drugs’ in-
cluded methylphenidate, modafinil, antidepressants, antidementia drugs, sedatives and
beta-blockers. Whilst the category ‘drugs of abuse including alcohol’ obviously refers to
alcohol, it also includes cannabis, cocaine, amphetamines, ecstasy and GHB/GBL. The
survey included questions regarding so-called ”soft enhancers” such as coffee, energy
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drinks or vitamins, although these were not included in the neuroenhancement drug
category. The lifetime prevalence of the participants for neuroenhancement according to
prescription drugs was 7.6%. The most frequently used prescription drug was methyl-
phenidate (4.1%), followed by sedatives (2.7%) and beta-blockers (1.2%). When focusing
on the usage of drugs of abuse including alcohol, 7.8% of the participants had taken it for
cognitive enhancement. The most common drug of abuse for such a purpose was alcohol
(5.6%), followed by cannabis (2.5%), amphetamines (0.4%) and cocaine (0.2%). When
asked about ”soft enhancers” around half of the students had used coffee and approx-
imately one-third had been drinking energy drinks in order to enhance their cognitive
function. The three most frequently chosen reasons for taking such products pertained
to increasing learning (66.2%), relaxation or sleep improvement (51.2%) and reducing
nervousness (39.1%). More senior students, those reporting higher levels of stress and
those who had previously used illicit drugs were more likely to have taken products for
neuroenhancement.
A survey analogue to the survey conducted by Meiners among German employees was
accomplished in Switzerland. The survey was ordered by ‘Suva’ (a Swiss accident in-
surance) and completed by 10’171 Swiss employees or people in education out of a
representative sample [75]. Of these participants, 4% had taken, at least on one oc-
casion, prescription drugs or drugs of abuse for enhancing cognitive function or mood
without having a medical indication for such a usage. The employees with enhancement
experience reported more often stress factors in the work place respectively as well as in
education. They also reported a high pace of work, high deadline pressure, unnecessary
breaks, a lack of control or a high competition pressure. Additionally, the average value
on a scale about perceived self-efficacy was significantly below the average value of the
sample.
Qualitative interviews with students concerning CE exist in Australia [76] and in the
US [77, 78, 79, 80]. Indeed, papers with surveys which I have excluded because of par-
ticipant numbers below 500 were surveys among: 372 medical students in the US [81];
144 medical students in the US [82]; 77 undergrad students in Italy [83]; 184 students
in the US [84]; 243 dental and dental hygiene students in the US [85], 308 health care
students in the US [86], and misuse among 115 students with prescriptions for ADHD
medications in the US [87].
Discussion of the Range of Frequencies
The observed range of frequencies for usage from 1% to 20% found in these studies (Ta-
ble 1.2) could be due to different products being defined and included as CE. Another
explanation could be the different data collection methods used in the surveys, such as
e.g. RRT. This randomised response technique tries to overcome the problem of desired
responses being given, due to stigmatisation and the social norms around illicit products,
by offering full privacy protection and by adding random noise to the data [61, 66]. For
example, a participant plays a dice and marks the answer ‘yes’ to a question whenever
a 6 appears, otherwise she or he answers based on the question. Such noise can than be
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subtracted from the data when the probability properties of the randomised device (here
1/6) are known. However, certain studies have shown that RRT does not improve the
results from online questionnaires [88]. A recent study revealed that when asking about
CE in an online survey, the best results were found with the ‘crosswise model’ technique,
when compared to RRT or no techniques [88]. In the crosswise model technique [89], two
questions are presented, of which one is sensitive (in our case the question if CE have ever
been used) whilst the other is an unrelated and non-sensitive question. The participants
only have to answer if their answers to both questions would be the same (2x yes or 2x
no) or different. If the answer to the non-related question remains unknown, the same
is the case for the sensitive question [88]. A non-sensitive question can be chosen only if
the prevalence distribution of that question is known. Following this, the calculation is
carried out in a similar way as for RRT. If the probability of answering the non-related
question with yes would again be 1/6, then 1/6 of all the participants who answered the
same to both questions answered yes to the sensitive question. Of the participants who
did not give the same answers to the sensitive and non-related questions 5/6 answered
the sensitive question with yes.
A comparison of web and mail surveys found that sensitive data was reported equally
often in both methods [90]. The authors compared the prevalence of secondary conse-
quences after substance use e.g. that an enjoyable event was spoiled, that sleep was
disrupted or that they took care of someone with a drinking or drug problem [90].
Apart from one survey in Germany [62], all of the other surveys in the tables 1.2 and 1.3
are cross-sectional, meaning that one sample at one time was questioned. Longitudinal
studies, whereby the same sample is questioned at different points in time, have an
advantage over cross-sectional studies in that conclusions regarding casualisations can
be drawn.
Taken together, a range of frequencies for usage was found in the studies (Table 1.2).
This could be due to the products included as well as the data collection methods. The
best results were found using the ‘crosswise model technique’ [88] whilst no differences
were observed when comparing online and paper-and-pencil studies [90].
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1.6.3 Surveys after 2010 - Physicians
Bergstro¨m et al. conducted a survey in 2006 among physicians in comparison with
people of the general public in Sweden [91]. Participants in the paper-and-pencil survey
came from a pool of randomly selected people and were 108 GPs and 517 people from
the general public. Both groups had a negative attitude regarding the use of CE. This
attitude was stronger amongst GPs than amongst the general public. Altruistic reasons
were more often accepted compared to egoistic ones for a usage of such CE (Table 1.3).
Another online survey comprising 212 physicians took place in Canada and the USA
[92]. The biggest concern for these physicians in relation to prescribing CE was possible
side effects. More physicians would prescribe a secure and effective CE to a 65 year old
person than to a 25 year old person (Table 1.3).
A paper-and-pencil survey was conducted in the USA [93]. The sample was randomly
selected from all licensed physicians in the US with the exclusion of certain disciplines
where patients would never ask for CE. 633 physicians participated (response rate:
46.4%). These physicians were very ambiguous with regard to CE. Most of them had
concerns about cognitive enhancement, and particularly the social justice aspects. At
the same time, many of these physicians answered that secure and efficient CE should
be available but not paid for by health insurance. Most of these physicians had received
requests for CE and partly prescribed them (Table 1.3).
A very recently published paper-and-pencil survey was sent to all 2753 registered
primary care physicians in Rhineland Palatine in Germany [94]. Around 1/3 of these
primary care physicians responded. More than 3/4 of them have at least once been asked
for prescribing CE and almost all of them have heard of CE before. But only a minority
stated that they are well informed about the possibilites of CE (Table 1.3).
In addition to this, a qualitative survey concerning wish-fulfilling medicine among 19
GPs and plastic surgeons in the Netherland also took place [95]. The interview analyses
illustrated that arguments relating to patient autonomy, risks and benefits, normality
and justice were mentioned with regard to limiting wish-fulfilling medicine. Arguments
in favour of wish-fulfilling medicine pertained to empathy, patient doctor relationship
and reassurance.
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Another survey, conducted among physicians, sought not to gauge their handling but
instead to gauge their usage [96]. In 2011, the authors distributed short questionnaires
at five international conferences of the German Society of Surgery to German-speaking
surgeons. With the help of RRT, the life prevalence was calculated at 8.9% in this sample
of 1145 surgeons (Table 1.2).
Surveys which I have excluded due to small sample size of less than 500 participants
comprised a survey on 130 physicians in Belgium [97] and one survey published in Dutch
which questioned 422 participants on the usage of physicians in the Netherlands [98].
All of the included surveys are presented in table 1.2.
1.7 Discussion and Legal Situation in Switzerland
In this final section of the introduction, I want to focus on the situation in Switzerland
as this is the country in which the two surveys among students and among physicians
of my Ph.D. took place.
Cognitive enhancement is a topic found in the media of Switzerland [e.g. 99, 100, 101,
102]. The government is supporting an informed discussion in the public by providing
booklets and reports on this topic [21, 103, 63]. Indeed, the Swiss Academy of Medical
Sciences has been working on human enhancement for some time. After holding a
conference on this topic in 2007, the SAMW defined ‘human enhancement’ as a core area
in 2008 [104] and has been generating a booklet on human enhancement published by the
Swiss Academies of Arts and Sciences in 2012 [105]. In 2011, the Swiss National Advisory
Commission on Biomedical Ethics in the field of human medicine (NEK-CNE) published
a statement concerning CE [106]. The seven recommendations of the NEK were: 1) the
physician is aware of changing the picture of medicine in public with a wide practice
of prescribing such CE; 2) personal freedom must be accepted but never at the cost of
justice and tolerance towards otherness; 3) a health risk of CE exists; 4) educational
institutions are duty bound when it comes to the psychological health of their wards
and employees and must counteract an overly high pressure to perform; 5) enhancement
should never be confused with treatment in health politics; 6) CE can especially limit
the freedom, personal rights and personal development of children wherefore parents and
institutions of education and other people in charge of the care and custody of the child
bear responsibility for each child but also for the future values and norms of our society;
and 7) the current practice of prescription of psychotropic drugs must be surveyed in
order to evaluate the reasons of a higher consumption and to protect children from
overuse.
The substances methylphenidate (e.g. Ritalin R©) and modafinil (e.g. Modasomil R©),
which are available in Switzerland, are both categorised as ‘A’ standing for a singular sub-
mission on prescription [107]. For Antidepressants, the memantine (antidementia drugs)
and the three acetylcholinesterase inhibitors donepezil, galantamine and rivastigmine
are classified as ‘B’. ‘B’ stands for submission on prescription [107]. The antidepressant
substances paroxetine, citalopram, reboxetine, fluoxetine, sertraline, fluvoxamine, mo-
clobemide, bupropion, venlafaxine, escitalopram and duloxetine are all classified as ‘B’
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whereas certain products consisting of bupropion are also classified as ‘A’ [107].
One possible way in which to access CE, apart from having a prescription or receiving
them from people with a prescription, is to purchase them from online pharmacies.
A study from the European Alliance for Access to Safe Medicine (EAASM) analysed
over 100 websites selling prescription-only medicines [108]. The study revealed that 90%
of these websites sold such medicines without having seen an authorised prescription
beforehand. The authors also ordered 36 prescription-only medicines, of which 62% were
revealed, by way of chemical analysis, to be counterfeits. Of the 38% of authentic drugs,
33% were posted without an instruction leaflet. A follow up campaign by the EAASM in
2012 was designed to warn people wishing to purchase medicines via the Internet. The
campaign involved the setting up of an apparently genuine online pharmacy website
[109].
Taken together, there does exist material to inform the Swiss public about cognitive
enhancers whilst the main institutions in the field of biomedical ethics have placed
particular emphasis on this topic for some years now. As will be seen in Chapter 2, 3/4
of 1843 students knew that Ritalin R©can be taken to enhance concentration or alertness
in healthy people. Indeed, information material is available in Switzerland and there are
indicators showing that at least some of the public are aware of CE. However, much of
this information comes from the media, with studies showing that possible benefits are
mentioned more often than potential risks and side effects [4, 2]. Bearing this in mind,
as well as the fact that such CE can be easily ordered via online pharmacies, fostering
a discussion in society relating to possible risks and side effects remains an important
issue.
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2 Survey among Students
2.1 Introduction
When starting my Ph.D. in 2010, no data about the usage of cognitive enhancers ex-
isted in Switzerland. As emphasised by the authors of the memorandum on cognitive
enhancement published in ‘Gehirn & Geist’ in 2009 [1], such data is important for fos-
tering an informed debate in society. As seen in section 1.4 on ethics and empirical data,
such data can play an important role in ethics by contributing to the steps describing
and assessing the moral question as well as evaluating decision-making.
Additionally, such data can uncover the views of students regarding cognitive en-
hancers. This is mainly important because as seen in section 1.1, a so called ‘media
hype’ concerning cognitive enhancers exists [4]. Studies have shown that data about the
possible benefits of cognitive enhancers are overexpressed in print media in relation to
the possible negative effects of such products [2, 4]. Additionally, the data that was
quoted for showing that the usage of such products is widespread are questionable [4].
By revealing the views of students and how their attitudes about cognitive enhancers
are made, one can observe if the so called ’media hype’ has an effect on the views and
attidues of students and specific actions can be introduced in the future.
The online survey among students took about 10-15 minutes and was open during
four months in the summer semester 2011. Four different ways of reaching students of
the University of Zurich were introduced. For being able to separate the participants
according to the way they have accessed the survey, four different URLs were given all
leading to the same online survey. The following e-mail was sent out through the Uni-
versity of Zurich reaching 8642 undergraduate and graduate students who allow such
emails to be sent to them.
Guten Tag,
Dein Verhalten und deine Meinung sind gefragt!
In den USA haben ca. 6 von 100 Studierenden schon einmal Ritalin oder A¨hnliches genommen,
um ihre Konzentration zu steigern.
Wie ist diese Verteilung an der Uni Zu¨rich?
Unabha¨ngig davon, ob du solche Produkte schon genommen hast oder nicht: Bitte nimm dir 15
Minuten Zeit fu¨r die Umfrage meines Doktorats und klicke auf den folgenden Link.
http://www.mnf.uzh.ch/umfrage1
Herzlichen Dank!
Regula Ott
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Additionally, the 32 student councils of the University of Zurich were contacted and
eight of these then distributed the survey email, reaching around 4300 students. The
e-mail was almost identical with the one above, where only the URL was replaced by:
http://www.mnf.uzh.ch/umfrage2, followed by the sentence: ‘Falls du diese Umfrage
bereits ausgefu¨llt hast, grosses Dankescho¨n und bitte nicht nochmals teilnehmen.’ But
such a second participation of a student would only be possible if different computers were
used or cookies forbidden. In all the other cases a note would have appeared saying that
the survey was already completed by that person. The third way for accessing the survey
was by a link written on the following flyer (Figure 2.1), which was distributed in 19
major lectures of different study courses after giving a short summary about the survey as
well as at the entrance of the University of Zurich. This way, around 3000 students were
informed about this survey. The fourth URL was given to 63 individual students I know
personally. For all three e-mails I used the address regula.ott@uzh.ch. Additionally,
the University of Zurich was mentioned as the place the survey was constructed and
not the Institute of Biomedical Ethics. This way we tried to reduce the pressure for
socially acquired answers in order to improve the quality of the data. Additionally, the
terms ’cognitive enhancement’ or ’neuro-enhancement’ and ’ethics’ were not used in the
survey. For the same purpose of reducing the pressure for socially acquired answers we
did not talk of drugs but only of products when referring to Ritalin R©, Adderall R©and
Modasomil R©. 1935 students started the questionnaire, of which 1765 students completed
Figure 2.1.: Flyers distributed in lectures and at the University of Zurich
the survey. The results are published in the paper included in the next section and will
be summarised in section 2.6.
2.2 Publication
The paper on the survey among students was published in the journal ‘Pharmacopsy-
chiatry’ in November 2013. A print of the publication is included in this section.
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 Neuroenhancement among Swiss Students – 
A Comparison of Users and Non-Users
lin, Adderall and/or Modasomil for increasing 
concentration and/or alertness as a healthy per-
son, in comparison to CE non-users in Switzer-
land. Rather than contributing to what has been 
called media hype  [ 20 ] , such data will lead to a 
better understanding of why some students are 
taking CE and others are not, and how students 
conceive of these products. By focusing on CE 
users as well as CE non-users, further aspects of 
the perception of neuroenhancement in society 
can be observed. These insights could enrich cur-
rent debates on how to deal with cognitive 
enhancers.
 Existing literature and surveys include various 
understandings of CE e. g.,  [ 1 ,  2 ,  19 ] . The deﬁ ni-
tion of CE we provided for the survey was pur-
posely very narrow: “The use of Ritalin, Adderall 
and/or Modasomil for increasing concentration 
and/or alertness in a healthy person”. Products 
very similar to these three were included (as 
 Introduction
 ̖
 Neuroenhancement has been a matter of contro-
versy in recent years, not only with regard to the 
moral and legal issues involved, but also in con-
sideration of the role of cognitive enhancers (CE) 
in the everyday lives of di  ̥erent populations  [ 1 –
 3 ] . A number of studies focus on various user 
groups and the frequency of usage  [ 4 – 11 ] , with 
some concentrating on students  [ 7 – 11 ] , whereas 
several others explore the experiences and per-
ceptions of prescribing physicians  [ 12 – 15 ] . Even 
though the ethical and policy issues of CE have 
been intensely debated in Switzerland  [ 16 ,  17 ] , so 
far only a single survey has been carried out 
investigating the attitudes of the general popula-
tion in one Swiss community  [ 18 ] .
 The goal of our survey was to add empirical data 
about the characteristics and motives of CE users, 
deﬁ ned as students who have already taken Rita-
 Authors  R.  Ott ,  N.  Biller-Andorno 
 A  ̶ liation    Institute of Biomedical Ethics, University of Zurich, Zurich, Switzerland 
 Abstract
 ̖
 Introduction:  This survey aims to contribute to 
the current discussion about neuroenhancement 
by comparing cognitive enhancer(s) (CE) users 
with CE non-users with a focus on their charac-
teristics and attitudes.
 Methods:  An online survey was sent out to all 
undergraduate and graduate students of the Uni-
versity of Zürich who allow such e-mails 
(n = 8 642), accompanied by advertisement for 
the survey in lectures. 1 765 students completed 
the survey, which was about healthy people’s use 
of Ritalin, Adderall and/or Modasomil to increase 
concentration and/or alertness. A complemen-
tary paper-and-pencil survey (n = 97 students, 
response rate: 95.1 %) was also carried out in 
order to compare data.
 Results:  Non-therapeutic CE users (6.2 %) were 
more often male, considered religion to be of less 
importance and had more experience with drugs. 
CE had been taken for study purposes by 4.7 % of 
all students. CE users had tried Ritalin most 
often, which about half of them received from 
friends and colleagues. The CE users had more 
reasons for and fewer concerns about taking CE 
than non-users. The most common reasons for 
both groups were “the e  ̥ects of learning quicker” 
and “for ﬁ nishing more work in less time”. The 
most common concerns for both groups were 
“the worries about possible side e  ̥ects” and “the 
goal of CE to achieve more”, and “an unnatural 
interference of such products with our bodies” 
(CE-users) or “the gut feeling of not using such 
products” (CE non-users).
 Discussion:  The comparison of CE users with 
CE non-users reveals insights about their atti-
tudes, which will add to the understanding of 
why students take or could imagine taking such 
products.
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explained in the Methods section). By avoiding the term “neu-
roenhancement”, we tried to prevent associations with various 
other possible deﬁ nitions.
 Our focus on the comparison between users and non-users 
rather than mainly investigating the users will add new data to 
the debate about CE and speciﬁ cally to the situation in Switzer-
land.
 Methods
 ̖
 Hypotheses
 The hypotheses were formulated according to possible associa-
tions between the usage of CE and the following: demographic 
data; drug or alcohol use; use of products like co  ̥ee; conduction 
of methods like autogenic training; concerns about and reasons 
for using CE; self-evaluation of risk behaviour and case studies. 
The hypotheses were established on the basis of previous stud-
ies about the usage of CE  [ 4 – 7 ] as well as proposed, possible 
associations concerning the usage of CE.
 Survey design
 The online survey of about 10–15 min was constructed with the 
software “Unipark” – a fee-based software for establishing 
online surveys. The questions were developed in line with cur-
rent methodological recommendations (Prost, 2009). To avoid 
possible bias due to di  ̥ering deﬁ nitions of “neuroenhance-
ment”, we did not use the term “neuroenhancement” but instead 
the phrase “Ritalin, Adderall and/or Modasomil to increase con-
centration and/or alertness in a healthy person”. Furthermore, 
we referred to Ritalin, Adderall and Modasomil as “products”, 
and not as “pharmaceuticals” or even “drugs”. We chose these 
three products as they are dominant in the current literature on 
neuroenhancement and are also used as reference products in 
other empirical surveys. The term “Ritalin” was deﬁ ned as 
including the products Concerta, Focalin, Equasym, Medikinet, 
Daytrana and Metadate; the term “Modasomil” included Provigil, 
Vigilant and Modaﬁ nil.
 Half-open answer categories were used when we could not be 
sure of covering all possible answers. The answer categories 
were presented in random order except when they represented 
a range.
 The questions were grouped into 3 parts: demographic data; 
usage of CE; and personal attitudes toward such products. A 
paper-and-pencil version of the questionnaire (in German) is 
available from the authors (regula.ott@ethik.uzh.ch) upon 
request.
 Students who had already taken Ritalin, Adderall and/or Modas-
omil to increase concentration or alertness without treating an 
illness (“CE users”) and students who had not yet taken such 
products or who had taken them only to address the symptoms 
of an illness (“CE non-users”) were separated with the help of 
ﬁ lters.
 The 2 questions addressing concerns about or reasons for taking 
CEs were based on arguments presented in the pre-existing 
Swiss questionnaire  [ 18 ] . The questions about alcohol consump-
tion and about risk were formulated in accordance with the 
standards of the Swiss Federal O  ̦ ce of Statistics.
 The questionnaire was reviewed by 2 outside survey experts, 
and tested by 11 individuals who were mostly students and by 
one person with experience in survey design. In the pilot study, 
a space for commentary was added after each question, which 
generated around 60 comments that were then used to improve 
the questionnaire for the main study. The ethics committee that 
is responsible for human subject research in the Canton of Zurich 
exempted the study from review.
 Di  ̥erent tools were applied to the survey to improve the quality 
of the data and to keep participants motivated: Plausibility 
checks triggering a comment if a participant’s answers were 
ambiguous, ﬁ lters and page triggers leading to speciﬁ c phrased 
questions in response to previous answers.
 The administration of the survey
 A link to the survey was sent to all the undergraduate and gradu-
ate students of the University of Zurich who had already given 
the University permission to send them e-mails for research 
purposes (n = 8 642).
 In addition, ﬂ yers advertising the survey were distributed dur-
ing 19 major lectures, through which around 3 000 students 
were informed about the survey. The 32 student councils of the 
University of Zurich were also contacted and 8 of these then dis-
tributed the link among their students (n § 4 300). 63 individual 
students (personal contacts of one of the authors, R.O.) received 
a personal e-mail inviting them to participate in the survey. We 
used di  ̥erent URLs to ensure that we could evaluate how the 
participant knew about the questionnaire. The survey was 
online for 4 months during the summer semester in 2011 (14 
March 2011–12 July 2011). When cookies were allowed, the sur-
vey could not be ﬁ lled out twice from the same computer.
 In order to increase the validity of the convenience sample of the 
online survey, the same questionnaire was used in a small 
paper-and-pencil survey of 103 Bachelor and Master’s students 
(biology) in a neurobiology lecture on 10 October 2011. The par-
ticipants in this small survey were not included in the main sur-
vey because of possible bias due to the di  ̥erent method of 
collecting the data. Therefore, the paper-and-pencil survey was 
used for comparison purposes only.
 Data analysis
 Analyses were conducted using SPSS statistic Version 19.0.0 
(SPSS Inc., Armonk, NY). Data cleaning was accomplished. We 
used univariate descriptive statistics to examine the distribution 
for the answer categories of each question. Bivariate analyses 
using Pearson’s Ȉ 2 tests and one t-test (question about risk) were 
completed to compare the group of CE users with the CE non-
users. A Fisher’s exact test was conducted if 20 % or more of 
expected values below the value of 5 or any expected values 
below 1 were found. A stepwise binary linear regression was cal-
culated with usage of CE as the dependent variable.
 Results
 ̖
 1 765 students of the University of Zurich completed the survey. 
Most of these students (n = 1 311) participated by responding to 
the e-mail sent out through the University (74.3 % of the 1 765 
participants) and the response rate for this subset was 15.2 % 
(1 311 of the 8 642 students who received the e-mail). The 
remaining 25.7 % of participants completed the survey either 
after receiving an e-mail from one of the student councils 
(n = 238, 13.5 %), after typing in the link on the ﬂ yer (n = 198, 
11.2 %) or after clicking on the link in a personal e-mail (n = 19, 
1.1 %).
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 Considering all of the students at the University of Zurich, 8.9 % 
of the students (licentiate, bachelor and master) ﬁ lled out the 
questionnaire (n Total = 18 823), as did 5.5 % of all Ph.D. students 
(n Total = 4 219). In absolute numbers, the most highly represented 
student groups were medical students (n = 275), followed by 
psychology students (n = 192) and law students (n = 158).
 To compare these results with those generated by a survey with 
a much higher response rate, students attending one major lec-
ture were asked to ﬁ ll out the questionnaire on paper (response 
rate: 95.1 %). Of these students, 4.1 % had taken CE to increase 
concentration and/or alertness (n = 4, n Total = 98). This is not sig-
niﬁ cantly di  ̥erent from the value of 6.2 % for CE-users in the 
main sample (p = 0.391).
 Demographic data
 1 197 people in this sample were female (61.9 %) and 732 were 
male (37.9 %; 4 people did not choose a gender (0.2 %). The 
median birth year was 1 986 (n Total = 1 923).
 114 people in this sample used Ritalin, Adderall and/or Modas-
omil at least once in their life for increasing concentration and/
or alertness as a healthy person (6.2 %). 87 of these 114 people 
had used it for study purposes (4.7 % of n Total = 1 835); the other 
27 people had used it as a “party drug” or out of curiosity and 
not in a speciﬁ ed situation.
 A signiﬁ cant univariate association with the usage of CE (p < 0.05) 
was found for gender, political view, and religion (  ̎  ̂    Table 1 ). No 
di  ̥erence was found due to age, ﬁ eld of study, level of study 
(undergraduate, teaching diploma, Ph.D.), average number of 
semesters, highest completed level of education of the mother or 
father, participation in student groups at the University, frater-
nity/sorority members, self-reported grades, housing or the 
ﬁ nancial situation of the person or their parents.
 There were strong associations between the use of CE and drugs 
(  ̎  ̂    Table 1 ). No di  ̥erence between the 2 groups was found in 
the frequency of alcohol consumption (the median for both 
groups was “1–2 times per week”).
 A stepwise logistic regression was calculated using the variables 
that had a positive association with the usage of CE (  ̎  ̂    Table 2 ). 
These variables are the ones in   ̎  ̂    Table 1 ; the legal products cof-
fee, Red Bull, guarana and cigarettes; autogenic training as a 
method for the purpose of increasing concentration and/or 
alertness; and their self-evaluation of the risk behaviour.
 The logistic regression model includes gender, Red Bull, guarana, 
autogenic training, ecstasy, cocaine, LSD and “none of these 
drugs taken” as predictors for belonging to the group of CE users 
and can explain 19.4 % of the variance (  ̎  ̂    Table 2 ).
 The model reveals that there is an increased chance of belonging 
to the group of CE users if male; having taken Red Bull or guar-
ana; having performed autogenic training for increasing concen-
tration and/or alertness; or having used ecstasy, cocaine or LSD. 
If none of these drugs had been taken, there was a decreased 
chance of belonging to the CE-user group.
 Table 1  Demographic and drug use data for CE users and CE non-users. 
 Variable  Answer categories  CE non-users  CE users  p-value 
(ȉ 2 test) 
 Odds ratio  Conﬁ dence 
interval 
 p-value 
(Odds ratio) 
 all (n Total )  –  1 722 (100 %)  116 (100 %)  –  –  –  – 
 gender 
 
 women*  1 096 (63.7 %)  49 (43.0 %)  0.000  –  –  – 
 men  624 (36.3 %)  65 (57.0 %)   2.330  1.588–3.419  0.000 
 political orienta-
tion 
 SP (left)  497 (28.9 %)  31 (27.2 %)  0.042    0.519 
 GPS (green, left)  221 (12.8 %)  12 (10.5 %)     0.390 
 CVP (Christian)  82 (4.8 %)  0 (0 %)     0.997 
 FDP (liberal)  161 (9.4 %)  20 (17.5 %)     0.299 
 GLP (green, liberal)  229 (13.3 %)  17 (14.9 %)     0.853 
 SVP (right)*  112 (6.5 %)  9 (7.9 %)     – 
 others  90 (5.2 %)  7 (6.1 %)     0.950 
 none  328 (19.1 %)  18 (15.8 %)     0.367 
 religion  evangelical reformed  589 (34.2 %)  28 (24.6 %)  0.004  0.478  0.296–0.774  0.003 
 roman catholic  530 (30.8 %)  27 (23.7 %)   0.513  0.315–0.835  0.007 
 others °  120 (7.0 %)  11 (9.6 %)     0.817 
 no a  ̦ liation*  483 (28.0 %)  48 (42.1 %)   –  –  – 
 importance of 
religion 
 very important  81 (4.7 %)  3 (2.6 %)  0.003    0.153 
 important  186 (10.8 %)  5 (4.4 %)   0.308  0.123–0.771  0.012 
 rather unimportant  488 (28.4 %)  22 (19.3 %)   0.517  0.320–0.838  0.007 
 not important*  964 (56.1 %)  84 (73.7 %)   –  –  – 
 drugs*  cannabis  924 (55.0 %)  89 (82.4 %)  0.000    0.797 
 ecstasy ( = MDMA)  88 (5.2 %)  37 (34.3 %)  0.000  2.848  1.385–5.858  0.004 
 cocaine  96 (5.7 %)  33 (30.6 %)  0.000    0.071 
 LSD  51 (3.0 %)  23 (21.3 %)  0.000  +   2.157  1.035–4.498  0.040 
 amphetamine (e. g. Speed)  60 (3.6 %)  29 (26.9 %)  0.000    0.100 
 thai-pills  5 (0.3 %)  4 (3.7 %)  0.001  +     0.562 
 magic mushrooms  120 (7.1 %)  22 (20.4 %)  0.000    0.272 
 crack  6 (0.4 %)  3 (2.8 %)  0.014  +     0.748 
 heroine  10 (0.6 %)  3 (2.8 %)  0.039  +     0.222 
 none of these drugs taken*  731 (43.5 %)  16 (14.8 %)  0.000    0.097 
 * Reference variable for odds ratio; odds ratio only mentioned when p-value was  < 0.05 
 ° Other Christian churches or communities, other churches or communities, Jewish, Muslim 
  +   Fisher’s exact test was completed. n Total can vary, due to missing values (between 0 and 4) and drop-outs (drug questions was more at the end of the questionnaire: n = 110 
and n = 1 679) 
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 Features of CE use
 A positive association between the use of CE and the use of prod-
ucts to increase concentration and/or alertness in the last 12 
months was seen for co  ̥ee, Red-Bull, guarana and cigarettes. A 
negative association with the use of CE was found if there had 
been no consumption of such products for this purpose. A posi-
tive association was also found between the use of CE and 
autogenic training for the same purpose.
 Within our sample of students, 74.1 % knew that Ritalin could be 
taken as a CE. At least one product from the group containing 
“Concerta, Focalin, Equasym, Medikinet, Daytrana, Metadate” 
was identiﬁ ed as a known CE product by 9.1 % of students. 
“Provigil, Vigil, or Modaﬁ nil” were known to be CE products by 
6.5 %, “Modasomil” by 3.9 % and “Adderall” by 2.8 % of students. 
269 persons knew more than one of these products could be 
used for such purposes (14.6 %). However around a third of stu-
dents (25.5 %) had not heard of any of these products being used 
for such a purpose. CE users knew each category of CE listed 
above signiﬁ cantly more often than the CE non-users (for all cat-
egories: p = 0.000).
 164 students had taken at least one of the products (Ritalin 
[n = 159], Adderall [n = 4] or Modasomil [n = 15]) or brand names 
mentioned above. 46 of these students had taken these products 
(Ritalin in all cases) as treatment for a medical condition. Of the 
remaining 114 students (4 students dropped out), 99 had taken 
Ritalin for non-therapeutic purposes, 4 had taken Modasomil 
and 11 students had already taken several of these products. 
Possible reasons for non-therapeutic use by CE users are pre-
sented in   ̎  ̂    Table 3 .
 CE non-users were also asked if they could imagine taking Rita-
lin, Adderall or Modasomil for the possible reasons mentioned 
in   ̎  ̂    Table 3 . Most of them gave the answers “no, rather not” or 
“no, never” to the reasons provided (n = 1 160, 68.8 %). In the 
cases where they could imagine taking these products, the most 
commonly chosen answer categories were “out of curiosity” 
(n = 358, 21.2 %), and “to be more concentrated” (n = 246, 14.6 %).
 Most of the CE-users (86.2 %) told at least one other person about 
their consumption. A little more than a quarter of CE non-users 
(27.2 %) knew at least one person using CE (most frequently 1–3 
persons). Still more CE non-users (42.8 %) had heard about at 
least one person who was taking CE (without having heard it 
directly from the individual). Almost half the CE users indicated 
that they had received a neutral reaction from other people 
about their use of CEs. This contrasts with only 22.0 % (n = 371) of 
the CE non-users from this sample claiming they would have 
reacted neutrally. Two-thirds of CE non-users thought that using 
CE was not a good thing to do (67.3 %) and only 0.9 % agreed with 
such use (9.5 % answered that they could not decide; missing 
values: n = 5, 0.3 %).
 Answers to questions about the frequency of CE use revealed 
that 44.4 % of the students who had taken Ritalin as a CE had 
already taken it more than 5 times in their life (n = 48). 34 stu-
dents had taken it 2–5 times in their life (31.5 %) and 26 people 
once in their life (24.1 %). Modasomil and Adderall were taken 
much less frequently. Most of the CE users received the product 
from colleagues, friends or acquaintances (  ̎  ̂    Table 4 ).
 When asked about their estimation of side e  ̥ects, signiﬁ cant 
di  ̥erences between the CE users and CE non-users were 
observed for Ritalin [Ȉ 2 (5) = 144.87, p = 0.000], with CE non-users 
more often choosing the options “rather critical” or “very criti-
cal”. The CE users formed their opinions about the side e  ̥ects 
most often by reading specialist literature (48.3 %, n = 42), 
whereas the CE non-users formed their opinions most often 
through the presentation of these products in the media (38.8 %, 
n = 343).
 Personal attitudes towards CE
 Study participants were presented with 3 case studies: 1) a 
25-year-old healthy person, who is described as a friend of the 
participant and studies with him/her, taking Ritalin to increase 
their concentration; 2) the same type of person, but in this case 
taking anabolics to increase muscle size; and 3) a 65-year-old 
healthy person taking a product to counteract an age-related 
decrease in intellectual performance. In all 3 scenarios, more CE 
users approved of these products being consumed than did CE 
non-users. Interestingly, signiﬁ cantly fewer students from both 
 Table 3  Why did you take Ritalin, Adderall and/or Modasomil? (Multiple 
answers possible). 
  CE users (n = 114) 
 to be more concentrated.  85 (74.6 %) 
 out of curiosity as to how it takes e  ̥ect.  66 (57.9 %) 
 to be more awake.  62 (54.4 %) 
 because I did not have enough time.  30 (26.3 %) 
 to receive better grades.  27 (23.7 %) 
 because I am stressed.  22 (19.3 %) 
 to get into the mood, e. g. at a party.  16 (14.0 %) 
 because others did it as well.  7 (6.1 %) 
 to decrease jet lag.  3 (2.6 %) 
 for another or additional reason, namely…  7 (6.1 %) 
 The answer categories one to nine were randomized. More than one of the answer 
categories could be chosen. No missing values and the median was 3 answers 
 
      Conﬁ dence interval 
 Variable  Regression 
coe  ̶ cient 
 Standard error  p-value  Odds ratio  Lower  Upper 
 gender  0.478  0.219  0.029  1.613  1.051  2.476 
 red bull  0.462  0.230  0.044  1.588  1.012  2.490 
 guarana  0.702  0.264  0.008  2.017  1.201  3.387 
 autogenic training  0.989  0.422  0.019  2.687  1.175  6.147 
 ecstasy  1.029  0.342  0.003  2.797  1.430  5.471 
 cocaine  0.690  0.322  0.032  1.993  1.061  3.746 
 LSD  0.821  0.354  0.021  2.272  1.135  4.549 
 none of these drugs taken  ï 0.797  0.297  0.007  0.451  0.252  0.806 
 The categorical covariates (all variables except the one about risk) were compared to either the last answer category (political orienta-
tion, religion, importance of religion) or the ﬁ rst answer category (all the other variables) 
 Table 2  Stepwise logistic regres-
sion.
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groups were ﬁ ne with the consumption of anabolics as com-
pared to the consumption of Ritalin for the 25-year-old 
described.
 Around one-third of the CE users agreed with the statement that 
the intake of such CE will be normal in 10 years, compared to 
18.4 % of the CE non-users. 90.6 % of the CE users would be pre-
pared to try a product without any side e  ̥ects to increase IQ and 
a little more than half of them (51.9 %) would try this “most 
probably more than once”. This compares with only 57.9 % of the 
CE non-users who claimed they would try such a product. A sur-
vey item containing a self-assessment of risk behaviour revealed 
that CE users considered themselves overall more ready to take 
risks than did the CE non-users.
 2 questions were asked about the acceptability of taking co  ̥ee 
or Ritalin before an exam. As expected, more of the CE users 
think that the use of Ritalin before an exam is acceptable than do 
the CE non-users; in general, more of the students in both 
groups think that the intake of co  ̥ee is more acceptable than 
taking Ritalin.
  ̎  ̂    Table 5 illustrates that CE non-users have more concerns 
about the use of CE than CE users and   ̎  ̂    Table 6 shows that CE 
users more often agreed with possible reasons for taking CE 
products than did CE non-users.
 Discussion
 ̖
 This survey was designed to obtain information about attitudes 
to neuroenhancement from a sample that allowed us to compare 
CE users with CE non-users. It was not constructed to be a repre-
sentative study of a population. The values gained for frequency 
of usage of CE by healthy people for study purposes (4.7 %) there-
fore must be understood with caution. The primary invitation to 
participate in the survey could only be sent to those students 
who allowed such e-mails, 33.7 % of all students. It was therefore 
not possible to gain a representative sample from a random 
selection.
 Concern about bias due to the study design could be addressed 
by comparing our sample results with those generated by a 
paper-and-pencil survey carried out with a further 97 students 
(response rate 95.1 %), although this comparator sample was also 
not representative of the whole student population because it 
included students from only one major subject and semester 
group. Due to this selection process, some di  ̥erences exist 
between the paper-and-pencil survey and the online survey, 
such as age (a median of 1988 compared to 1986) and the 
number of semesters (a median of 5.0 compared to 6.0); how-
ever, there were no di  ̥erences with regard to gender. The major 
subject biology (n = 60 in the paper-and-pencil survey) was also 
the fourth most common subject in absolute numbers for the 
online sample.
 Table 4  Source of product. 
 a) Where did you get the product in question? (Multiple answers 
possible) 
  Ritalin 
(n = 106) 
 Adderall 
(n = 4) 
 Modasomil 
(n = 14) 
 from colleagues, friends or 
acquaintances. 
 59 (55.7)  2  6 
 from a physician.  25 (23.6)  1  5 
 from someone in my family.  14 (13.2)  0  0 
 in a pharmacy.  12 (11.3)  0  1 
 via the Internet.  5 (4.7)  1  2 
 via another route, namely…  7 (6.6)  0  2 
 b) did you require a prescription for the supply of the product? If yes, 
from where did you get it? (Multiple answers possible) 
  (n = 104)  (n = 3)  (n = 14) 
 no, I did not require a prescrip-
tion. 
 77 (74.0)  2  11 
 yes I did require a prescription. 
I received it from a physician. 
 23 (22.1)  1  3 
 yes I did require a prescription. 
I ﬁ lled it out by myself. 
 0 (0.0)  0  0 
 yes I did require a prescription. 
I received it from some other 
non-physician. 
 4 (3.8)  0  0 
 The answer categories one to ﬁ ve for the ﬁ rst question were randomized. When the 
sixth answer category was chosen, no other answer categories were possible. Miss-
ing values in the ﬁ rst question: Ritalin: 1, Adderall: 7, Modasomil: 7. Missing values 
in the second question: Ritalin: 0, Adderall: 7, Modasomil: 7. Median for all products 
in both questions: one answer 
 Table 5  Concerns about the use of CE. 
 CE users: Which of the following possible concerns, about EXCESSIVE use of Ritalin, Adderall and/or Modasomil to increase concentration or alertness, do you agree with? 
CE non-users: Which of the following concerns, about the use of Ritalin, Adderall and/or Modasomil to increase concentration or alertness do you agree with? 
 CE-users (n = 108); CE-non-users (n = 1 689)  I agree  I don’t agree  I don’t know  p-value* 
 worries about possible side e  ̥ects.  63.9  81.9  28.7  11.1  7.4  6.6  0.000 
 the goal when taking these products is that one can achieve more. I ﬁ nd such 
pressure to achieve more questionable. 
 59.3  74.5  36.1  17.5  4.6  7.6  0.000 
 these products represent an unnatural interference with our bodies.  55.6  73.1  39.8  17.2  4.6  9.3  0.000 
 there is a danger of becoming addicted.  51.9  68.9  38.9  18.2  9.3  12.4  0.000 
 if a lot of people do this, it could have bad e  ̥ects on society.  48.1  57.3  41.7  21.7  10.2  20.4  0.000 
 my gut feeling tells me that we should keep our hands o  ̥ such products.  40.7  76.2  49.1  15.8  10.2  7.8  0.000 
 that I would change and not being myself anymore.  33.3  49.9  61.1  31.8  5.6  17.8  0.000 
 I could not be proud of my own achievements anymore.  18.5  42.4  76.9  41.5  4.6  15.7  0.000 
 I would somehow be betraying people who do not use such products.  17.6  34.2  76.9  50.7  5.6  14.6  0.000 
 God created humans according to his plan. we should not try to improve upon 
this with such products. 
 2.8  9.1  88.0  74.3  9.3  16.0  0.014 
 The answer categories were randomized. For each sentence, one answer category could be chosen. There are no missing values for the CE users. Some missing values exist for 
the CE non-users (n = 4–10, 0.2–0.6 %) 
 * The p-value was calculated with a Ȉ 2 -test and the ‘I don’t know’ answers were treated as missing values. The CE users were in the following question asked what they deﬁ ne as 
an excessive use 
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 Furthermore, the ﬁ ndings from our survey are in line with previ-
ous data from surveys of students  [ 7 – 11 ] , especially with those 
of German students. A mailed survey from the USA with 10 904 
students (data from 2001) revealed a lifetime prevalence of non-
medical prescription stimulant use (Ritalin, Dexedrine or Adder-
all) of 6.9 %  [ 7 ] . A paper-and-pencil survey carried out in 
Germany with 512 students and 1 035 school pupils showed 
that 1.6 % of the students and 0.8 % of the school pupils had taken 
Ritalin, Concerta, Adderall or Modaﬁ nil as a healthy person for 
non-therapeutic reasons at least once in their lives  [ 8 ] . An online 
survey carried out with 8 000 students in Germany showed that 
around 5 % of participants took prescription substances to deal 
with the requirements of studying  [ 9 ] . Using the randomized 
response technique (RRT) in a paper-and-pencil survey among 
2 569 students in Germany, the estimated 12-month prevalence 
of cognitive-enhancing drug use (stimulant drugs, ca  ̥eine tab-
lets, cocaine, methylphenidate and mephedrone) was found to 
be 20 %  [ 10 ] . The lifetime prevalence for the non-medical usage 
of psychostimulants, such as methylphenidate or amphetamine 
salts was found to be 18 % in an online survey of 2 732 medical 
students in the USA  [ 11 ] . Future representative studies in Swit-
zerland will reveal if our data concerning the number of CE-
users are biased. In such surveys, we propose to include less 
common products, such as Metoprolol (a beta blocker), Aricept 
(an antidementia drug consisting of the substance donepezil) 
and Strattera (atomoxetine).
 The wide range of frequencies for usage found in these studies 
could be due to di  ̥erent products being deﬁ ned and included as 
CE. We focused in our survey on Ritalin, Adderall and Modasomil 
because these 3 products are the most dominant ones in the 
current literature about NE as well as in previous surveys. 
Another reason for the wide range of frequencies could be due to 
di  ̥erent data collection methods and techniques, such as RRT 
 [ 10 ] . This randomized response technique is used to try to over-
come the problem of desired responses being given, due to stig-
matization and the social norms around illicit products, by 
o  ̥ering full privacy protection and by adding random noise to 
the data  [ 21 ] . For example, a participant plays a die and marks 
the answer “yes” to a question whenever a 6 appears; otherwise 
she/he answers based on the question. Such noise can than be 
subtracted from the data when the probability properties of the 
randomized device (here 1/6) are known. Some studies have 
shown, however, that RRT does not improve the results from 
online questionnaires  [ 21 ] . A very recent study revealed that 
when asking about CE in an online survey, the best results were 
found with the “crosswise model” technique, as compared to 
RRT or no technique  [ 21 ] .
 To keep the rate of untruthful but “desired” answers as low as 
possible, we tried hard to phrase the questions in a non-sugges-
tive way and had them tested by survey experts. For the same 
reason, we also removed any reference to the Institute of Bio-
medical Ethics as a sponsor of the study, and only referred to the 
University of Zürich as the place where the survey was gener-
ated. We also used the more neutral term “products” instead of 
drugs or medicines when summarizing di  ̥erent CE. The term 
“neuroenhancement” did not appear in our survey either, in an 
attempt to keep the inﬂ uence of the many media-driven per-
spectives as low as possible. Such careful use of neutral terms 
could have been confusing or misleading for participants who 
may have noticed that the term “neuroenhancement” was miss-
ing. However, we believe that the exclusion of this term had a 
greater beneﬁ t on the quality of our data than the negative e  ̥ect 
of possibly misleading some participants. None of the 146 com-
ments received from the participants refer to them expecting to 
have seen the term “neuroenhancement”.
 Study participants were assured at the very beginning of the 
survey that their anonymity would be guaranteed. Also, at the 
start, participants were given more general questions before 
being gradually and successively guided toward more sensitive 
questions about CE-use.
 To keep the number of drop-outs as small as possible, many ﬁ l-
ters were used that allowed us to tailor subsequent questions 
based on previous answers. Another way to further decrease 
drop-outs could have been to use a paper-and-pencil survey in 
lectures, which generally leads to a higher response rate  [ 22 ] . 
However, we decided to conduct an online survey, and to there-
fore rely on participants’ intrinsic motivation rather than the 
pressure of ﬁ lling out a paper questionnaire while being 
observed. For the same reason, no incentives were o  ̥ered. In 
this way, we hope to have kept the rate of false answers as low as 
possible for this type of study design.
 The reliability and validity of each question was not tested in a 
previous methodological study due to the time frame of this 
work. We tried to increase the validity of the data through a 
 Table 6  Reasons for the use of CE. 
 What are/could be reasons for you to take Ritalin, Adderall and/or Modasomil? 
Please evaluate each statement INDEPENDENTLY of how you feel about the consumption of these products overall. 
 CE users (n = 106); CE non-users (n = 1 665)  I agree  I don’t agree  I don’t know p-value*
 I could ﬁ nish much of my work in less time and would therefore have more free 
time and less stress. 
 64.2  35.6  34.9  54.3  0.9  9.8  0.000 
 I could learn more quickly by using these products and perhaps understand 
things that I did not understand before. 
 59.4  38.9  35.8  51.7  4.7  9.3  0.000 
 I could regain lost mental vigour, because sometimes I don’t feel as ﬁ t mentally 
as I did previously. 
 44.3  22.9  49.1  65.3  6.6  11.5  0.000 
 I could achieve more and better results and would progress more quickly in life. 
I would earn more money and live a more comfortable life. 
 38.7  21.1  50.9  68.9  10.4  9.8  0.000 
 I could gain more acceptance and respect because of a higher level of achieve-
ment attained by using such products. 
 22.6  13.1  67.0  78.7  10.4  7.9  0.010 
 These products could act as some sort of prevention. If my brain became ﬁ tter, 
I might su  ̥er less from forgetfulness and related problems once I’m old. 
 17.9  9.9  76.4  78.3  5.7  11.5  0.010 
 The answer categories were randomized. For each sentence, one answer category could be chosen. There were 3–4 missing values (0.2 %) for the CE non-users, and none for 
the CE users 
 *The p-value was calculated with a Ȉ 2 -test and the ‘I don’t know’ answers were treated as missing values 
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 pretest of the questionnaire, an attempt to neutrally phrase the 
questions, the usage of established and well tested questions 
whenever possible (some about the demographic data and the 
self-assessment of the risk-behaviour) and di  ̥erent tools like 
plausibility checks and ﬁ lters that were applied to the survey.
 Understanding the characteristics and motivations of CE users is 
key to formulating an appropriate public health response. One 
ﬁ nding from this survey that might be important with a view to 
potential future regulation, was that more than half of the CE 
users received the product(s) from friends or colleagues, and 
only a little less than a quarter of the students from a physician. 
Another insight gained from this survey is that the ranking of 
reasons for, and concerns about, CE given by both of CE users and 
CE non-users was similar; however, unsurprisingly, possible rea-
sons for CE use are more frequently a  ̦ rmed by users, and pos-
sible concerns about CE use more often by non-users.
 We hope that these data about attitudes toward CE use, together 
with existing empirical data, will lead to a more balanced media 
presentation of CE use, and a better informed public debate. The 
ﬁ ndings from this survey can lead to a better understanding of 
why some students are already taking such products and can 
also add to the discussion on social norms and values in the con-
text of legalizing or prohibiting such products.
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2.3 Results of each Question
This section includes the analyses of each question of the survey among students and
will give a detailed picture of the sample as well as of the two subgroups of CE-users
and -nonusers. The questionnaire is included in the Appendix A (p. 117).
2.3.1 Part One - Demographic Data
In absolute numbers was the most chosen major subject human medicine (n=275), fol-
lowed by psychology (n=192) and law (n=158). When calculated in relation to the ab-
solute numbers of each major subject in the spring semester 2011, the subjects with the
highest percentage numbers were German language and literature, major in language
and linguistics (28.6%, n=6), biochemistry (26.6%, n=17) and earth sciences (26.1%,
n=6). The range of these values lies between 3.0% and 28.6% with an average value
of 11.0%. When focusing on major subject with more than 100 students in total, cul-
tural anthropology (23.5%, n=81) is followed by chemistry (20.1%, n=30) and human
medicine (19.1%, n=275) are the most represented subjects. Analysed by the education
level, 86.8% of the participants are Bachelor- and Master students and 12.1% are Ph.D.
students with a total of 1933 students.
What is the highest finished education of your…? 
(n=1912) Mother Father 
Primary school  49 (2.6%) 34 (1.8%) 
Secondary school  102 (5.3%) 60 (3.1%) 
Apprenticeship 701 (36.7%) 600 (31.4%) 
Apprenticeship with special academic courses 154 (8.1%) 112 (5.9%) 
'Gymnasium'*(High/School)* 221 (11.6%) 83 (4.3%) 
University / ETH 384 (20.1%) 762 (39.9%) 
Others:  274 (14.3%) 227 (11.9%) 
Unknown 23 (1.2%) 28 (1.5%) 
 
Figure 2.2.: The answer categories were not randomized. Only single answers were possible. For the
question about the mother’s education, four missing values exist (0.2%) and for the question
about the father, missing values are 6 (0.3%).
As seen in figure 2.2, the most common finished education of the mother was an
apprenticeship (36.7%), followed by a degree from the University or ETH (20.1%). For
the father, the order of these two is vice versa, 39.9% have a degree from the University
or the ETH and 31.4% finished an apprenticeship.
The following question revealed that 9.0% (n=170) of the participants are actively
involved in the student union or other organizations of the University of Zurich and
5.3% (n=100) of the students are members in fraternities.
As seen in figure 2.3, the most common range of the average mark of all modules at
the University was ‘5.0-.5.4’. Due to the assumption that these values differ in relation
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In which range lays your approximate average mark of all the so far attended modules of your major subject? 
 All (n=1883) 
2.5-2.9 1 (0.1%) 
3.0-3.4 8 (0.4%) 
3.5-3.9 25 (1.3%) 
4.0-4.4 219 (11.6%) 
4.5-4.9 470 (25.0%) 
5.0-5.4 546 (29.0%) 
5.5-6.0 252 (13.4%) 
Difficult to say, because the majority of my modules of the major subject are graded with 
‘passed’ / ‘not passed’. 
349 (18.5%) 
 
Figure 2.3.: The answer categories were not randomized. Only single answers were possible. 13 partici-
pants did not answer this question and are therefore missing values (0.7%).
to the faculty, the answers were split according to the major subject. The highest
percentage value for the answer ‘5.0-5.4’ was found for the faculty of theology, the faculty
of economics, business administration and information technology and the faculty of
arts. The most common answer for the other faculties, which are the faculty of law, of
medicine, of science and the Vetsuisse-faculty, was ‘4.5-4.9’.
For being able to calculate if the housing type has an influence on the possible use
of Ritalin R©, Adderall R©or Modasomil R©for CE, the participants where asked where they
live (Figure 2.4).
Where do you live? 
 All (n=1878) 
With my parents / my parent. 697 (37.1%) 
In a shared flat. 495 (26.3%) 
As a couple in a flat, in a house. 324 (17.3%) 
By myself in a flat. 219 (11.7%) 
As a couple with children in a flat, in a house. 91 (4.8%) 
In a student house. 24 (1.3%) 
In:  30 (1.6%) 
 
Figure 2.4.: The answer categories one to six were randomized. Only single answers were possible. There
are no missing values.
Most of the participants live at their parent’s place (37.1%) and 26.3% of these students
in a shared flat (nTotal=1878). The following question was asking about the political view
of the participants (Figure 2.5).
The distribution of the political view is wide, with the highest value for the social
democratic party (28.6%) followed by the green liberal and the green party (13.4%;
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If there would be national council voting next Sunday, to which party would you mainly give your vote? (Independent if you 
are entitled to vote or not) 
 All (n=1878) 
Social democratic party (SP) 537 (28.6%) 
Green liberal party (GLP) 251 (13.4%) 
Green party (GPS) 240 (12.8%) 
Liberal party (FDP) 186 (9.9%) 
Conservative party (SVP) 126 (6.7%) 
Christian democratic party (CVP) 85 (4.5%) 
Others 99 (5.3%) 
None (not enough overlap, absence of knowledge or politically uninterested) 352 (18.7%) 
 
Figure 2.5.: The answer categories one to six were randomized. Only single answers were possible. There
are two missing values (0.1%).
12.8%). 18.7% of the participants choose the category ’none’ because of the reasons seen
in figure 2.5. The following question of the first part of the questionnaire was about
religion (Figure 2.6).
Which confession respectively religion do you belong to? 
 All (n=1875) 
Evangelic Reformed church 628 (33.5%) 
Roman Catholic church 570 (30.4%) 
Other Christian churches or communities 69 (3.7%) 
Jewish denomination 14 (0.7%) 
Islamic denomination 28 (1.5%) 
Other churches or communities 23 (1.2%) 
No affiliation 543 (29.0%) 
 
Very 
important 
Important 
Rather not 
important 
Not important 
How important is religion for you in your daily life? 88 (4.7%) 198 (10.6%) 514 (27.4%) 1071 (57.1%) 
 
Figure 2.6.: The answer categories were not randomized. The order of the answer was the frequency in
Switzerland. Only single answers were possible. There are no missing values for the first
question and four missing values for the second question (0.2%).
Around one third of the participants each are part of the evangelic reformed church
respectively Roman Catholics. A bit less than 1/3 are not part of any Church and for
more than half of the participants is religion not important in their daily life. When
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How much money in total do you have at present for your disposal (contributions from your parents or other family 
members, own earning, scholarship, leans, etc.)? 
 All (n=1857) 
0-999 Fr. 605 (32.6%) 
1000-1999 Fr. 580 (31.2%) 
2000-2999 Fr. 263 (14.2%) 
3000-3999 Fr. 163 (8.8%) 
4000-4999 Fr. 62 (3.3%) 
5000 Fr. or more 113 (6.1%) 
Not specified 71 (3.8%) 
 
Figure 2.7.: The answer categories were not randomized. Only single answers were possible. There are
no missing values.
divided according to the different religion, the highest absolute and percentage value of
‘very important’ was found for ‘other Christian churches or communities’ (n=30, 43.5%).
The last demographic questions were about money; in detail about how much money
the participants has for his or her own use per month figure 2.7) and how their family
income is related to the average pre-tax household income (Figure 2.8). Around 1/3 of
the participants each have 0-999 Swiss francs respectively 1000-1999 Swiss francs per
month for their own use. In figure 2.8 are the answers to the question, how much their
parents earn in comparison with the monthly pre-tax household income of 9150 Swiss
francs.
The average monthly pre-tax household income amounts to ∼9150.- Fr. In 2008 in Switzerland. How is the pre-tax household 
income of your parental home in relation to that (income of the parents or a parent due to work, income on investments, 
social contributions, alimony, renting, etc.)? 
 All (n=1857) 
Below average 398 (21.4%) 
At average 508 (27.4%) 
Above average 597 (32.1%) 
Far above average 73 (3.9%) 
I cannot answer that question reasonable.  278 (15.0%) 
 
Figure 2.8.: The answer categories were not randomized. Only single answers were possible. There are
three missing values (0.2%).
When combining the question about money with the question about the housing situ-
ation, one can see that most of the students, who have 0-999 sFr per month for their own
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Which, if any, of the following products did you consume in the last 12 months to increase the concentration and/or 
alertness? 
 All (n=1850) 
Coffee 1282 (69.3%) 
Coca Cola 740 (40.0%) 
Red Bull 653 (35.3%) 
Grape sugar (e.g. Dextro Energen) 641 (34.6%) 
Black tea 520 (28.1%) 
Cigarettes  252 (13.6%) 
Guaranà (as pills, as add-ons in beverages or chewing gums, etc.) 215 (11.6%) 
Khat 2 (0.1%) 
I did not consume any of these products for increasing the concentration and/or alertness in the 
last 12 months. 
206 (11.1%) 
 
Figure 2.9.: The answer categories one to eight were randomized. More than one of the answer categories
one to eight could be chosen. If the last category was chosen, no other answer were next
to it selectable. There are no missing values and the median is the choosing of two answers
(n=500). The median in this and all the following tables is calculated without the answers
for which, if selected, no other answer were allowed to choose.
use, live at their parents’ place (75.7% of all the students, who have 0-999 sFr and 66.4%
of all the students, who live at their parents’ place). The students who have ‘between
1000-2000 sFr. per month for their own disposal live most often in a shared flat and
the ones having 3000-4000 sFr. as a couple in a flat or in a house. The last category
‘5000 sFr or more’ is the most common answer of the students who life as a couple with
children in a flat or in a house.
2.3.2 Part Two - Attitudes towards CE
The first two questions of part two were about different products and activities that
could be taken for CE. As seen in figure 2.9, most of the students are drinking coffee to
increase their concentration and/or alertness. Of these coffee-drinkers have a bit more
than 10% also used Guarana`.The most common activity to increase concentration and/or
alertness while studying was learning pauses (79.2%, figure 2.10). Of the 303 participants
who chose the category ‘others/furthers’ the most common entry was napping or similar
expressions.
Figure 2.11 shows in detail of which products the students know of that they could
be used as CE. As seen in the Appendix A.1 about the structure of the questionnaire
among student, the question presented in figure 2.12 was the filter question to separate
the CE-users from the CE-non-users from each other. The students were asked if they
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What do you do to increase the concentration and/or alertness while learning or studying? (Multiple answers possible) 
 All (n=1850) 
Learning pauses 1466 (79.2%) 
Sport  975 (52.7%) 
Walks 734 (39.7%) 
Stretching 224 (12.1%) 
Yoga 132 (7.1%) 
Autogenic training 65 (3.5%) 
Others/furthers:  303 (16.4%) 
No specific activities. 159 (8.6%) 
 
Figure 2.10.: The answer categories one to six were randomized. More than one of the answer categories
one to seven could be chosen. If the last category was chosen, no other answer were next
to it selectable. There is one missing values and the median is the choosing of two answers
(n=687).
From which of the following products or group of product do you know that it can be taken by healthy people to increase the 
concentration or alertness? (Multiple answers possible) 
 
All 
(n=1841) 
CE-users 
(n=114) 
CE-nonusers 
(n=1722) 
p-vaule 
Ritalin 1364 (74.1%) 106 (93.0%) 1253 (72.8%) .000 
Concerta, Focalin, Equasym, 
Medikinet, Daytrana, Metadate 
168 (9.1%) 39 (34.2%) 128 (7.4%) .000 
Provigil, Vigil, Modafinil 120 (6.5%) 23 (20.2%) 97 (5.6%) .000 
Modasomil 72 (3.9%) 19 (16.7%) 52 (3.0%) .000+ 
Adderall 52 (2.8%) 15 (13.2%) 36 (2.1%) .000+ 
From none of these products 470 (25.5%) 7 (6.1%) 463 (26.9%) .000 
 
Figure 2.11.: The answer categories one two five were randomized and more than one category could be
chosen from the first five answers. If the last category was chosen, no other answer were
next to it selectable. There are two missing values and the median is the choosing of one
answer (n=1100, without the 470 persons who haven choosen the last category). + If at
least one of the expected values was below 5, a Fisher’s exact test was completed.
have ever taken one of the following products at least once in their life (Figure 2.12).
Ritalin R©, Adderall R©and/or Modasomil R©have been taken at least once by 164 persons
of this sample (=1840-1676). These 164 students where than asked, for what they have
taken Ritalin R©, Adderall R©and/or Modasomil R©(Figure 2.13). For each product appeared
a separate question according to their answers given in 2.12. The other 1676 students
were led to the first question for the CE-non-users (Figure 2.23).
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Have you ever taken one of the following products at least once in your life? Ritalin and Modasomil stand here and in all the 
following questions ALWAYS also for the products in the brackets. (Multiple answers possible) 
 
All 
(n=1840) 
Ritalin (=Concerta, Daytrana, Metadate, Equasym, Medikinet) 159 (8.6%) 
Adderall 4 (0.2%) 
Modasomil (=Provigil, Vigil, Modafinil) 15 (0.8%) 
No, I have never taken one of these three products.  1676 (91.1%) 
 
Figure 2.12.: The answer categories were not randomized. More than one of the answer categories
RitalinR©, AdderallR©, and ModasomilR©could be chosen. If the last category was chosen,
no other answer were next to it selectable. There are no missing values (which would
also not be possible, because this was one of the four questions which was mandatory for
all participants). The median is one answer (n=152 without the 1676 persons who haven
chosen the negative answer).
Of the 164 students who saw the question in figure 2.13, 46 were led to the ques-
tions of the CE-non-users because they answered that they have used these products
only for the treatment of an illness (45 have taken Ritalin R©and one person has taken
Ritalin R©and Modasomil R©). Four persons stopped filling out the questionnaire. There-
fore, 114 persons used Ritalin R©, Adderall R©and/or Modasomil R©at least once in their
life for increasing concentration and/or alertness as a healthy person (6.2%; n Total:
1835, (164-46-4). The term ’Ritalin R©’, ’Adderall R©’ and ’Modasomil R©’ were defined as
standing also for the other products mentioned in the question of figure 2.12.
Nine students of the 114 CE-users tried already two of these three products (R+A=1,
R+M=7, A+M=1) and two persons have used all three products. The other 103 persons
used most often Ritalin R©(n=99). Four persons took only Modasomil R©and no one took
only Adderall R©.
The 21 students, who have chosen the third answer category in figure 2.13 and all
the students, who would have taken one product as a treatment and another for CE (as
seen was no one), saw the information: ‘In the following questions I ask you to consider
ONLY the consumption for increasing concentration or alertness. Therefore please do
NOT take the the use of such a product to treat an illness into account. Thank you!’
The ten questions for the CE-users
The first of the ten questions for the CE-users was about possible recommendations
for the consumption of Ritalin R©, Adderall R©and/ or Modasomil R©(Figure 2.14). Most
of the 78 persons (68.4%) having received an advice got it from colleagues, friends and
acquaintances.
Most of the students have taken Ritalin R©, Adderall R©and/or Modasomil R©in the prepa-
ration time before an exam (Figure 2.15). 67 students have chosen one answer category,
33 participants two answers and three students have clicked on all three answers. The
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For what did you take Ritalin? …Adderall? …Modasomil? 
 
Ritalin 
(n=159) 
Adderall 
(n=4) 
Modasomil 
(n=15) 
For the treatment of ADHS* or another illness, which 
was diagnosed for me.  
46 (28.9%) 0 (0.0%) 1 (6.7%) 
To increase the concentration WITHOUT that ADHS* 
was diagnosed by a physician.  
88 (55.3%) 4 (100.0%) 14 (93.3%) 
Both. To treat an illness and to increase the concentration 
as a healthy person. 
21 (13.2%) 0 (0.0%) 0 (0.0%) 
 
Figure 2.13.: *For ModasomilR©, Narcolepsy was written instead of ADHS. The answer categories were
not randomized. Only single answers were possible. Four students stopped filling out the
questionnaire after answering that they have taken RitalinR©(Figure 2.11). There are no
missing values.
Was the consummation of Ritalin, Adderall and/or Modasomil advised by someone? (Multiple answers possible) 
 CE-users (n=114) 
Yes, by colleagues, friends or acquaintances. 52 (45.6%) 
Yes, by other students. 25 (21.9%) 
Yes, by my physician.  14 (12.3%) 
Yes, by someone of my family.  4 (3.5%) 
Yes, by someone other/further, namely: 4 (3.5%) 
No, by no one.  36 (31.6%) 
 
Figure 2.14.: The answer categories one to four were randomized. More than one of the answer categories
one to five could be chosen. If the last category was chosen, no other answer were next to
it selectable. There are no missing values and the median is one answer (n=58; without
the 36 persons who chose the exclusive answer ‘No, by no one’).
35 students who have chosen the answer ‘In an other/further situation, namely’ have
most often written that they were taking it as a party drug (n=13). Three students
have taken it for working and 10 students for finishing the licentiate or for studying in
general. Six students have taken it out of curiosity and two people, who have chosen
also other categories in this answer, for treating side effects of a medication. One person
did not specify his or her use.
Taken together, 87 students have taken it in preparation of an exam or/and in an exam,
or chose only the semi-open answer and wrote about the use for studying purposes. In
relation to the sample of our survey, this means that 4.7% of all the participants have
used Ritalin R©, Adderall R©and/or Modasomil R©in the preparation time of an exam or in
an exam (of which 25 students have taken it in both circumstances).
In figure 2.16, 20 students have chosen one out of 10 answers why they have taken
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When did you take Ritalin, Adderall and/or Modasomil? (Multiple answers possible) 
 CE-users (n=114) 
In the preparation time before an exam. 76 (66.7%) 
In an exam. 31 (27.2%) 
In an other/further situation, namely: 35 (30.7%) 
In no specific situation. 11 (9.6%) 
 
Figure 2.15.: The answer categories were not randomized. More than one of the answer categories one
to three could be chosen. If the last category was chosen, no other answer were next to it
selectable. There are no missing values and the median is one answer (n=67; without the
11 persons who chose the exclusive answer ‘No, by no one’).
Why did you take Ritalin, Adderall and/or Modasomil? (Multiple answers possible) 
 CE-users (n=114) 
To be more concentrated. 85 (74.6%) 
Out of curiosity as to how it takes effect. 66 (57.9%) 
To be more awake. 62 (54.4%) 
Because I did not have enough time. 30 (26.3%) 
To receive better grades. 27 (23.7%) 
Because I am stressed. 22 (19.3%) 
To get into the mood, e.g. at a party. 16 (14.0%) 
Because others did it as well. 7 (6.1%) 
To decrease jet lag. 3 (2.6%) 
For another or additional reason, namely… 7 (6.1%) 
 
Figure 2.16.: The answer categories one to nine were randomized. More than one of the answer categories
could be chosen. There are no missing values and the median is three answers (n=31).
CE. The other 94 students have clicked on two to seven answer categories. Of the seven
students who clicked on the last category, four of them have only taken Ritalin R©and
wrote: ‘for a better sleep’, ‘I have since my childhood trouble to focus, but no diagnose of
ADHD’ and ‘increasing of performance sport’. One did not write anything. The students
who have given the first two answers clicked also on the item: ‘To be more concentrated’.
One person who took Ritalin R©and Modasomil R©wrote: ‘excessive demand’ and did not
clicked on any of the closed items. The seventh person of the ones chosen the semi-
open answer has taken Ritalin R©and Adderall R©and wrote: ‘exam anxiety reduction’ in
combination with the closed item ‘to be more concentrated’.
Two questions about the frequency of the use of Ritalin R©, Adderall R©and/or Moda-
somil R©are presented in figure 2.17. The two numbers each stand for the absolute number
of students respectively after applying a filter according to the answers given in the key
question in 2.12. Three differences between these numbers were seen. One student was
saying that she has never taken Ritalin R©, even though she was answering in a previ-
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How often in your life have you taken Ritalin, Adderall and/or Modasomil ONLY for increasing the concentration or the 
alertness?  
CE-users (n=113) Ritalin Adderall Modasomil 
Never before. 5 / 1 100 / 0 91 / 0 
Once in my life. 26 / 25 2 / 2 4 / 3 
Two- to five times in my life. 34 / 34 1 / 1 5 / 5 
More than five times in my life. 48 / 48 1 / 1 5 / 5 
When have you taken Ritalin, Adderall or Modasomil? Please do NOT take a possible consummation for treating an 
Illness in account, like f.e.ADHS or Narcolepsy.  (n=107, n=12; n=21) 
NOT taken in the last 12 months.  38 / 37 8 / 3 9 / 5 
NOT taken in the last 30 days. 44 / 44 0 / 0 5 / 4 
Taken in the last 30 days. 25 / 25 1 / 1 4 / 4 
 
Figure 2.17.: The answer categories were not randomized. Only single answers were possible. The first
numbers stand for the absolute numbers of people who gave these answers and the second
numbers stand for n, when a filter was used taking only these students in account, who
have answered in the question about why they took one of these products with ‘for CE’
or ‘for both, treatment and CE’. Missing values for the first question are for R=0, A=9,
M=8. For the second question: R=0, A=3, M=3.
When ‘never before’ was answered in the first question, the second question was not seen
for this CE. But the students who did not fill out the first question (=missing values)
did see the second question for all three CEs. These students are the explanation of the
additional numbers for AdderallR©and ModasomilR©in the first row of ‘NOT taken in the
last 12 months’. Two students stopped filling out the questionnaire after the first question
in figure 2.17.
ous question (Figure 2.12) that she has taken Ritalin R©, next to Modasomil R©, for CE.
Another person was answering that she has taken Ritalin R©once in her life, even though
she was choosing ‘never before’ for Ritalin R©in the question of figure 2.12 and saw the
questions for users only because she was declaring that she has taken Modasomil R©for
CE in figure 2.12. This person was answering in the second question about frequency
that she has NOT taken it in the last 12 months. For Modasomil R©, one person answered
in the key question that he has only taken Ritalin R©, but answered in the question about
the frequency that he was taken Modasomil R©once, but not in the last 30 days. These
changes in the responses of these three students do not have a great impact on our data
because we mainly focused on the number of students having taken CE at least once in
their life. All these three students are included when focusing on their answers given in
figure 2.12 as well as when focusing on the data in figure 2.17.
Most of the students received the product from colleagues, friends or acquaintances
(Figure 2.18). The two comments were for Ritalin: ‘From a home where I worked, there
existed redundant boxes’ and one student wrote for Ritalin R©and Modasomil R©: ‘stayed
abroad’. Differences between the value of the absolute numbers and when linked to
the key question in figure 2.12 was seen for Ritalin R©and for Modasomil R©each (from
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Where did you get the product in question? (Multiple answers possible) 
 
Ritalin 
(n=106/ n=105) 
Adderall 
(n=12/ n=4) 
Modasomil 
(n=21/ n=13) 
From colleagues, friends or acquaintances.  59 / 58 2 / 2 6 / 5 
From a physician. 25 / 25  1 / 1 5 / 5 
From someone in my family. 14 / 14 0 / 0 0 / 0 
In a pharmacy. 12 / 12  0 / 0 1 / 1 
Via the Internet. 5 / 5 1 / 1 2 / 2 
Via another route, namely… 7 / 7 1 / 0 2 / 2 
 
Figure 2.18.: The answer categories one to five were randomized. More than one answer category could
be chosen. The question was presented one to three times depending on the answers for
the first question about the frequency The first numbers stand for the absolute numbers
of people who gave these answers and the second numbers stand for n, when a filter was
used taking only these students in account, who have answered in the question about why
they took one of these products with ‘for CE’ or ‘for both, treatment and CE’. There is one
missing value for RitalinR©and seven missing values each for AdderallR©and ModasomilR©.
The median for RitalinR©and ModasomilR©is the choosing of one answer and for AdderallR©it
is cero answer.
colleagues, friends or acquaintances) and one for Adderall R©(open answer). The persons
who were responsible for these different numbers for Ritalin R©and Modasomil R©where
the same students as described previously. The person who chose the open question
for Adderall R©, even though he did not declare in the key question of having taken
Adderall R©ever was not giving an answer about the frequency (missing value in the first
question of figure 2.17). Therefore he is most probably a person who did not take
Adderall R©at all as declared in the key question in figure 2.12.
Most of the CE-users did not require a prescription (Figure 2.19). This is in line with
the fact that most of the CE-users received the product from friends. Almost all of the
students who have received the CE form friends have answered that they did not need
a prescription.
When asked how people reacted when telling about their use of CE, about half of
the students reported a neutral reaction (Figure 2.20). 18 persons have chosen more
than one answer and various combinations were given. The most common one was
approving and neutral (n=6), followed by neutral and diverse (n=4). The last two
questions specifically for the CE-users were about possible concerns of an excessive use of
Ritalin, Adderall R©and Modasomil R©and the student’s understanding of excessive (Figure
2.21 and figure 2.22). The choice of these categories is explained in the method section
of the publication. Highest agreement was found for the statement about possible side
effects, followed by the one about the pressure to achieve more and about the unnatural
interference. The concerns, where most of the students did not agree to, was about God,
followed by the concern about betraying other people and about pride. The highest
value of ‘I don’t know’ was seen for the concerns about bad effects on the society and
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Did you require a prescription for the supply of the product? If yes, from where did you have it? (Multiple answers possible) 
 
Ritalin 
(n=104) 
Adderall 
(n=12) 
Modasomil 
(n=21) 
No, I did not require a prescription. 77 / 76 4 / 3 11 / 10 
Yes I did require a prescription. I received 
it from a physician.  
23 / 23 1 / 1 3 / 3 
Yes I did require a prescription. I filled it 
out by myself.  
0 / 0 0 / 0 0 / 0 
Yes I did require a prescription. I received 
it from some other non-physician.  
4 / 4 0 / 0 0 / 0 
 
Figure 2.19.: The answer categories were not randomized. More than one answer category could be
chosen. If the negative answer was chosen, no other answer was possible. The question
was presented one to three times depending on the answers for the first question about
the frequency. The first numbers stand for the absolute numbers of people who gave these
answers and the second numbers stand for n, when a filter was used taking only these
students in account, who have answered in the question about why they took one of these
products with ‘for CE’ or ‘for both, treatment and CE’. There are no missing values for
RitalinR©and seven missing values each for AdderallR©and ModasomilR©. The median for
AdderallR©and ModasomilR©is the choosing of cero answer and the median for RitalinR©is
one answer (n=27, without the 77 persons who chose the negative answer). No multiple
answers were observed.
Have you told at least one person about your consummation of Ritalin, Adderall and/or Modasomil? If yes, how were the 
reactions all in all? (Multiple answers possible) 
 CE-users (n=109) 
Yes I have told it and the reaction was approving about my action. 26 (23.9%) 
Yes I have told it and the reaction was neutral about my action. 51 (46.8%) 
Yes I have told it and the reaction was dismissive about my action. 14 (12.8%) 
Yes I have told it and the reaction was diverse about my action. 26 (23.9%) 
No, I have not told it anyone.  15 (13.8%) 
 
Figure 2.20.: The answer categories were not randomized. More than one answer category could be
chosen. If the first category was chosen, no other answer were next to it selectable. There
are no missing values and the median is the choosing of one answer (n=91).
about the gut feelings. This question was the most complex and therefore time intensive
one. Fortunately, only one person chose 10 times ‘I agree’, 3 persons have clicked ten
times on ‘I don’t agree’ and one person chose for every item ‘I don’t know’. Most of
the students who have taken Ritalin, Adderall R©or Modasomil R©for CE define a daily
consumption as excessive (Figure 2.22).
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Which of the following possible concerns, about EXCESSIVE use of Ritalin, Adderall and/or Modasomil to increase 
concentration or alertness do you agree with?  
CE-users (n=108) I agree 
I don't 
agree 
I don't 
know 
Worries about possible side effects. 69 (63.9%) 31 (28.7%) 8 (7.4%) 
The goal when taking these products is that one can achieve more. I find such 
pressure to achieve more questionable. 
64 (59.3%) 39 (36.1%) 5 (4.6%) 
These products represent an unnatural interference with our bodies. 60 (55.6%) 43 (39.8%) 5 (4.6%) 
There is a danger of becoming addicted. 56 (51.9%) 42 (38.9%) 10 (9.3%) 
If a lot of people do this, it could have bad effects on society. 52 (48.1%) 45 (41.7%) 11 (10.2%) 
My gut feeling tell me, that we should keep our hands off such products. 44 (40.7%) 53 (49.1%) 11 (10.2%) 
That I would change and not being myself anymore.  36 (33.3%) 66 (61.1%) 6 (5.6%) 
I could not be proud anymore about my own achievement.  20 (18.5%) 83 (76.9%) 5 (4.6%) 
I would somehow be betraying people, who do not use such products.   19 (17.6%) 83 (76.9%) 6 (5.6%) 
God created humans due to his plan. We should not try to improve upon this 
with such products.  
3 (2.8%) 95 (88.0%) 10 (9.3%) 
 
Figure 2.21.: The answer categories were randomized. For each sentence, one answer category could be
chosen. There are no missing values.
From when roughly would you call a consummation as excessive?  
 CE-users (n=108) 
Several consummations per day.  20 (18.5%) 
One consummation per day. 35 (32.4%) 
One consummation per week. 21 (19.4%) 
One consummation per two weeks. 8 (7.4%) 
One consummation per month. 8 (7.4%) 
One consummation per six months. 1 (0.9%) 
I cannot define it.  15 (13.9%) 
 
Figure 2.22.: The answer categories were not randomized. Only single answer were possible. There are
no missing values.
The six to seven questions for the CE-non-users
These questions were for all students, who have answered in the key question that they
have never taken Ritalin, Adderall R©or Modasomil R©or that they have taken it only for
treating the symptoms of a disease, which was diagnosed by a physician.
All the questions for the CE-users, which were not linked directly to a consumption of
products for CE were asked as well to the CE-non-users, often in a slightly different
formulation. These were the questions about an advised consumption (Figure 2.23),
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about concerns (Figure 2.25) and when the participants could imagine taking Ritalin,
Adderall R©or Modasomil R©(Figure 2.26). The last question is about the number of people
they have heard of and of people they know personally who have taken CE and was
compared to the question of the CE-users about the reaction in the publication in section
2.2 (Figure 2.27 and figure 2.20).
Was the consummation of Ritalin, Adderall and/or Modasomil at least once advised to you? Please do NOT consider any 
advises for the treatment of an illness. If yes, of who? (Multiple answers possible) 
 CE-nonusers (n=1719) 
Yes, by colleagues, friends or acquaintances. 143 (8.3%) 
Yes, by other students. 130 (7.6%) 
Yes, by my physician.  19 (1.1%) 
Yes, by someone of my family.  16 (0.9%) 
Yes, by someone other/further, namely: 18 (1.0%) 
No, by no one.  1449 (84.3%) 
 
Figure 2.23.: The answer categories one to four were randomized. More than one of the answer categories
one to five could be chosen. If the last category was chosen, no other answer were next to
it selectable. There are no missing values and the median is the choosing of one answer
(n=217, without the 1449 person who have chosen the last category).
84.3% of the CE-non-users have never received an advice to consume Ritalin, Adderall R©
or Modasomil R©. When comparing these results with the answers of the CE-users in fig-
ure 2.14, one can see that more CE-users have received a recommendation for the use of
CE than the non-users (see section on hypotheses, number 18 (p. 64)).
The 270 students who received an advice to take at least on of these three products
where led to the following question about for what these products were suggested to take
(Figure 2.24). The answer categories in figure 2.24 are very similar to the one presented
in figure 2.16. Only the answer categories in figure 2.16 ‘out of curiosity how it takes
effect’ and ‘to get into the mood, e.g. at a party’ was not presented in this question as
a possible answer and the question was slightly different. A similar question as seen in
figure 2.16 was asked at a later stage to the CE-non-users (see figure 2.26).
As seen in figure 2.25, the concerns to which most of the CE-non-users agreed to was
the worries about possible side effects, followed by the concern about the gut feeling and
the pressure to achieve more. The concerns with the highest value of ‘I don’t know’ were
about the bad effects on society, followed by the concern about change of oneself and
about God. The answer categories were the same as in figure 2.21. The only difference
was the absence of the word ‘excessive’ in the question.
About 2/3 of the CE-non-users chose one of the two negative answers when asked if
they could imagine circumstances where they would take CE (Figure 2.26). The most
common positive answer was the one about curiosity of the effects (21.2%). Comments
written in the semi-open answer were often similar to the quote ‘If I have no other op-
tions to pass or to handle the work load’. The results of the comparison of the answers
50
Why respectively for what was Ritalin, Adderall and/or Modasomil advised to you? (Multiple answers possible) 
CE-nonusers, who received an advice (n=270) 
To be more concentrated. 213 (78.9%) 
To be more awake. 102 (37.8%) 
To receive better grades. 75 (27.8%) 
Because I did not have enough time. 50 (18.5%) 
Because others did it as well. 27 (10.0%) 
Because I am stressed. 23 (8.5%) 
As a pharmaceutical. 20 (7.4%) 
To decrease jet lag. 4 (1.5%) 
For an other or additional reason, namely… 30 (11.1%) 
 
Figure 2.24.: The answer categories one eight were randomized. More than one of the answer categories
could be chosen. There is one missing value and the median is the choosing of two answers
(n=93).
Which of the following possible concerns, about the use of Ritalin, Adderall and/or Modasomil to increase concentration or 
alertness do you agree with?  
CE-nonusers (n=1689) I agree I don't agree I don't know 
Worries about possible side effects. 1383 (81.9%) 188 (11.1%) 111 (6.6%) 
My gut feeling tell me, that we should keep our hands off such 
products. 
1287 (76.2%) 267 (15.8%) 131 (7.8%) 
The goal when taking these products is that one can achieve more. I 
find such pressure to achieve more questionable. 
1258 (74.5%) 295 (17.5%) 129 (7.6%) 
These products represent an unnatural interference with our bodies. 1234 (73.1%) 291 (17.2%) 157 (9.3%) 
There is a danger of becoming addicted. 1163 (68.9%) 308 (18.2%) 210 (12.4%) 
If a lot of people do this, it could have bad effects on society. 968 (57.3%) 367 (21.7%) 344 (20.4%) 
That I would change and not being myself anymore. 842 (49.9%) 537 (31.8%) 301 (17.8%) 
I could not be proud anymore about my own achievement. 716 (42.4%) 701 (41.5%) 265 (15.7%) 
I would somehow be betraying people, who do not use such products.    578 (34.2%) 856 (50.7%) 246 (14.6%) 
God created humans due to his plan. We should not try to improve 
upon this with such products. 
154 (9.1%) 1255 (74.3%) 270 (16.0%) 
 
Figure 2.25.: The answer categories were randomized. For each sentence, one answer category could be
chosen. Missing values do exist for this question and n lies between four and ten (0.2-0.6%).
of the CE-users with the CE-non-users are seen in the next section 2.4 on the hypothe-
ses (see number 19) and in the conclusion on p. 68. In the last question only for the
CE-non-users answered more than half of the participants have not heard of someone
who has taken Ritalin, Adderall R©or Modasomil R©and even more of them know someone
personally.
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Could you imagine taking Ritalin, Adderall or Modasomil under the following circumstances? (Multiple answers possible) 
 CE-nonusers (n=1686) 
Yes, because out of curiosity as to how it takes effect. 358 (21.2) 
Yes, to be more concentrated. 246 (14.6) 
Yes, to be more awake. 133 (7.9) 
Yes, if I did not have enough time. 122 (7.2) 
Yes, to receive better grades. 102 (6.0) 
Yes, If I am stressed. 83 (4.9) 
Yes, to get into the mood, e.g. at a party. 43 (2.6) 
Yes, to decrease jet lag. 38 (2.3) 
Yes if others do it as well. 22 (1.3) 
For an other or additional reason, namely… 50 (3.0) 
No, rather not. 583 (34.6) 
No, never. 577 (34.2) 
 
Figure 2.26.: The answer categories one to nine were randomized. More than one of the answer categories
could be chosen. When one of the two last answers was chosen, no other answer was possible.
The numbers in brackets are percentages. There is one missing value and the median is
the choosing of two answers (n=108).
The four to five questions about side effects and drug and alcohol use
The CE-users and the -nonusers were asked how they estimate the side effects, separately
for Ritalin, Adderall R©and Modasomil R©(Figure 2.28). If they did not chose the category
‘hard to say, because one does not know enough about it’ or ‘I do not know the product
well enough’ for all three product, they were let to the follow-up question about how
their opinion was established (Figure 2.29). Three-fourth or more of the students have
chosen this last answer for Adderall R©and Modasomil R©, where more of the CE-non-users
chose it compared to the CE-users. For Ritalin, more students have already made up
their mind about the side effects; 57.0% of the CE-non-users and 93.5% of the CE-users.
The opinion about the side effects was most often formed by the presentation of these
products in the media, followed by the reading of specialist literature (Figure 2.29).
The most common answers of the students who chose the semi-open answer were about
persons (mainly children) who are taking Ritalin R©against ADHD, self-experience or
education. For the CE-users, the answer about reading specialist literature is the first
one, followed by the one about conversations with friends who are taking it and the one
about media.
The data in figure 2.30 shows that more CE-users have experiences with these drugs.
The calculation of a χ 2-test showed that these differences are significant. The two most
common reasons for the use of drugs were significantly equally chosen when comparing
the CE-users and the CE-non-users (Figure 2.31). For the other items, more students
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Please consider in the following questions on this page only persons, who have taken Ritalin, Adderall or Modasomil 
exclusively for increasing the concentration or the alertness! This means, please do NOT consider persons, who took these 
products for the treatment of an illness. 
CE-nonusers (n=1684) 0 1-3 4-6 7-9 10 and more 
Of how many people have you heard of that 
they have taken in the last 12 months at 
least once Ritalin, Adderall or Modasomil? 
964 (57.2%) 611 (36.3%) 68 (4.0%) 12 (0.7%) 20 (1.2%) 
How many people have told you personally 
that they have taken in the last 12 months at 
least once Ritalin, Adderall or Modasomil? 
1228 (72.9%) 414 (24.6%) 27 (1.6%) 2 (0.1%) 4 (0.2%) 
 
Do you think it is right, if someone is taking Ritalin, Adderall or Modasomil without the diagnosis of an illness against 
which Ritalin, Adderall or Modasomil would be prescribed?                                                                     (n=1684) 
Yes, I think that is good. 15 (0.9%) 
No, I think this is not good.  1133 (67.3%) 
I cannot decide yet. 160 (9.5%) 
I do not care.  371 (22.0%) 
 
Figure 2.27.: The answer categories were not randomized and only one answer for each question was
selectable. Missing values are nine each for the first and the second question (0.5% each)
and five for the third question (0.3%).
How do you estimate the side effects of Ritalin, Adderall or Modasomil? 
 
Ritalin 
(n=108 / n=1683) 
Adderall 
(n=108 / n=1683) 
Modasomil 
(n=108 / n=1683) 
Not critical 16 (14.8) 38 (2.3) 2 (1.9) 10 (0.6) 4 (3.7) 12 (0.7) 
Rather not critical 38 (35.2) 199 (11.8) 2 (1.9) 28 (1.7) 8 (7.4) 34 (2.0) 
Rather critical 24 (22.2) 472 (28.0) 7 (6.5) 95 (5.6) 5 (4.6) 104 (6.2) 
Very critical 9 (8.3) 175 (10.4) 4 (3.7) 46 (2.7) 3 (2.8) 42 (2.5) 
Hard to say, because 
one does not know 
enough about it. 
14 (13.0) 74 (4.4) 3 (2.8) 37 (2.2) 5 (4.6) 38 (2.3) 
I do not know the 
product well enough.  
7 (6.5) 724 (43.0) 88 (81.5) 1465 (87.0) 81 (75.0) 1451 (86.2) 
 
Figure 2.28.: The answer categories were not randomized. Only single answers were possible. Missing
values are for Ritalin: 0 and 1 (0.1%); for AdderallR©: 2 (1.9%) and 2 (0.1%); and for
ModasomilR©: 2 (1.9%) and 2 (0.1%). The question was presented in the transformed
way, where the answer categories were the columns and the product names the rows. The
numbers in brackets are percentages.
having experiences with CE were choosing them except the answer category about if
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How was your opinion about the evaluation of the side effects formed? (Multiple answers possible) 
 CE-users CE-nonusers 
Through the presentation of these products in the media (print media, TV, internet) 32 (36.8) 343 (38.8) 
Through reading of specialist literature. 42 (48.3) 295 (33.4) 
In conversations with friends and acquaintance who do not take them.  12 (13.8) 251 (28.4) 
In conversations with trained persons (physicians, pharmacists, nursing staff) 22 (25.3) 215 (24.3) 
In conversations with friends and acquaintance who take them. 33 (37.9) 195 (22.1) 
Through nothing concretes, more my gut feelings. 11 (12.6) 144 (16.3) 
Through something else/further, namely: 15 (17.2) 106 (12.0) 
 
Figure 2.29.: The answer categories one to six were randomized. More than one of the answer categories
one to seven could be chosen. There is one missing value and the median is the choosing
of two answers (n=295). The numbers in brackets are percentages.
Have you one or multiple of the following substances at least once in your life consumed? (Multiple answers possible) 
 CE-users (n=108) CE-nonusers (n=1679) 
Cannabis 89 (82.4) 924 (55.0) 
Magic mushrooms 22 (20.4) 120 (7.1) 
Cocaine 33 (30.6) 96 (5.7) 
Ecstasy (=MDMA) 37 (34.3) 88 (5.2) 
Amphetamine (e.g. Speed) 29 (26.9) 60 (3.6) 
LSD  23 (21.3) 51 (3.0) 
Heroine 3 (2.8) 10 (0.6) 
Thai-pills 4 (3.7) 5 (0.3) 
Crack 3 (2.8) 6 (0.4) 
Others, furthers substances, namely:  10 (9.3) 58 (3.5) 
No, I have not ever consumed one of these substances. 16 (14.8) 731 (43.5) 
 
Figure 2.30.: The answer categories one to nine randomized. More than one of the answer categories
one to nine could be chosen. If the last category was chosen, no other answer were next to
it selectable. There are two missing values and the median is the choosing of one answer
(n=749; without the last category). The numbers in brackets are percentages.
others do it as well. The three persons of the CE-users who chose the answer ‘for
treating an illness’ did all use Ritalin R©as a treatment against an illness and as a CE
(one of these three persons did next to Ritalin R©also use Modasomil R©as a CE).
Most of the students reported that they drink alcohol 1-2 times per week (Figure 2.32).
No differences according the use of alcohol was found between CE-users and -nonusers
(see section 2.4 on the hypotheses, number 27).
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Why did you take one or multiple of the substances listed in the last question? (Multiple answers possible) 
nTotal=1787-(16+731)=1040 CE-users (n=92) CE-nonusers (n=948) 
Out of curiosity as to how it takes effect. 69 (75.0) 747 (78.8) 
Because I enjoy the feeling, that is caused by the drug. 52 (56.5) 393 (41.5) 
To get into the mood, e.g. at a party. 36 (39.1) 223 (23.5) 
Because others did it as well. 8 (8.7) 161 (17.0) 
To be more awake. 13 (14.1) 17 (1.8) 
To be more concentrated. 11 (12.0) 7 (0.7) 
To increase my achievement. 10 (10.9) 7 (0.7) 
For an other or additional reason, namely… 12 (13.0) 83 (8.8) 
For treating an illness. 3 (3.3) 12 (1.3) 
 
Figure 2.31.: The answer categories one to seven were randomized. More than one of the answer cate-
gories could be chosen. The numbers in brackets are percentages. There are two missing
values and the median is the choosing of one answer (n=529).
How often do you drink in general alcoholic beverages (beer, wine, champagne or high percentage alcohol)?  
 CE-users (n=108) CE-nonusers (n=1678) 
3 times or more per day. 0 4 (0.2) 
1-2 times per day (e.g. in each case before meals) 2 (1.9) 23 (1.4) 
3 times or more than three times per week. 22 (20.4) 247 (14.7) 
1-2 times per week. 48 (44.4) 627 (37.4) 
1-3 times per month. 23 (21.3) 470 (28.0) 
Less than monthly. 10 (9.3) 205 (12.2) 
Never, abstinent. 3 (2.8) 102 (6.1) 
 
Figure 2.32.: The answer categories were not randomized. Only one answer category could be chosen.
The numbers in brackets are percentages. There are no missing values.
2.3.3 Part Three - Personal Attitudes
In this section, the students were asked about their personal attitudes. The first three
questions were about a case study (Figures 2.33, 2.34 and 2.35).
Most of the students do not agree to both case studies, where more students think
the case study with Ritalin R©is fine for them (see hypothesis number 28.b). More of the
CE-users chose in each of the cases ‘that is fine for me’ when compared to the CE-non-
users (see hypothesis number 28.a). When applying the first case study to a 65 years old
person, more of the CE-users are fine with such a use of CE (Figure 2.34; see hypothesis
number 29.a). About half of the CE-users and even more of the CE-non-users think that
the use of CE by the 25 years person is not the same compared to the one by the 65 years
old person. Significantly more of the CE-users compared to the -nonusers answered with
yes (see hypothesis number 29.b).
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Please imaging a healthy 25 years old person. You are friends with that person and you are studying together. How would 
you react, when this person tells you, that he or she is taking… 
All (n=1783) 
That is fine 
for me. 
That is NOT 
fine for me. 
Neutral, that is 
his, her business.  
I don’t know how I 
would react. 
… Ritalin to increase the concentration. 58 (3.3%) 822 (46.1%) 736 (41.3%) 167 (9.4%) 
…Anabolics to increase the muscle size.  21 (1.2%) 1058 (59.3%) 593 (33.3%) 111 (6.2%) 
 
Figure 2.33.: The answer categories were not randomized. Only single answers for each row were possible.
There are no missing values. Underneath this question was a field for explanatory notes.
Please imaging a healthy 65 years old person, who is taking a product against the normal, age related intellectual degradation. 
What do you think of that?  
 
 
CE-users (n=108) CE-nonusers (n=1671) 
That is fine for me. 72 (66.7) 602 (36.0) 
That is NOT fine for me. 2 (1.9) 198 (11.8) 
Neutral, that is his, her business. 32 (29.6) 619 (37.0) 
I don’t know how I would react. 2 (1.9) 251 (15.0) 
 
Figure 2.34.: The answer categories were not randomized. Only one answer category could be chosen.
The numbers in brackets are percentages. There is one missing value for the CE-non-users
(0.1%).
The question about normality seen in figure 2.36 revealed that more of the CE-users
think that an intake of CE will be normal in ten years time (see hypothesis number 30).
The following question asked about their appraisal of the use of coffee or Ritalin R©before
an exam. These two questions were presented at the same time and therefore have to be
interpreted together (Figure 2.37). As expected, more of the CE-users do think the use
of Ritalin R©before an exam is acceptable (see hypothesis number 31.a). In general, more
of the students think that the intake of coffee is acceptable than the one of Ritalin R©(see
hypothesis number 31.b).
The following question is the complement question to the one in figure 2.21 respec-
tively in figure 2.25 about possible concerns of an (excessive) use of CE (Figure 2.38).
The choice of these categories is explained in the methods.
The highest percentage of agreement was found for the reasons: ‘I could learn quicker’
followed by ‘I could thereby finish much of my work in less time’ for the CE-non-users.
For the CE-users these two items were also the top ones but in the opposite order. The
differences in the percentage of agreement between the CE-users and the CE-non-users
are significant for all six categories (see hypothesis number 35.b). Next to that, the
CE-users chose more often the answer ‘I agree’ than the CE-non-users (see hypothesis
number 35.a).
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Do you find the consummation of a healthy, 65 years old person due to the reason mentioned above the same as when a 
healthy 25 years old person takes the same product for increasing the concentration?  
 Yes No Undecided 
CE-users (n=108) 39 (36.1) 56 (51.9) 13 (12.0) 
CE-nonusers (1671) 369 (22.1) 1012 (60.6) 289 (17.3) 
All (n=1779) 408 (22.9) 1068 (60.0) 302 (17.0) 
 
Figure 2.35.: The answer categories were not randomized. Only one answer category could be chosen.
The numbers in brackets are percentages. There is one missing value for the CE-non-users
(0.1%). Underneath this question was a field for explanatory notes.
Du you think that it will be normal in 10 years to take products like Ritalin, Adderall or Modasomil for increasing 
productivity?  
 Yes No Undecided 
CE-users (n=108) 34 (31.5) 44 (40.7) 30 (27.8) 
CE-nonusers (n=1671) 308 (18.4) 1008 (60.3) 354 (21.2) 
All (n=1779) 342 (19.2) 1052 (59.1) 384 (21.6) 
 
Figure 2.36.: The answer categories were not randomized. Only one answer category could be chosen.
The numbers in brackets are percentages. There is one missing value for the CE-non-users
(0.1%).
Do you think it is acceptable if someone is taking coffee before an exam to increase his/her alertness and/or concentration? 
 Yes No Undecided 
CE-users (n=108) 105 (97.2) 2 (1.9) 1 (0.9) 
CE-nonusers (n=1670) 1617 (96.8) 8 (0.5) 44 (2.6) 
All (n=1778) 1722 (96.9) 10 (0.6) 45 (2.5) 
Do you think it is acceptable if someone is taking Ritalin before an exam to increase his/her alertness and/or concentration? 
 Yes No Undecided 
CE-users (n=108) 63 (58.3) 21 (19.4) 24 (22.2) 
CE-nonusers (n=1670) 271 (16.2) 1011 (60.5) 387 (23.2) 
All (n=1778) 334 (18.8) 1032 (58.0) 411 (23.1) 
 
Figure 2.37.: The answer categories were not randomized. Only one answer category for each question
could be chosen. The numbers in brackets are in percentage. There is one missing value
for both questions for the CE-non-users (0.1% each).
The frequencies of the answers of the question about taking a CE or not if it is without
any side effects and for a finite number of time are presented in figure 2.39. More of the
CE-users would give it a try and also chose more often ‘most probably more than once’.
The CE-non-users chose more often the negative answer.
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What are/could be reasons for you, to take Ritalin, Adderall and/or Modasomil? 
Please evaluate each statement and INDEPENDENTLY of how you feel about the consumption of these products overall.    
CE-users / CE-nonusers = 106 / 1665 I agree I do not agree Undecided 
I could learn more quickly by using these products and perhaps 
understand things that I did not understand before.   
59.4% / 38.9% 35.8% /51.7% 4.7% / 9.3% 
I could finish much of my work in less time and would therefore 
have more free time and less stress. 
64.2% / 35.6% 34.9% / 54.3% 0.9% / 9.8% 
I could regain lost mental vigour, because sometimes I don't feel 
as fit mentally as I did previously. 
44.3% / 22.9% 49.1% / 65.3% 6.6% / 11.5% 
I could achieve more and better results and would progress more 
quickly in life. I would earn more money and live a more 
comfortable life.  
38.7% / 21.1% 50.9% / 68.9% 10.4% / 9.8% 
I could gain more acceptance and respect because of a higher 
level of achievement attained by using such products. 
22.6% / 13.1% 67.0% / 78.7% 10.4% / 7.9% 
These products could act as some sort of prevention. If my brain 
became fitter, I might suffer less from forgetfulness and related 
problems once I'm old. 
17.9% / 9.9% 76.4% / 78.3% 5.7% / 11.5% 
 
Figure 2.38.: The answer categories were randomized. For each sentence, one answer category could be
chosen. Missing values are 3-4 (0.2%) for the CE-non-users and none for the CE-users.
Would you take a product that would increase your IQ for a defined period of time and would be without any side effects? 
 
CE-users  
(n=108) 
CE-nonusers 
(n=1663) 
Yes, once to give it a try. 41 (38.7) 611 (36.7) 
Yes and most probably more than once. 55 (51.9) 353 (21.2) 
No, I would not try such a product. 7 (6.6) 487 (29.3) 
Undecided. 3 (2.8) 212 (12.7) 
 
Figure 2.39.: The answer categories were not randomized. Only one answer category could be chosen.
The numbers in brackets are percentages. There are no missing values.
An association between the items ‘they would not accept it’ and ‘that I study is very
important for them’ and the use of CE was found (Figure 2.40; see hypothesis number
33). Another association has been found between the self-assessment of risk behaviour
where CE-users considered themselves overall more ready to take risks than did the
CE-non-users (Figure 2.41).
The last question of this survey was about the possible sources of which they have
heard about the survey (Figure 2.42). Most of the students who participated in this
survey had received an e-mail from the University of Zurich.
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How do you think would your parents react if you tell them, that you want to quit your studies and start a apprenticeship, for 
which you would have already a place? (multiple answers possible) 
nTotal=1769 CE-users CE-nonusers 
They would be surprised. 63 (59.4) 1091 (65.6) 
They would accept it. 61 (57.5) 1053 (63.3) 
Essential is that I do find my way. 54 (50.9) 910 (54.7) 
They would be disappointed. 41 (38.7) 511 (30.7) 
That I study is very important for them.  29 (27.4) 282 (17.0) 
They would not accept it. 9 (8.5) 105 (6.3) 
They would be happy. 9 (8.5) 100 (6.0) 
They would not mind. 3 (2.8) 55 (3.3) 
I do not know how they would react. 1 (0.9) 42 (2.5) 
 
Figure 2.40.: The answer categories one to eight were randomized. More than one of these answer
categories could be chosen. If the last question was chosen, no other answer was possible.
The numbers in brackets are percentages. There are no missing values and the median is
the choosing of three answers (n=671).
How would you assess yourself: Are you in general a risky person or do you try to avoid risks? 
On a ten-stage scale means a cross on the very left side ’not risky at all’ and on the very right side ‘very risky’. In between 
there are gradations.  
 1 2 3 4 5 6 7 8 9 10 
CE-users 
(n=106) 
1  
(0.9) 
6  
(5.7) 
8  
(7.5) 
14 
(13.2) 
7  
(6.6) 
12 
(11.3) 
23 
(21.7) 
20 
(18.9) 
12 
(11.3) 
3  
(2.8) 
CE-nonusers 
(n=1659) 
27 
(1.6) 
131 
(7.9) 
324 
(19.5) 
232 
(14.0) 
181 
(10.9) 
279 
(16.8) 
253 
(15.3) 
172 
(10.4) 
48 
(2.9) 
12 
(0.7) 
 
Figure 2.41.: The answer categories were not randomized. Only one answer category could be chosen.
The numbers in brackets are percentages. There are no missing values.
From where did you learn about this survey? (multiple answers possible) 
 nTotal=1765 
I received an e-mail from the University of Zurich (‘Rechtsdienst’) 1205 (68.3) 
I received an e-mail from a student union or via a mailing list of a study subject. 291 (16.5) 
I received a flyer. 195 (11.0) 
A lecturer mentioned the survey.  77 (4.4) 
I received a personal e-mail. 77 (4.4) 
‘open answer’ 32 (1.8) 
 
Figure 2.42.: The answer categories were not randomized. More than one of these answer categories
could be chosen. The numbers in brackets are percentages. There is one missing value and
the median is the choosing of one answer (n=1670).
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2.4 Hypotheses
The following hypotheses were formulated while constructing the questionnaire. As
mentioned in the publication, they were established on the basis of previous studies
about the usage of CE as well as proposed, possible associations concerning the usage
of CE. If H0 was rejected, the information was included into the publication.
If the p-value of the χ 2-test was smaller than 0.05, the hypothesis H0 was rejected.
In this case, an association was found (for defining if such an association is a cause or
an effect, a longitudinal study would have to be accomplished).
A requirement for the performance of such a χ 2-test was that the sampling distribution
has to have an approximate χ 2 distribution. If more than 20% of the expected values
were smaller than 5 or any expected value smaller than 1, this is not given anymore and
the test looses statistical power meaning that the test may fail to detect an effect [110].
In such cases, the Fisher’s test had to be used.
If the p-value of the χ 2-test was smaller than 0.05 respectively the p-value of the
Fisher’s test, H0 was rejected. In such cases are the accepted hypotheses in the follow-
ing highlighted in green. Otherwise, ’H0’ is coloured in yellow.
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Part 1 and CE-users vs. CE-non-users
1. Gender (χ 2-test p=.000; 0<5)
H0: Around as many men as women are taking CE.
H1: More men are taking CE.
H2: More women are taking CE.
2. Age (χ 2-test: p=.995; 74<5 (66.1%); Fisher’s test: 1.000)
H0: The use of CE is independent of the age.
H1: Younger students are more often taking CE.
H2: Older students are more often taking CE.
3.a Major subject: ‘Student group’ (χ 2-test: p=.031; 3<5 (37.5%); Fisher’s test: 1.000)
H0: The use of CE is independent of the study subject.
H1: Students of particular study subjects are more often taking CE.
3.b Major subject: ‘Which faculty’ (χ 2-test: p=.092; 5<5 (22.7%))
H0: The use of CE is independent of the faculty.
H1: Students of particular study subjects are more often taking CE.
4. Semester (χ 2-test: p=.816; 29<5 (53.7%))
H0: The use of CE is independent of the number of semesters.
H1: The more semesters one student was at University, the higher the chance of taking CE.
H2: The less semesters one student was at University, the higher the chance of taking CE.
5.a Education of the mother (χ 2-test: p=.419; 2<5 (12.5%))
H0: The use of CE is independent of the education of the mother.
H1: Students with mothers with a higher education take more often CE (higher social pressure to gain
a similar education?)
H2: Students with mothers with a lower education take more often CE
5.b Education of the father (χ 2-test: p=.828; 6<5 (33.3%))
H0: The use of CE is independent of the education of the father.
H1: Students with fathers with a higher education take more often CE.
H2: Students with fathers with a lower education take more often CE.
6. Student union (χ 2-test: p=.260; 1<5 (16.7%))
H0: The use of CE is independent of the activity in student unions.
H1: Students being active in the student union take more often CE.
H2: Students being not active in the student union take more often CE.
7. Student fraternities (χ 2-test: p=.414; 1<5 (16.7%))
(If answer: ‘I do not know’ → missing value: χ=1.676; df=2; p=.195; 0<5))
H0: The use of CE is independent of the activity in student fraternities.
H1: Students being active in student fraternities take more often CE.
H2: Students being not active in student fraternities take more often CE.
8.a Average marks (0 and ‘hard to say?’ → missing values): χ 2-test: p=.005; 4<5 (28.6%), Fisher’s
test: 1.000)
If: 2.5-4.4 and 4.5-6.0: (χ=2.054; df=1; p=.152; 1<5)
H0: The use of CE is independent of the average marks.
H1: Students with lower marks are more often taking CE.
H2: Students with higher marks are more often taking CE.
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8.b Categories of marks (df=1; x<5, x>20% → Fisher’s test: p: .15-.920 (Phil1: .115))
H0: The average mark and the faculty do not correlate.
H1: The average mark is for some faculties higher then for others.
9. Housing form (χ 2-test: p=.186; 2<5 (14.3%))
H0: The use of CE is independent of the housing form.
H1: Students, who are living in a shared flat or a student house, take more often CE.
10. Politics (χ 2-test: p=.042; 0<5)
H0: The use of CE is independent of the political position.
H1: Students with certain political positions take more often CE.
10.b Politics and activity (out of curiosity= (χ 2-test: p=.001; 8<5 (33.3%); Fisher’s test: 1.000)
H0: Students active in the student union show the same distribution of political positions as the non-
active students.
H1: Students with a ‘left’ political position are more often active in the student union.
11.a Religion (χ 2-test: p=.001; 4<5 (28.6%); Fisher’s test: 1.000)
H0: The use of CE is independent of the religion.
H1: Religious students take less often CE.
11.b combined categories of religion: Evangelic reformed, Roman Catholic, others, none.
Religion (χ 2-test: p=.004; 0<5)
H0: The use of CE is independent of the religion.
H1: Religious students take less often CE.
12. Importance of religion (χ 2-test: p=.003; 0<5)
H0: The use of CE is independent of the importance of religion.
H1: Students for who relgion is more important take less often CE.
13. Money (χ 2-test: p=.062; 2<5 (14.3%), Fisher’s test: 1.000)
H0: The use of CE is independent of the money.
H1: Student who have more money per month take more often CE.
14. Income of the family (χ 2-test: p=.198; 1<5 (12.5%), Fisher’s test: 1.000)
H0: The use of CE is independent of the income of the family.
H1: Students from richer families take more often CE.
Part 2 and CE-users vs. CE-non-users
15. Coffee and others
15.a Coffee (χ 2-test: p=.004, 0<5)
H0: The use of CE is independent of the use of coffee.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.b Red-Bull (χ 2-test: p=.000, 0<5)
H0: The use of CE is independent of the use of Red-Bull.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.c Grape sugar (χ 2-test: p=.130, 0<5)
H0: The use of CE is independent of the use of grape sugar.
H1: Consumers take more often CE.
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H2: Non-consumers take more often CE.
15.d Guarana (χ 2-test: p=.000, 0<5)
H0: The use of CE is independent of the use of Guarana.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.e Khat (χ 2-test: p=.716, 2<5 (50%))
H0: The use of CE is independent of the use of khat.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.f Black tea (χ 2-test: p=.826, 0<5)
H0: The use of CE is independent of the use of black tea.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.g Coca Cola (χ 2-test: p=.890, 0<5)
H0: The use of CE is independent of the use of Coca Cola.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.h Cigarettes (χ 2-test: p=.000, 0<5)
H0: The use of CE is independent of the use of cigarettes.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
15.i ‘Nothing taken’ (χ 2-test: p=.007, 0<5)
H0: The use of CE is independent of the use of.
H1: Students who chose answer ‘nothing taken’ take more often CE.
H2: Students who chose answer ‘nothing taken’ take more often CE.
16 Meditation and others
16.a Sport (χ 2-test: p=.264, 0<5)
H0: The use of CE is independent of sport.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
16.b Stretching (χ 2-test: p=.788, 0<5)
H0: The use of CE is independent of stretching.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
16.c Yoga (χ 2-test: p=.239, 0<5)
H0: The use of CE is independent of yoga.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
16.d Walking (χ 2-test: p=.298, 0<5)
H0: The use of CE is independent of walking.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
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16.e Learning pauses (χ 2-test: p=.279, 0<5)
H0: The use of CE is independent of learning pauses.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
16.f Autogenic training (χ 2-test: p=.009, 1<5 (25-0%), Fisher’s test: .017)
H0: The use of CE is independent of autogenic training.
H1: Consumers take more often CE.
H2: Non-consumers take more often CE.
16. g ‘no specific activities’ (χ 2-test: p=.436, 0<5)
H0: The use of CE is independent of.
H1: Students who chose answer ‘no specific activities’ take more often CE.
H2: Students who chose answer ‘no specific activities’ take more often CE.
Part 2-separated questions between CE-users and CE-non-users
17. Known NEPs. (χ 2-test: p=.000 for all three CE)
H0: The use of CE is independent of the knowledge about CE.
H1: Consumers know of more CE.
H2: Non-consumers know of more CE.
18. Recommendations for the use of CE (χ 2-test: p<0.001, 0<5)
H0: No differences between CE-users and CE-non-users.
H1: CE-users have received more recommendations for the use of CE.
19. Why CE
H0: No difference in the order of the answer items between CE-users and CE-non-users.
H1: There is a difference.
20. Number of concerns (χ 2-test: p=.000, 0<5)
(Calculated with category ‘BedAll Anzahl’ = expected values below 1 → Fisher’s test: 1.000. But be-
cause of high df, beta-error is likely → generated new cateogory: BedAll Anz Kat)
H0: No difference between the number of concerns of CE-users compared to CE-non-users.
H1: The CE-non-users agree to more concerns than the CE-users.
21. Selection of the concerns (‘I do not know→ vmissing value; p=.000 for all concerns expect for ‘God’:
p=.014).
H0: No differences were found in the selection of concerns between CE-users and CE-non-users.
H1: There exists a difference between CE-users and CE-non-users.
22. CE as an illness and frequency. (Only reasonable for Ritalin, for the others: n is too small!, p=.334,
3<5 (37.5%), Fisher’s test: 1.000)
H0: Students who have received CE for a treatment of an illness, do not more often take is as a CE.
H1: Students who have received CE for a treatment of an illness, take it more often as a CE.
23. Number of students who are taking CE (χ 2-test: p=.311)
H0: There is no difference found compared to the study done in the US.
H1: Less students of this survey take CE compared to the survey in the US.
H2: More students take CE in this survey.
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Part 2-together
24.a Side effects (0 and ‘I do not know the product enough’ = missing values)
Ritalin: χ 2-test: p=.000, 0<5; AdderallR©: 6<5 (42.9%), Fisher’s test: 1.000; ModasomilR©: 6<5
(42.9%), Fisher’s test: 1.000)
H0: No differences were found between CE-users and CE-non-users (for AdderallR©und ModasomilR©).
H1: Students who are taking CE estimate the side effects as less critical. (for Ritalin)
H2: Studetns who are taking CE estimate the side effects as more critical.
nonusers[.4cm] 24.b x taken: yes/ no and side effects (Ritalin: χ 2-test: p=.000, 1<5 (8.3%); AdderallR©:
p=.000, 6<5 (50.5%)→ Fisher’s test: 1.000; ModasomilR©: p=.000, 5<5 (41.7%)→ Fisher’s test: 1.000)
H0: No differences were found between the estimation of side effects of CE-users when comparing their
used product and other CE. (AdderallR©, ModasomilR©)
H1: Person who have taken a CE, to estimate the side effects of the used CE as less critical than the
side effects of other CE. (Ritalin)
25. Formation of the opinion about the side effects (sig. for ‘specialist literature’, for ‘friends who are
taking it’ and for ‘friends who are not taking it’)
H0: No differences were found between CE-users and CE-non-users.
H1: There exists a difference between CE-users and CE-non-users.
26.a Drug consumption (χ 2-test: p=.000-.039, if x<5: x>0 → Fisher’s exact test)
H0: No differences were found between CE-users and CE-non-users.
H1: More CE-users have taken drugs compared to the CE-non-users.
26.b Why have drugs been consumed (χ 2-test: significant for alertness (.000*), mood (.001), concentra-
tion (.000*), use of others (.040), performance (.000*), feeling (.005); *=Fisher’s test p-value)
H0: No differences were found between CE-users and CE-non-users.
H1: There exists a difference between CE-users and CE-non-users concerning the resons for taking drugs.
27. Alcohol consumption (χ 2-test: p=.224; 3<5 (21.4%) → Fisher’s test: 1.000)
H0: No differences were found between CE-users and CE-non-users.
H1: More of the CE-users are drinking more often alcohol then the CE-non-users.
Part 3
28.a RitalinR©and Anabolics and CE-users vs. CE-non-users (For RitalinR©as well as for Anabolics: χ
2-test: p=.000, 1<5 = 12.5%)
H0: No differences were found between CE-users and CE-non-users.
H1: CE-users were more often answering that such a usage of RitalinR©as well as Anabolics is fine for
them.
28.b RitalinR©and Anabolics (χ 2-test: p<.001)
H0: No differences were found between the estimation of the case study about RitalinR©when comparing
to the one Anabolics.
H1: More of the students find the case study about Anabolics fine compared to the one about Ritalin.
H2: More of the students find the case study about RitalinR©fine compared to the one about anabolics.
29.a 65 years old person and CE-users vs. CE-non-users (χ 2-test: p=.000; 0<5)
H0: No differences were found between CE-users and CE-non-users.
H1: CE-users find it more often fine.
29.b Comparison and CE-users vs. CE-non-users (χ 2-test: p=.003; 0<5)
H0: No differences were found between CE-users and CE-non-users.
H1: CE-users find it more often the same.
H2: CE-non-users find it more often the same.
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29.c 25 and 65 years old person (χ 2-test: p<.001)
H0: Most of the students find these two cases the same.
H1: The students find the use of the 65 year old person more often fine.
29.d Reaction of CE-non-users and 25 years old person to increase concentration (40.0% (n=6) of person
with reaction: ‘Yes, that is fine for me’ → fine in cast study. 64.7% (n=729) of students with reaction:
‘no, I am not fine with that’ → , not fine in case study. Internet: 6,1,5,72, problem: too small numbers
for χ 2-test)
H0: No correlation between the rating of others and the case study.
H1: There is a positive correlation between the answers to these two questions.
30. Normality (χ 2-test: p=.000; 0<5)
H0: No differences were found between CE-users and CE-non-users.
H1: More of the CE-users do think it will be normal in ten years to use CE.
31.a Coffee and RitalinR©in exams (coffee: χ 2-test: p=.102; 2<5 (33.3%), Fisher’s test: 1.000; Ritalin:
p=.000, 0<5)
H0: No differences were found between CE-users and CE-non-users.
H1: More of the CE-users find RitalinR©acceptable.
31.b Coffee and RitalinR©in exams (Chi-quadrat test: p<0.001)
H0: No differences were found looking at all students between coffee and Ritalin.
H1: Less students accept RitalinR©than coffee.
H2: Less students accept coffee than Ritalin.
31.c answer ‘no’ in question about acceptance of RitalinR©in exams and the two answers ‘no?’ in question
if one could imagine to take CE. H0: No correlation between these answers. H1: Both ‘no’ answers about
imaging a use of CE find the use of RitalinR©more often inacceptable.
H2: Only more of the student who chose the strict no-answer find the use of RitalinR©more often inac-
ceptable. (79.8%:50.5%)
31.d Rating of Ritalin-use in exams and rating of a use by the CE-non-users (χ 2-test: p=.000; 2<5
(16.7%), Fisher’s test: 1.000)
H0: Most of the students do show no difference between the general rating of CE and the rating of a use
of RitalinR©in this combined question with coffee.
H1: Most of the students refuse a use of RitalinR©less strongly in this combined question with coffee than
in the general question about a usage of CE.
32.a Product to increase of IQ and CE-users vs. CE-non-users (χ 2-test: p=.000; 0<5)
H0: No differences were found between CE-users and CE-non-users.
H1: More of the CE-users would use such a product.
32.b. Product to increase of IQ and gender (χ 2-test: p=.000; 0<5, =in line with hypothesis 1)
H0: No differences were found between men and women.
H1: More men would take such a product compared to women.
33. Parents for trying to evaluate an aspect of social pressure
(Higher value for CE-users: ‘That I study is very important for them’ (χ 2-test: p=.006, 0<5) and a
tendency for ‘they would be disappointed’ (p=.087, 0<5). But no correlation for ‘they would not accept
it’ (p=.376, 0<5).
H0: No differences were found between CE-users and CE-non-users.
H1: More of the CE-users chose the categories which show some social pressure from the parents (‘not
acceptable’, ‘very important to study’ and perhaps ‘would be disappointed’).
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H2: There are differences but not specifically for the answers about social pressure.
34. Self-evaluation of handling with risk (χ 2-test: p=.000; 3<5 (15.0, x=0.90 → fisher’s test: 1.000))
H0: No differences were found between CE-users and CE-non-users.
H1: More of the CE-users say that they are riskier than most of the CE-non-users.
35.a. Number of reasons vs. CE-users and CE-non-users (χ 2-test: p=.000, 1<5 (10.0%))
H0: No differences were found between CE-users and CE-non-users.
H1: The CE-users agree to more reasons than the CE-non-users.
35.b Reasons vs. CE-users and CE-non-users (χ 2-test: p=.000 expect for ‘respect’ and ‘prevention’:
p=.010; for all reasons: 0<5).
H0: No differences were found between CE-users and CE-non-users.
H1: There are differences between the CE-users and the CE-non-users.
The information of these 35 hypotheses were included in the publication if H0 was
rejected. Additional hypotheses were formulated about possible correlations between
the question about concerns respectively about reasons to take CE and other questions.
These analyses revealed for the question about concerns for all participants that: Women
agreed to more concerns than men, students who answered ’no affiliation’ in the question
about religion (Figure 2.6) agreed to a fewer concerns and correlations between the
political view (Figure 2.5) and the selection of the concerns were found. The highest
values of agreement to the concern about not being oneself anymore was found for CVP
and GPS, to the concern about the goal of CE to achieve more for the parties ’Others’,
SP and GPS, and to the concern about God for the parties SVP and CVP. Students of
the non-users who have chosen the negative answers when asked if they could imaging
to take CE (Figure 2.26) agreed to more concerns than the other non-users.
When focusing on the question about reasons for using CE, the analyses revealed that:
Older students agreed less often to reasons than younger students and more students
sharing the political view of SP and FDP agreed to the reason about finishing more work
in less time compared to the percentage values of other political parties.
67
2.5 Conclusion
The survey among 1765 students of the University of Zurich revealed that 4.7% of the
participants have taken CE for study purposes. These students have taken Ritalin R©,
Adderall R©and/or Modasomil R©at least once in their life to increase their concentration
and/ or alertness as a healthy person. As seen in the discussion section of the paper,
these findings are in line with previous studies, especially with those surveys accom-
plished in Germany (see table 1.2, page 21). A closer comparison with the very recent
study done by Larissa Maier and her colleagues is of interest because it has been accom-
plished among a very similar population in Switzerland [74]. In her study, 13.8% of the
participants had experiences with CE. CE was defined as the following: The usage of
prescription drugs or drugs of abuse including alcohol to directly or indirectly enhance
brain function (e.g. concentration, alertness, and a reduction of nervousness). 13.8% of
the participants have at least once in their life taken such CE. When focusing only on
prescription drugs, 7.6% of the participants have taken them as CE. In this group are
the following products included: methylphenidate, modafinil, antidepressants, antide-
mentia drugs, sedatives and beta-blockers. When focusing on the numbers of each of
these products, comparisons with our study are possible. For methylphenidate, the life
time prevalence as a CE was 4.1% and for Modafinil R©0.3% in the study of Maier [74]. In
our survey among students, 4.7% of the participants have taken Ritalin R©, Adderall R©or
Modasomil R©as a CE for study purposes. This number is not significantly different from
4.1% (if all modafinil users have also taken Ritalin R©: p-value: 0.209) nor from 4.4%
(Ritalin R©- and modafinil-users are different participants: p-value: 0.561). These num-
bers of the study of Larissa Maier and her colleagues are significantly different from 6.2%
standing for all the participants in our study who have taken CE for non-therapeutic
use. But there are also 27 additional students included who took it out of curiosity or as
a ‘party drug’. Such students are most probably all excluded in the definition of Larissa
Maier and her colleagues where the enhancement of brain functions was explicitly men-
tioned in the given definition of CE.
Both of these surveys accomplished among students in Switzerland are not representa-
tive. This is because the link of the survey was not sent out to all students or, more
realistic, to a sample that was weighted to construct a representative sample, but rather
to a sample which was constructed of all students, who allow the University to share
their email address for such purposes. Therefore, having now our survey in comparison
with the survey of Larissa Maier and colleagues and also with our small paper-and-pencil
survey resulting in similar results, there is most probably no significant bias in our sur-
veys influencing the number of CE-users.
Specific to our survey was the focus on personal attitudes about CE to evaluate the
rating of arguments coming form the discussion in the field of ethics. We have asked
questions about reasons and concerns about the usage of CE, presented three case stud-
ies about young and old person taking steroids or Ritalin R©, and asked if they think such
a usage is right or wrong, if the participants think it will be normal to take such CE in
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10 years and if they would take such a CE if it would have no side effects at all (for the
results, please see section 2.2. or in more details: subsection 2.4.3). Larissa Maier and
her colleagues asked also a few questions about the personal attitudes presenting dif-
ferent arguments for or against neuroenhancement but no information about how these
arguments were selected was available in the publication.
Taken together, our survey provides the first data about students in Switzerland con-
cerning the usage and handling of CE of users in comparison with non-users as well as
their personal attitudes about such products. Having now set a starting point of eval-
uating empirical data concerning CE in Switzerland, further methods could be used to
overcome possible limitations of quantitative surveys, e.g. with the help of qualitative
interviews, personal attitudes could be evaluated in more details.
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3 Survey among Physicians
3.1 Introduction
The Swiss Academy of Medical Sciences (SAMW) has been working on human enhance-
ment for some time (Section 1.7). After the SAMW held a conference on human en-
hancement in 2007, they defined this topic as a core area in 2008. Under the direction
of Prof. Nikola Biller-Andorno, a working group was established to focus on human
enhancement from 2008 until 2012 in coordination with the Centre for Technology As-
sessment (TA-Swiss) and the Swiss Advisory Commission on Biomedical Ethics in the
field of human medicine (NEK-CNE). The working group looked in particular at the
role of medicine concerning the topic of human enhancement. The working group au-
thorized the Institute of Biomedical Ethics of the University of Zurich to accomplish a
paper-and-pencil survey among general practitioners and psychiatrists in Switzerland.
The recommendations of the working group are included in the last chapter of the in-
formation booklet on ‘Medizin fu¨r Gesunde? Analysen und Empfehlungen zum Umgang
mit Human Enhancement’ (for more information, please see chapter 4).
Rachel Neuhaus Bu¨hler and Nicole Miller developed together with Nikola Biller-
Andorno a questionnaire after conduction eight qualitative, half-standardised interviews
with psychiatrists and general practitioners in the region of Zurich and defined the sam-
ple containing of 1600 Swiss practicing physicians. In summer 2011, I was involved in
this project by conducting the pre-test. After integrating the recommendations, I sent
out the questionnaire twice to the pre-defined sample of 1600 Swiss practicing psychia-
trists and general practitioners (800 from the German and 800 from the French speaking
part of Switzerland). The core centre of the questionnaire consists of four case scenarios
of different people asking their physician for a cognitive enhancer (in details explained
in the method section of the publication in 2.2). 379 physicians completed the question-
naire (response rate 24.7%) and their answers are presented in the publication in the
following section and will be briefly summarized in the conclusion section in 3.3.
3.2 Publication
The paper on the survey among physicians was published in the journal ‘Swiss Medical
Weekly’ in November 2012. A print of the publication is included in this section.
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Knowledge of term and immediate response
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Concepts of disease and treatment
2>;D 7IA;: M>?9> 9H?J;H?7 F7HJ?9?F7DJI MEKB: KI; <EH :;	
J;HC?D?D= M>;J>;H 7 :OI<KD9J?ED I>EKB: 8; 9EDI?:;H;: 7
:?I;7I; ZIK8@;9J?L; IK<<;H?D=[ M7I J>; CEIJ <H;GK;DJBO
9>EI;D 9H?J;H?ED <EBBEM;: 8O ZD;=7J?L; 9EDI;GK;D9;I <EH
;L;HO:7O78?B?JOJEMEHA[J78B;

2>;D 7IA;: >EM J>;O MEKB: :;9?:; ?< 7 F7J?;DJ 7IA;: <EH
7 FH;I9H?FJ?ED M?J>EKJ 7D ?D:?97J?ED J>; C7@EH?JO E< J>;
F7HJ?9?F7DJI 
 n   nTotal   9>EI; J>; 7D	
IM;H Z$D =;D;H7B $ :E DEJ FH;I9H?8; 7DOJ>?D= M?J>EKJ 7D
?D:?97J?ED
 #EM;L;H ?< IK8@;9J?L; IK<<;H?D= ?I IJHED= 7D:
J>; F7J?;DJ M7DJI JE JHO M>7J;L;H ?I FEII?8B; $ C?=>J FH;	
I9H?8; IEC;J>?D= M?J>EKJ 7 9B;7H ?D:?97J?ED
 />?I :;F;D:I
ED J>; IK8IJ7D9; 7D: ?JI 9EDJH7?D:?97J?EDI 7D: KD:;I?H;:
I?:; ;<<;9JI
[  JEJ7B E< 
 E< J>; F7HJ?9?F7DJI n 
 7DIM;H;: Z2?J>EKJ ?D:?97J?ED $ :E DEJ FH;I9H?8; 7DO	
J>?D=
[ *DBO 7 C?DEH?JO E< J>; F7HJ?9?F7DJI 
 n  
9>EI; JE H;FBO Z$ ?D<EHC J>; F7J?;DJ 9ED9;HD?D= J>; FEI	
I?8B; H?IAI E< 7 :;I?H;: :HK= 7D: M>;D I>;>; IJ?BB M7DJI ?J
I>;>;I>EKB:8;<H;;JEJHO?J
[
$D J>; GK;IJ?ED 78EKJ M>?9> C;:?97J?ED F7HJ?9?F7DJI MEKB:
FH;I9H?8; M?J>EKJ 7 9B;7H ?D:?97J?ED ?D H;IFEDI; JE 7 F7	
J?;DJ]I H;GK;IJ 7DJ?:;FH;II7DJI M;H; 9>EI;D <HEC 7 B?IJ M?J>
 ?J;CI 8O 
 H7DA?D= <?<J> 7<J;H ).$I 

1?7=H7 
 B7N7J?L;I 
 7D: 8;DPE:?7P;F?D;I


 />; EJ>;H I?N EFJ?EDI D;KHEB;FJ?9 :HK=I 

7DJ?8?EJ?9I 
 EF?E?:I 
 7D: J>H;; FEJ;DJ?7B D;KH	
E;D>7D9;HI Y 7DJ?	:;C;DJ?7 :HK=I 
 C;J>OBF>;D?:7J;

 7D: CE:7<?D?B 
 Y M;H; EDBO 9>EI;D 8O 7
IC7BBC?DEH?JO

The case scenarios
+7HJ?9?F7DJI M;H; 9ED<HEDJ;: M?J> J>; <EKH 97I; I9;D7H?EI
:;I9H?8;: 78EL;
 />; ?DJHE:K9J?ED E< ;79> I9;D7H?E M7I
<EBBEM;: 8O GK;IJ?EDI 78EKJ M>?9> IK8IJ7D9;I J>;O MEKB:
Table 1: *34.3:1?301:77:B492>?,?0809?>.:80>.7:>0>??:D:@=:B9>;:9?,90:@>=0,.?4:9?:?3049.=0,>492@>0:1;0=1:=8,9.0093,9.492/=@2>8@7?4;70,9>B0=>
;:>>4-70
Yes, n (%) No, n (%) Undecided, n (%) nTotal
 ,=/7D>@=;=4>492?3,??34>4>3,;;09492B309/08,9/>,9/
.:8;0?4?4A0;=0>>@=0.:9?49@0?:=4>0
228 (62.5)   
$90>3:@7/;@?,>?:;?:?30>0?3492> 183 (51.8)  
 
A0=D-:/D4>=0>;:9>4-701:=34>	30=:B9,.?4:9> 212 (58.6)   
%0:;703,A0,7B,D>?=40/?:48;=:A0?304=;0=1:=8,9.0:1100,9/
&0/@77,=0,7=0,/D,=:@9/4?K>5@>??3,??30=,920:1;:>>4-474?40>
4>49.=0,>492
234 (65.0)   

(34>4>,>B=:92,>/:;49249>;:=?> 194 (53.7) 
  
(3034230>?A,7@01:=0,.3.=4?0=4:94>49-:7/70??0=>(309@8-0=>:1?30?3=00,9>B0=.,?02:=40>/4110=>429414.,9?7D1:=,7714A0=0,.?4:9>p 




Table 2: *309D:@3,A0?:/0.4/0B30?30=,/D>1@9.?4:93,>/4>0,>0A,7@0GB3,?.=4?0=4,,=0/0.4>4A01:=D:@8@7?4;70,9>B0=>;:>>4-70
Yes, n (%) No, n (%) Sometimes, n (%) nTotal
'@-50.?4A0>@110=492 317 (83.6)  
 
7,>>414.,?4:9,..:=/492?:!	'" 165 (43.5)  

 
$-50.?414.,?4:9B4?37,-:=,?:=D	A4>@,780?3:/> 165 (43.5) 
 
 
#02,?4A0.:9>0<@09.0>1:=0A0=D/,D,-474?D?:B:=6 290 (76.5)   
(3034230>?A,7@01:=0,.3.=4?0=4:94>49-:7/70??0=>(309@8-0=>:1?30?3=00,9>B0=.,?02:=40>/4110=>429414.,9?7D1:=,771:@=.=4?0=4,p 




Original article 'B4>>"0/*67D
B

'B4>>"0/4.,7*0067DL%:1?30:97490A0=>4:9LBBB>8B.3 %,20:1
FH;I9H?8; ?< 7DO 7D: ?< J>;O >7: H;9;?L;: IK9> H;GK;IJI ?D
J>;?H9B?D?97BFH79J?9;

I 7DIM;HI JE J>; <?HIJ GK;IJ?ED 78EKJ >EM F7HJ?9?F7DJI
MEKB: 79J <EKH IJ7J;C;DJI M;H; E<<;H;: J78B; 
 />; IJ7J;	
C;DJ Y Z$ MEKB: EDBO FH;I9H?8; :HK=I ?< FIO9>EJ>;H7F;KJ?9
C;J>E:I EH 9ECF7H78B; C;7IKH;I M;H; DEJ >;BF<KB ;DEK=>[
Y M7I J>; CEIJ FEFKB7H EL;H7BB
 $J M7I ;D:EHI;: 8O CEIJ
E< J>; F7HJ?9?F7DJI <EH J>; J>?H: 97I; I9;D7H?E 9ED9;HD?D=
J>; I>O MEC7D 7D: >7: B;7IJ IKFFEHJ ?D J>; 97I; E< J>;
H;DEMD;:I9?;DJ?IJ7IA?D=<EHCE:7<?D?B

/>; IJ7J;C;DJ Z$ MEKB: FH;I9H?8; 7 :HK= B?A; -?J7B?DU (E	
:7IEC?BU 7DJ?:;FH;II7DJI EH 7DJ?	:;C;DJ?7 :HK=I[ M7I H;	
@;9J;: 8O J>; C7@EH?JO E< F7HJ?9?F7DJI
 #EM;L;H 78EKJ ED;
J>?H: MEKB: >7D: EKJ 7 FH;I9H?FJ?ED JE J>; I>O MEC7D 7D:
78EKJ 7 GK7HJ;H JE J>; I?D=B; CEJ>;H
 *F?D?EDI M;H; :?	
L?:;: 78EKJ J>; IJ7J;C;DJ Z$ FH?D9?F7BBO FH;I9H?8; DE :HK=I
?D IK9> I?JK7J?EDI[ ?J >7: B;7IJ IKFFEHJ ?D J>; 97I; E< J>;
I?D=B; CEJ>;H 7D: J>; I>O MEC7D
 />; IJ7J;C;DJ Y Z$ :E
DEJ FH;I9H?8; :HK=I ?D IK9> I?JK7J?EDI 8KJ H;<;H JE J>; FEI	
I?8?B?JO J>7J J>; F7J?;DJ 9EKB: 9EDIKBJ IEC; E< CO EJ>;H 9EB	
B;7=K;I EH EH:;H L?7 J>; $DJ;HD;J[ Y M7I EL;HM>;BC?D=BO H;	
@;9J;:8OF7HJ?9?F7DJI

(EIJ E< J>; F7HJ?9?F7DJI M>E MEKB: FH;I9H?8; 7 :HK= ?D J>;
<?HIJ I9;D7H?E 9>EI; 8;J7 8BE9A;HI J78B;  <EBBEM;: 8O 7D	
J?:;FH;II7DJI 7D: -?J7B?DU C;J>OBF>;D?:7J;
 $D J>; I;9ED:
7D: J>?H: 97I; I9;D7H?EI J>; C7@EH?JO 9>EI; 7DJ?:;FH;II	
7DJI
 (E:7IEC?BU CE:7<?D?B M7I I;B;9J;: 8O CEIJ E< J>;
F7HJ?9?F7DJI M>E MEKB: FH;I9H?8; 7 :HK= ?D J>; <EKHJ> 97I;
I9;D7H?E
 *L;H7BB 7DJ?:;FH;II7DJI M;H; 8O <7H J>; CEIJ <H;	
GK;DJBO9>EI;D:HK=I

/>; D;NJ GK;IJ?ED JKHD;: <HEC >OFEJ>;J?97B GK;IJ?EDI JE 7D
;NFBEH7J?ED E< M>;J>;H F7HJ?9?F7DJI >7: ?D <79J 8;;D 9ED	
<HEDJ;: M?J> H;GK;IJI <EH ;D>7D9?D= FHE:K9JI ?D J>;?H 9B?D	
?97BFH79J?9;J78B;

2>;H;7I J>; ZIJK:;DJ[ 7D: J>; ZI>O MEC7D[ >7: 8;;D ;D	
9EKDJ;H;: 8O 78EKJ >7B< E< F7HJ?9?F7DJI IB?=>JBO <;M;H F7H	
J?9?F7DJI >7: 8;;D 9ED<HEDJ;: M?J> J>; I?D=B; CEJ>;H 97I;
7D: EDBO 78EKJ ED; <?<J> M?J> J>; H;DEMD;: I9?;DJ?IJ I9;D	
7H?E
 
 E< J>; F7HJ?9?F7DJI D   AD;M 7BB I9;D7H?EI
?D 9EDJH7IJ JE 
 M>E >7: DEJ ;NF;H?;D9;: 7DO E< J>;C
D  
 />; IK8=HEKF 7D7BOI?I 799EH:?D= JE MEHA ;DL?H	
EDC;DJI I>EM;: J>7J J>; ZI>O MEC7D[ I9;D7H?E >7: 8;;D
;NF;H?;D9;: 8O 
 E< F7HJ?9?F7DJI M?J> 7 ZH7J>;H HKH7B[
IKHHEKD:?D= 9ECF7H;: JE 
 E< J>EI; FH79J?I?D= ?D 7
ZH7J>;H KH87D[ I;JJ?D= ^n    
 p  


/>?I 7IIE9?7J?ED 8;JM;;D ;NF;H?;D9; E< J>; J>?H: I9;D7H?E
7D: J>; ;DL?HEDC;DJ ?I IC7BB H7C;H]I 1  

 />; <H;	
GK;D9O E< H;GK;IJI M7I H;FEHJ;: JE 8; H7J>;H BEM ?D CEIJ
97I;I Y J?C;I F;H O;7H <EH I9;D7H?E Y 7D: ZL;HO H7H;BO[
<EH I9;D7H?E 
 
 E< J>; F7HJ?9?F7DJI >7L; ;NF;H?;D9;:
7JB;7IJED;E<J>;<EKH97I;I9;D7H?EI

Personal attitudes
$D J;HCI E< J>;?H F;HIED7B 7JJ?JK:;I JEM7H:I )  J>; C7@EH	
?JO E< F7HJ?9?F7DJI M;H; KDIKH; ?< J>;O MEKB: 9EKDJ J>;C	
I;BL;I 7CED= J>EI; M>E FH?D9?F7BBO EFFEI; ) 
 J J>;
I7C; J?C; >7B< E< J>; I7CFB; MEKB: 9EDI?:;H J>; :;9?I?ED
<EH EH 7=7?DIJ ) ?D J>; B?=>J E< IF;9?<?9 9?H9KCIJ7D9;I

';II J>7D  MEKB: ;C8H79; 7 9EDIKC;H CE:;B M?J>
C;:?97B:;9?I?EDI=K?:;:8OF7J?;DJFH;<;H;D9;IJ78B;

$D EH:;H JE H;79> 7 8;JJ;H KD:;HIJ7D:?D= E< F>OI?9?7DI] :;	
9?I?EDI <EH EH 7=7?DIJ FH;I9H?8?D= F;H<EHC7D9;	;D>7D9?D=
:HK=I F7HJ?9?F7DJI M;H; 9ED<HEDJ;: M?J> :?<<;H;DJ FEII?8B;
9H?J;H?7 J78B; 
 />; 9H?J;H?7 M;H; :;L;BEF;: <HEC FH;F7H	
7JEHO?DJ;HL?;MIM?J>F>OI?9?7DI

/>; :7J7 ?D J78B;  I>EM J>7J EDBO J>; <?HIJ J>H;; IJ7J;C;DJI
ED 
 IK8@;9J?L; IK<<;H?D= 
 J>; J?C;	B?C?J;: KI; E<
Table 3:  :BB:@7/D:@=0,.??:,=0<@0>?1:=?30;=0>.=4;?4:9:1,90@=:093,9.492>@->?,9.0
Prescription Only if no therapeutic
alternative
No prescription Referral
'.09,=4:>?@/09?  180 (54.4)  
'.09,=4:>492708:?30=  176 (52.9) 137 (41.4) 14 (4.5)
'.09,=4:>3DB:8,9 
 244 (70.1) 88 (26.8) 19 (6.1)
'.09,=4:=09:B90/>.409?4>?  52 (16.1) 193 (54.1) 35 (10.7)
(30;:>>4-70,9>B0=>B0=0HD0>I,9/H9:I?30?,-70.:9?,49>?30A,7@0>1:=?30,9>B0=HD0>I nTotal =,920>-0?B009
,9//@0?:84>>492A,7@0>
Table 4: !9.,>0:1/=@2;=0>.=4;?4:949?307,>?<@0>?4:9B34.3:1?301:77:B492>@->?,9.0>B:@7/D:@;=0>.=4-049?30/0>.=4-0/>4?@,?4:98@7?4;70,9>B0=>;:>>4-70
Ritalin©
(methylphenidate)
Modasomil©
(modafinil)
Antidepressants Anti-
dementia
drugs
Beta
blockers
nTotal
'.09,=4:>?@/09?    
 56 (29.6%) 

'.09,=4:>492708:?30=  
 72 (37.3%) 
  

'.09,=4:>3DB:8,9  
 110 (43.8%) 
  
'.09,=4:=09:B90/>.409?4>?  24 (32.4%)    
(3034230>?A,7@04>8,=60/1:=0,.3>.09,=4:(30.:7@89HnTotalI=010=>?:,77;,=?4.4;,9?>B3:3,/49/4.,?0/49?30;=0A4:@><@0>?4:9?3,??30DB:@7/;=0>.=4-0,/=@2
Table 5: :D:@69:B:1>@.3=0<@0>?>1=:8D:@=:B9B:=6
Yes, n (%) No, n (%) nTotal p-value
'.09,=4:>?@/09? 

   

'.09,=4:>492708:?30= 
 215 (58.0)  



'.09,=4:>3DB:8,9 
 
 
 

'.09,=4:=09:B90/>.409?4>?  270 (78.3)  




(30 pA,7@0>:1?30MG?0>?,=09:?0/49?307,>?.:7@89


F;




F;

;


!1?30A,7@0>/4110=>429414.,9?7D;

?3034230=A,7@04>49-:7/70??0=>
Original article 'B4>>"0/*67D
B

'B4>>"0/4.,7*0067DL%:1?30:97490A0=>4:9LBBB>8B.3 %,20:1
J>; :HK= 7D: 
 7LE?:?D= J>; :;L;BEFC;DJ E< IEC;J>?D=
MEHI;M;H;H;B;L7DJ<EHJ>;C7@EH?JOE<F7HJ?9?F7DJI

!?D7BBO F7HJ?9?F7DJI M;H; 7IA;: JE 9EDI?:;H J>H;; IJ7J;	
C;DJI ED ) J78B; 
 />; C7@EH?JO 9EDI?:;H;: J>; IJ7J;	
C;DJ J>7J ) ?I 7 C7JJ;H E< ?D:?L?:K7B 9EDI9?;D9; 7I <7?HBO
EH 9ECFB;J;BO H?=>J
 8EKJ 7 GK7HJ;H M;H; KD9;HJ7?D ?< ) 
I>EKB: 8;9EC; 7D ?DJ;=H7B F7HJ E< C;:?9?D; M?J> J>; H;	
C7?D:;H 7=H;;?D= EH :?I7=H;;?D= ?D ;GK7B C;7IKH;
 ::?	
J?ED7BBO J>; C7@EH?JO J>EK=>J J>7J F>OI?9?7DI] FK8B?9 ?C7=;
7D: JHKIJ MEKB: IK<<;H ?< J>;O CEL;: 7M7O <HEC J>; 9EH;
8KI?D;IIE<JH;7J?D=I?9AF;EFB;

.K8=HEKF 7D7BOI;I 799EH:?D= JE B7D=K7=; ";HC7D
!H;D9> =;D:;H IF;9?7B?JO J?JB; FIO9>?7JHO=;D;H7B FH79	
J?9; 7D: MEHA ;NF;H?;D9; Y O;7HI   O;7HI H;L;7B;:
IEC; :?<<;H;D9;I ^ 	/;IJ M?J> 7 p	L7BK; 
 H;=7H:?D=
J>; F7HJ?9?F7DJI] F;HIED7B 7JJ?JK:;I
 !EH ;N7CFB; !H;D9>	
IF;7A?D= F7HJ?9?F7DJI H7J;: J>; 9H?J;H?ED E< IK8@;9J?L; IK<	
<;H?D= <EH FH;I9H?8?D= D;KHE;D>7D9;HI >?=>;H ?J;C  E<
J78B;  p  
 H7C;H]I 1  
 M>?B; ";HC7D
IF;7A;HI 7D: =;D;H7B FH79J?J?ED;HI =7L; CEH; M;?=>J JE J>;
?CFEHJ7D9; 7D: L7BK; E< J>; H;7IED <EH J>; H;GK;IJ JE ;D	
>7D9; ?J;C  E< J78B;  p  
 H7C;H]I 1  


2EC;D M;H; CEH; 9ED9;HD;: 78EKJ 7D ;HEI?ED E< F7J?;DJ
JHKIJ J>?H: IJ7J;C;DJ E< J78B;  p  
 H7C;H]I 1 



J J>; ;D: E< J>; GK;IJ?EDD7?H; J>; F>OI?9?7DI M;H; 7IA;:
JE I;B;9J FEII?8B; I?:; ;<<;9JI JE >;7BJ>O F;EFB; <HEC 7D	
J?:;FH;II7DJI "?DA=E C;J>OBF>;D?:7J; -?J7B?DU 7DJ?	:;	
C;DJ?7 :HK=I 7D: CE:7<?D?B (E:7IEC?BU <HEC 7 B?IJ
D/EJ7B  
 />; JME CEIJ <H;GK;DJBO 9>EI;D 7DIM;HI
M;H; <EH 7DJ?:;FH;II7DJI D;HLEKID;IIIB;;F :?IEH:;HI

 7D: B?L;H :OI<KD9J?ED 
 <EH "?D=AE DED;

 7D: D;HLEKID;IIIB;;F :?IEH:;HI 
 <EH
C;J>OBF>;D?:7J; -?J7B?DU D;HLEKID;IIIB;;F :?IEH:;HI

 7D: 7::?9J?ED 
 <EH 7DJ?	:;C;DJ?7 :HK=I
D;HLEKID;IIIB;;F :?IEH:;HI 
 7D: B?L;H :OI<KD9J?ED

 <EH CE:7<?D?B (E:7IEC?BU D;HLEKID;IIIB;;F
:?IEH:;HI 
 7D: 7HH>OJ>C?7 

 />; F;H9;DJ7=;
E< J>EI; M>E :?: DEJ 9>EEI; 7DO E< J>; 7DIM;HI M;H;

 <EH 7DJ?:;FH;II7DJI 7D: 
 <EH "?D=AE 

<EH C;J>OBF>;D?:7J; -?J7B?DU 
 <EH 7DJ?	:;C;DJ?7
:HK=I7D:
<EHCE:7<?D?B(E:7IEC?BU

Table 6: %0=>:9,7,??4?@/0
I agree,
n (%)
Undecided,
n (%)
I do not agree,
n (%)
nTotal p-value
>,;3D>4.4,9!=01@>0#,9/B:@7/90A0=;=0>.=4-0>@.3
>@->?,9.0>


 145 (41.1) 

  



/0.4>4:91:=:=,2,49>?#4>.:9?0C?/0;09/09?!/:9:?
.,?02:=4.,77D>,D9:
171 (49.0)    




*309?30;,?409?4>491:=80/,-:@??30>4/00110.?>,9/=4>6>:1?30
/0>4=0//=@2>-@?>?477B,9?>4?!=0>;0.??34>/0.4>4:9,9/;=0>.=4-0
?30/=@2
  217 (63.1)  




(30 pA,7@0>:1?30MG?0>?,=0B=4??0949?307,>?.:7@89


F;




F;

;


!1?30A,7@0>/4110=>429414.,9?7D;

?3034230=A,7@04>49-:7/70??0=>
Table 7: *34.3.=4?0=4,4917@09.0D:@=/0.4>4:9=02,=/492?30;=0>.=4;?4:9:1/=@2>49?30/4110=09?>.09,=4:>8@7?4;70,9>B0=>;:>>4-70
Yes, n (%) No, n (%) nTotal p-value
(30>@-50.?4A0>@110=4924>49?09>0 294 (88.3)   




&,?30=1:=?08;:=,=D@>0?3,91:=,9@9/01490/?480>;,9 275 (82.8)   




(:,A:4/,/0A07:;809??3,?B:@7/-0B:=>0 233 (75.6)  
 




*309?30;0=>:9.:9.0=90//4/9:?;=:A:60?30>4?@,?4:9>30:=30
4>49


 228 (74.0) 
 




*30?30=?302:,74>:-A4:@>7D48;:=?,9?,9/A,7@,-70:=/:0>,7>:
-09014?:?30=>


 201 (69.1)  




*3094?4>.70,=?3,??30;0=>:9.:9.0=90/?=40/3,=/09:@23?:
=0,.3?302:,7?3=:@2334>:=30=:B9011:=?>
  
 

(30 pA,7@0>:1?30MG?0>?,=0B=4??0949?307,>?.:7@89


F;




F;

;


!1?30A,7@0>/4110=>429414.,9?7Dp 

?3034230=A,7@04>49-:7/70??0=>
Table 8: %70,>00A,7@,?0?301:77:B492>?,?0809?>
Statements Completely
wrong, n (%)
Fairly wrong,
n (%)
Undecided,
n (%)
Fairly right,
n (%)
Completely right,
n (%)
A0=D;3D>4.4,9>3:@7//0.4/01:=30=	348>071B30?30=>30	30
B,9?>?:;=,.?4.0#:=9:?
 
  110 (30.0 


#0@=:093,9.0809?80,>@=0>,=0,=0,74?D4A09?34>1,.??30D
>3:@7/-0.:80;,=?:180/4.,7;=,.?4.01:=?30-09014?:1?3:>0B3:
B4>3?:@>0?308(34>B,D?30,>>0>>809?,9/>@=A0477,9.0:1
=4>6>,9/@9/0>4=0/>4/00110.?>.,9-02@,=,9?00/
   99 (27.9 
(30;@-74.;0=.0;?4:9:1;3D>4.4,9>B477-0/,8,20/,9/?=@>?:1
;,?409?>/0.=0,>041;3D>4.4,9>8:A0,B,D1=:8?30.:=0,.?4A4?D:1
?=0,?492/4>0,>0
 
  156 (43.1 
Original article 'B4>>"0/*67D
B

'B4>>"0/4.,7*0067DL%:1?30:97490A0=>4:9LBBB>8B.3 %,20:1
Discussion
Participants’ familiarity with the term and experience
of requests for NE
(EH; J>7D JME	J>?H:I E< H;IFED:?D= =;D;H7B F>OI?9?7DI 7D:
FIO9>?7JH?IJI :?: DEJ ADEM J>; J;HC ZD;KHE;D>7D9;C;DJ[

(EH; J>7D >7B< >7: DEJ >;7H: E< Z8H7?D :EF?D=[
 />?I ?I
IKHFH?I?D= 9EDI?:;H?D= J>7J J>; JEF?9 ?I ;NJ;DI?L;BO :?I	
9KII;: ?D J>; FK8B?9 FH;II DEM7:7OI
 #EM;L;H M>;D J>;
<EKH 97I; I9;D7H?EI M;H; :;I9H?8;: CEH; J>7D  >7:
>7: ;NF;H?;D9; E< I?JK7J?EDI I?C?B7H JE J>EI; E< J>; IJK:;DJ
EH J>; I>O MEC7D ?D J>;?H EMD C;:?97B FH79J?9; <EBBEM;:
?D <H;GK;D9O 8O J>; EL;H8KH:;D;: I?D=B; CEJ>;H 

7D: J>; ;N>7KIJ;: I9?;DJ?IJ 
 J78B; 
 />?I <?D:?D=
I>EMI J>7J C7DO F7HJ?9?F7DJI C7O DEJ 8; L;HO <7C?B?7H M?J>
J>; FK8B?9 :?I9KII?ED E< J>; F>;DEC;DED 8KJ 97D ?:;DJ?<O
9ECF7H78B; I?JK7J?EDI <HEC J>;?H EMD FH79J?9;
  I?=D?<?9	
7DJ DKC8;H E< F>OI?9?7DI 7H; 9ED<HEDJ;: ZL;HO H7H;BO[ EH
KF JE JM?9; 7 O;7H M?J> IK9> H;GK;IJI 7D: EDBO 7 C?DEH?JO
E< J>; I7CFB; >7L; F7J?;DJI M>E 7IA <EH 9E=D?J?L; ;D	
>7D9;C;DJ M;;ABO EH CEDJ>BO
 )EJ IKHFH?I?D=BO 9;HJ7?D H;	
GK;IJI <EH ) 7H; CEH; <H;GK;DJ ?D 7 ZH7J>;H KH87D[ I;J	
J?D= 
 ?D 9ECF7H?IED JE 7 ZH7J>;H HKH7B[ ED; 

M>?9> C?=>J 8; :K; JE 7 CEH; 9ECF;J?J?L; ;DL?HEDC;DJ
>?=>;H ;NF;9J7J?EDI H;=7H:?D= 9E=D?J?L; 7D: FIO9>EIE9?7B
<KD9J?ED?D= ?D KH87D MEHAFB79;I 7D: ;7I?;H 799;II JE ?D	
<EHC7J?ED78EKJD;KHE;D>7D9;HI

Attitudes towards NE measures
$J ?I ?DJ;H;IJ?D= JE DEJ; J>7J 7BJ>EK=> 7BCEIJ >7B< E< J>; F7H	
J?9?F7DJI :;9B7H;: J>;O MEKB: 7I 7 C7JJ;H E< FH?D9?FB; DEJ
FH;I9H?8; 7DO :HK=I ?D 97I;I IK9> 7I J>; 97I; I9;D7H?EI
8;JM;;D  7D:  MEKB: >7L; FH;I9H?8;: 7 :HK= B?A;
-?J7B?DU C;J>OBF>;D?:7J; (E:7IEC?BU CE:7<?D?B 7DJ?	
:;FH;II7DJI EH 7DJ?	:;C;DJ?7 :HK=I
 $D <79J ?D J>; 78I;D9;
E< 7 J>;H7F;KJ?9 7BJ;HD7J?L; CEIJ H;IFED:;DJI MEKB: FH;	
I9H?8; 7 :HK= ;N9;FJ <EH J>; 97I; E< J>; @;J	B7==;: I9?;DJ?IJ

*L;H7BB 7DJ?:;FH;II7DJI M;H; C;DJ?ED;: CEIJ <H;GK;DJBO
7I J>; IK8IJ7D9;I J>7J MEKB: >7L; 8;;D FH;I9H?8;:
 />;H;
C7O 8; B;II >;I?J7J?ED JE FH;I9H?8; ?< F>OI?9?7DI >7L; BED=	
IJ7D:?D= ;NF;H?;D9; M?J> 7 :HK= 7D: ?< J>; 97I; ?I I?C?B7H JE
7 9ED:?J?ED J>7J 97D 8; 9B7II?<?;: 7I 7 :?I;7I; IK9> 7I IE	
9?7B F>E8?7 ?D J>; 97I; E< J>; I>O MEC7D
 />; EJ>;H 97I;
I9;D7H?EI Y J>; IJK:;DJ M>E :?: DEJ FH;F7H; ?D J?C; <EH >?I
;N7C J>; ;N>7KIJ;: CEJ>;H 7D: J>; @;J	B7==;: I9?;DJ?IJ Y
7H;7BBH7J>;H<7HH;CEL;:<HEC7F7J>EBE=?97B:?7=DEI?I

(EIJ F7HJ?9?F7DJI  >7: 7 H7J>;H FH7=C7J?9 7JJ?JK:;
JEM7H:I )  7BJ>EK=> ?D =;D;H7B J>;O :E DEJ FH;I9H?8;
M?J>EKJ 7D ?D:?97J?ED J>;O MEKB: 9EDI?:;H :E?D= IE ?< J>;H;
M;H; DE J>;H7F;KJ?9 7BJ;HD7J?L;I J>; :HK= M7I <7?HBO I7<;
7D: ?< J>; F7J?;DJ IK<<;H;: 9EDI?:;H78BO 7D: ?DI?IJ;: ED J>;
:HK=
 />; IJK:O E< 7D@E ;J 7B
 56 I>EM;: J>7J J>; I7<;JO
E< 9E=D?J?L; ;D>7D9;HI M7I 7BIE 7 C7?D 9ED9;HD <EH F>OI?	
9?7DI ?D 7D7:7 7D: J>; 0.
 $D EKH IJK:O  7DIM;H;:
Y ?D 799EH:7D9; M?J> J>; FHE<;II?ED7B =K?:;B?D;I Y J>7J J>;O
:E DEJ FH;I9H?8; :HK=I M?J>EKJ 7D ?D:?97J?ED
  IC7BB 8KJ
I?=D?<?97DJ C?DEH?JO  ;IFEKI;: 7 9B;7HBO B?8;H7B FE?DJ
E< L?;M FH;I9H?8?D= :HK=I 7J J>; H;GK;IJ E< ?D<EHC;: F7	
J?;DJI

3;J F7HJ?9?F7DJI 7H; IEC;M>7J 7C8?L7B;DJ ?D :;7B?D= M?J>
J>; ?IIK; E< ) 
 2>;D 7IA;: ?< J>;O MEKB: F;HIED7BBO IK8	
I9H?8; JE 7 97J;=EH?97B H;<KI7B E< )   M;H; KD:;9?:;:
J78B; 
 />?I 7C8?L7B;D9; 7BH;7:O 8;9EC;I 7FF7H;DJ ?D
J>; 8;=?DD?D= E< J>; GK;IJ?EDD7?H; M>;D F7HJ?9?F7DJI M;H;
7IA;: 78EKJ J>;?H IFEDJ7D;EKI H;79J?EDI JE F;H<EHC7D9;	
;D>7D9?D= :HK=I
 />;H; ?I 7 H7J>;H 9EDIJ7DJ 7FFHEL7B H7J;
E< CEH; J>7D  JE L;HO :?<<;H;DJ IJ7J;C;DJI IK9> 7I
ZD;KHE;D>7D9;C;DJ >7I 7BM7OI 8;;D 7HEKD:[ EH ZJ>?I ?I 7I
MHED= 7I :EF?D= ?D IFEHJI[ EH Z;L;HOED; ?I H;IFEDI?8B; <EH
>?I>;HEMD79J?EDI[J78B;

/>;H; ?I 7BIE IEC; KD9;HJ7?DJO 7D: :?I7=H;;C;DJ 7I JE >EM
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3.3 Conclusion
Our survey among 379 physicians revealed that the participants were confronted with
requests for CE, but not very often as one can see in their responses about the case
scenarios. A bit more than half of the participants were familiar with the case scenario
about the student, followed by the case scenario about the shy women. The willingness to
prescribe such CE depends on the expected alleviation of suffering, the lack of therapeutic
alternatives, the safety of the drug and the preferences of the individual. Overall, most
of the participants embrace a pragmatic position towards cognitive enhancement. More
than half of the participants would prescribe a CE to the student, the single mother
or the shy women if no therapeutic alternatives were available with a maximum for the
shy women of 70.1% of agreement. For that case scenario was also the highest value of
positive answers for a prescription observed, leading to our suggestion that some of the
participants ascribed a social phobia to the shy woman.
Overall, we observed a high degree of uncertainty regarding a categorical refusing of
prescribing CE. Out of ten participants were 4 physicians undecided and about 3 people
did agree to a categorical refusing respectively did not agree to it. Only a minority
would agree to a consumer model where physicians would prescribe CE if patients or,
more precisely in such cases, clients would ask for it. More than 60% of the physicians
did not agree to such a consumer model whereas a bit less than 30% were undecided.
Overall our data provides evidence that a minority of patients do ask for CE and that
about half of the physicians decide on a case-to-case basis if they prescribe CE. The
analysis of the survey among physician in Switzerland provides evidence that there is a
need for fostering discussions about CE in public.
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4 Publications on Surveys in non-peer-reviewed
Journals
4.1. Akademien der Wissenschaften Schweiz - Anwendungskontext Neu-
roenhancement (p. 44-56), 2012. German.
4.2. Bulletin SAGW - Braindoping im Alltag (p. 50 and photo front
page), 2012. German.
4.3. SA¨Z, Schweizerische A¨rztezeitung - Die Bedeutung des Neuroen-
hancement in der a¨rztlichen Praxis (p. 504-507), 2013. German.
4.4. SuchtMagazin - Einstellungen und Umgang von A¨rztInnen mit Neu-
roenhancement (p. 25-27), 2013. German.
The following four articles are all in German and published in non-peer-reviewed journals
in Switzerland. The goal of these publications was to foster the discussion in society by
contributing to the information flow between research and society. Additionally, we
wanted to work against a so called media hype concerning the reported prevalence of
use of CE in the media [4]. Therefore, these four articles are in line with the newspaper
articles in appendix B containing information about my work as well as in line with one
of the goals of this work. By evaluating data about usage and handling of CE as well as
attitudes about CE, we want to add data to the discussion taken place in literature as
well as in society.
The four articles were published (1) in a information booklet called ‘Medizin fu¨r
Gesunde? Analysen und Empfehlungen zum Umgang mit Human Enhancement’, pub-
lished by the Swiss Academies of Arts and Sciences in 2012 (edition: 1200 examples in
German, 500 examples in French). (2) in the quarterly published journal of the Swiss
Academy of Humanities and Social Sciences of 3. July 2012 (edition: 2850 examples); (3)
in the weekly published Swiss physician magazine of the Swiss Medical Association of 27.
March 2013 (edition: 36’360 examples in total in French and German); and (4) in the bi-
monthly published magazine ‘Suchtmagazin’ number 3 of 2013 (edition: 1400 examples).
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SAGW Schweizerische Akademie der Geistes- und Sozialwissenschaften
ASSH Académie suisse des sciences humaines et sociales
ASSM Accademia svizzera di scienze umane e sociali
ASSM Academia svizra da scienzas moralas e socialas
SAHS Swiss Academy of Humanities and Social Sciences
Gesundheitssystem im Wandel
Akademien der Wissenschaften Schweiz: FuturICT – Der CERN der Sozialwissenschaften?
SAGW-News: Assemblée annuelle 2012 – Sous le signe de la coopération et de la visibilité
Schwerpunkte: Die erste spanische Übersetzung von Erasmus’ «Lob der Torheit» entdeckt
Dossier | Gesundheitssystem im Wandel 
50 In gewissem Sinne betreiben wir alle «Braindoping». Der Es-
presso nach der Mittagspause, eine ausgiebige Nachtruhe, 
ein Waldlauf – das alles sind Versuche, unser Gehirn mög-
lichst fit zu machen für die Anforderungen, die uns erwar-
ten. Doch wie sieht es aus, wenn wir den Begriff enger fassen 
und darunter die Einnahme von Medikamenten durch gesun-
de Personen zur Steigerung von Gehirnleistungen verstehen?
Wie verschiedene Studien aus den USA, Deutschland 
sowie der Schweiz zeigen, konsumieren zwischen 1,3% 
und 6,9% der Studierenden Mittel zur Steigerung von 
Konzentration oder Wachheit, z.B. Ritalin® oder Pro-
vigil®. Dabei sind es in der Regel nicht die hervorra-
genden Studierenden, die solche Produkte eingesetzt 
haben, sondern diejenigen mit eher schlechten Noten. 
Übrigens greifen durchaus auch Professoren bisweilen 
zu solchen «kleinen Hilfen».
Ärztinnen und Ärzte mit Anfragen konfrontiert
Wie eine Studie ergab, die vom Institut für Biomedizi-
nische Ethik (IBME) der Universität Zürich im Rahmen 
der AG «Human Enhancement» der Akademien der 
Wissenschaften Schweiz durchgeführt wurde, hat die 
Mehrheit der 379 befragten praktizierenden ÄrztInnen 
in den Bereichen Psychiatrie und Hausarztmedizin be-
reits Anfragen für solche Produkte erlebt, wenn auch 
nur circa ein- bis zweimal pro Jahr. Etwa die Hälfte der 
StudienteilnehmerInnen nehmen dabei eine pragmati-
sche Position gegenüber Braindoping ein: Auch wenn 
sie im Allgemeinen keine Medikamente ohne Indika-
tion verschreiben würden, könnten sie sich vorstellen, 
dies zu tun, falls es keine therapeutischen Alternativen 
gäbe, das Medikament ziemlich sicher wäre und der 
subjektive Leidensdruck hoch wäre. Etwa ein Drittel 
der Befragten würde sich dem Braindoping kategorisch 
verweigern, und eine Minderheit von etwa 10% der Ärz-
tInnen würde eine radikal liberale Position einnehmen 
und informierten Patienten allein aufgrund ihres Wun-
sches Medikamente verschreiben. 
Entlastung mit Konsequenzen
Noch sind die Möglichkeiten effektiven, risikoarmen 
Braindopings beschränkt. Doch sollten dereinst ent-
sprechende medikamentöse Möglichkeiten zur Verfü-
gung stehen, ist anzunehmen, dass ein signifikanter 
Teil der Bevölkerung einem Konsum – sei es mit ärztli-
cher Verschreibung oder in Eigenregie – nicht abgeneigt 
wäre. In einer Studie des IBME mit über 1700 Studie-
renden der Universität Zürich konnte gezeigt werden, 
dass etwa ein Drittel der Personen, die bereits mindes-
tens einmal in ihrem Leben ein Medikament als Brain- 
doping konsumiert haben, davon ausgingen, dass es in 
zehn Jahren normal sein wird, solche Produkte zu neh-
men. 
 Doch während dem überlasteten Individuum mit 
medikamentösem Braindoping möglicherweise kurz-
fristig geholfen wäre, würden sich die Normen weiter 
verschieben – Ansprüche an Leistung, Verfügbarkeit 
und Mobilität würden weiter steigen, auf Kosten der 
Toleranz für Unpässlichkeiten und Unangepasstheiten, 
die aber zugleich das Humane einer Gesellschaft aus-
macht. 
Ziel der Studie
Die AG «Human Enhancement» hat einen Ansatz ge-
wählt, der medizinische, sozial- und geisteswissen-
schaftliche Perspektiven zusammenführt. Mit ihren 
Erwägungen möchte sie nicht nur Hilfestellung für 
eine Positionierung der Ärzteschaft bieten, sondern 
auch zu einer breiteren gesellschaftlichen Debatte bei-
tragen. 
Braindoping im Alltag
Regula Ott, Nikola Biller-Andorno, Institut für Biomedizini-
sche Ethik, Universität Zürich
-W.
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5 Cognitive Enhancement and Productivity
5.1 Introduction
The main aim of this work is to look critically at the claim that increased productivity
is a benefit of cognitive enhancers as it has been stated in literature on cognitive en-
hancement. Using the term ‘productivity’, the focus of this chapter is (1) to reveal that
in the literature about cognitive enhancers (CE), an assumption is sometimes made that
productivity is necessarily a good thing, and (2) to indicate why we should be critical of
this claim. In the literature on cognitive enhancers, different authors have highlighted
that such products could be used to fulfil unjust or undesirable social norms. I want
to specify such a concern by focusing on possible influences of the social structure on
our understanding of productivity. For that, I will analyse the connection between the
evaluating of cognitive enhancers and productivity as well as between productivity and
the social structure we live in. By highlighting social norms, which could influence our
evaluating of productivity, I want to challenge the claim made in the literature of CE of
simply assuming that increased productivity is desirable. I ask for a discussion about
these social norms if we want to support and reinforce them by adapting ourselves to
them or if we rather want to subvert or supplement these social norms. This way we can
decide if we want to use such a claim about increased productivity in favour of CE in
the debate of weighing up different ethical values against each other deciding if cognitive
enhancement is a good or bad thing to do.
I want to point out that this argument states only that the system we live in, in
our case late capitalism, could have an influence on our understanding of productivity.
Because of such a possible influence, we ask for a critical view on the claim that increased
productivity is per se something desirable and seen as a reason for taking CE. I am aware
that other arguments in favour of CE exist that are not based on increased productivity
and can therefore most probably not be linked to late capitalism at all, or only less
directly. For example the argument about the reduction of valuable human diversity
when being able to control how we are along with the lack of imagination regarding how
various we could be [51].
Neither do I want to criticize productivity in itself. When looking at various definitions
given in dictionaries, I conclude that productivity is mostly understood as work produc-
tivity, defined as output divided by work input [111, 112]. Rarely, a creative definition of
productivity is included, which is very close to the opposite of work productivity. The
main difference between work productivity and creative productivity is: Work produc-
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tivity is focusing on the input in relation to the output whereas creative productivity
looks only at the output, independent of the input. The quotes given above about CE
and productivity can relate to work or to creative productivity. Does it refer to e.g.
an academic who finds a new solution to a problem (creative productivity) or a worker
on the assembly line, who is taking Modasomil for being able to cope better with shift
hours (work productivity)?
Allen Buchanan defined productivity in the broad sense as ”how good we are at using
existing resources to create things we value” [113, p. 44]. He explicitly does not want
to reduce productivity on such a narrow definition as the ”efficiency in the production
of economic goods” [113, p. 44]. He states that increased productivity in such a narrow
definition does not guarantee increased well-being, because it can be that the things we
value economically turn out not be good for us. This is exactly what I am asking for –
a careful use of the term productivity as done e.g. by Allen Buchanan. What I want to
indicate for being critical about it is seeing increased productivity as desirable by seeing
ourselves as ”entrepreneurial self” [114]. Taking CE would in such an understanding
increase our productivity leading to more output and therefore more success, which is
than linked to a higher quality of life. In this chapter, I will analyse each of these steps
of such a connection of productivity and quality of life in relation to late capitalism and
provide reasons for a more critical view of such an understanding.
5.2 The Assumption about Productivity
Different definitions exist for the well-known term ‘cognitive enhancement’. I will work
with a slightly adapted definition deriving from a frequently quoted paper of Greely et al
[5]. Our definition of cognitive enhancement is the following: The usage of medications
used to treat psychiatric and neurological conditions for improving directly the cognitive
performance standing for the improvement of the short- and long-term memory as well as
effects on the executive functioning of a healthy person.’ These medications are standing
for the so-called CE. I will focus here on arguments raised in the field of cognitive
enhancement in relation to increased productivity but will integrate arguments raised
in the broader debate about human enhancement. The reasons given here for a critical
view also apply for human enhancement in general, if similar claims to the once observed
in the context of CE are made.
In the same paper of Greely et al [5] was an argument given for the usage of CE. The
authors claim that ”In a world in which human workspans and lifespans are increasing,
cognitive enhancement tools - including the pharmacological - will be increasingly useful
for improved quality of life and extended work productivity, as well as to stave off normal
and pathological age-related cognitive declines. Safe and effective cognitive enhancers
will benefit both the individual and society.” Other authors in the field of cognitive
enhancement proposed that: ”We can expect greater productivity or more creative and
intellectual breakthroughs, which is why individuals would want to be enhanced in the
first place.” [115]. Productivity is mentioned in several chapters of the book edited
by Julian Savulescu and colleagues on enhancement [116]. In the various essays of this
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collection, increased productivity is seen unquestionably desirable and not scrutinised in
itself.
Henry Greely and colleagues state the effect of CE of increased productivity on the
same level as improved quality of life. The authors see an extended productivity as
something that is good in itself and therefore something desirable and an argument for
the usage of CE. Other authors say that increased productivity is good because it leads
inevitably to increased quality of life. This is done explicit by e.g. Martha Farah [117]
or more implicit as I understand the argumentation given e.g. by Allhoff et al [115].
The main question here is not, if the products actually lead to an increased produc-
tivity. What I want to address here is the assumption that an increased productivity
is something desirable. The concerns raised in the quoted papers are about the safety,
freedom and fairness of increased productivity by means of CE but the assumption about
productivity being a good thing is not questioned.
5.3 Why We Should be Critical about this Claim
For showing why I ask for a critical view of such a claim about the positive evaluation
of increased productivity, I will first focus on ‘social structure’. In a second step, I will
look closer at social norms about productivity for than being able to elaborate possible
influences of the social structure we live in, namely late capitalism, on our understanding
of productivity.
Various definition of social structure exists and are based on the work of social theorists
from Herbert Spencer in 1873 and later mile Durkheim in 1893 [118, p. 12f], through
Talcott Parsons and others in the 1940ies to the 60ies to Claude Le´vi-Strauss (1968),
Michel Foucault (60ies and 70ies) and Pierre Bourdieu (70ies and 80ies). Jose´ Lo´pez and
John Scott attempt to address these diversities and develop a clear and explicit concept
of social structure[118]. For our work, the more general parts of these various definitions
focusing on the common features of social structure will be sufficient. Referring to the
online version of 2012 of ’the Oxford Dictionary of Sociology’ by John Scott and Gordon
Marshall [119], social structure is defined as ”a term referring to any recurring pattern
of social behaviour; or, more specifically, to the ordered interrelationships between the
different elements of a social system or society. [...] The core institutional norms and
meanings are cultural phenomena that exist only as shared ideas and representations
in the minds of individuals. For this reason, socialization into a culture is central to
the maintenance of a social structure” [119]. For testing if such influence of the social
structure on values and norms of the individuals could exist, one can look at real life
situation. A population should be at best split into two and then exposed to different
social structure and, to see an influence of another social structure once again, being
reunited afterwards. A situation like that existed in Germany. For example a comparison
of Eastern and Western Germany focusing on institutional changes and the attitudinal
changes revealed that: ”New institutions create new normative expectations that lead
to new attitudes towards public policies [120].” Such real life events do not give clear
experimental data, but it gives some evidence that the social structure can influence the
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attitudes and social norms of the individuals living within it.
In sum, the social structure refers to any recurring pattern of social behaviour. These
behaviours are influences by social norms that exist as shared ideas in a culture to which
we get access by socialisation into the culture. In am going to consider some of the key
work so far on social norms and CE or human enhancement in general in the following
paragraphs.
Nikolas Rose has mentioned this aspect of careful analyse in the context of CE [121,
p. 41]. He argued that when we use technology to adapt to a work regime, we should
carefully analyse if the system we adapt to is acceptable or intolerable. If the latter
is true, than we should change the working conditions for humanize work rather than
changing the employee. An example is the use of video conferencing rather than tak-
ing Modafinil to overcome jetlag [121, p. 41]. But the use of e.g. video conferencing
emphasises the position of humans as components of a system [121, p. 41]. So even if
we prefer to change working conditions rather than the employees themselves, we have
to carefully consider as to whether this is acceptable. The working conditions provide
employees with a range of activities and interactions for an appropriate balance of stress
and intellectual demands. Additionally, employees have to have adequate levels of con-
trol over their work [121, p. 41]. An example that is given is the need for sufficient breaks
for air traffic controllers. CE as concentration aids could also allow these employees to
work better for longer, but a system that relies on such CE may have negative impacts
on the jobs. Such impacts are that such jobs are less satisfying and with a higher risk
of failure mechanisms as well as long-term risks to health and well-being according to
prolonged exposure to demanding working conditions [121, p. 41]. Taken together, the
authors of report on human enhancement and the future of work [121] state by referring
to Nikolas Rose that changes of the employees or of the work environment have to be
carefully considered if they are acceptable. This is only the case if employees have an
appropriate balance between stress and intellectual demands, have some control over
their work and not having any long-term risks to health and well-being according to
prolonged exposure to demanding working conditions.
Margaret Little wrote about social norms and human enhancement in general by
presenting three case studies about (1) a man who wants to have a double chin because
this is seen in the society he lives in as beautiful; (2) a boy who wants his ears that stick
straight out by surgery closer to his head; and (3) a black man wanting to have surgery to
look more like a white person and a healthy woman who wants to look like a supermodel
[52]. Margaret Little concludes that the social norms of appearance behind the third
case study are unjust. The author mentions two main reasons for such a conclusion
of seeing the third case as morally problematic. Firstly, that the cost society imposes
on individuals if they are failing to life up to such norms of appearance are ‘excessive,
punitive, unfair or cruel’ [52]. Another important source of moral unease about such
surgeries are that the very content of such norms about appearance are morally suspect.
Such content are the broader system of attitudes and actions by which the norms of
appearance are grounded in or get life from.
Maartje Schermer and her colleagues adapt the examples of Margaret Little to the
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context of CE [53]. The authors ask if such unjust attitudes and actions like racism and
sexism behind norms of appearance are also playing a part in the context of CE. The
authors conclude that these kinds of suspect norms are not applicable in the context
of CE. They are giving examples of other norms in the context of CE like the society’s
emphasis on cognitive performance, 24/7 economic activity, or individual happiness.
Maartje Schermer and her colleagues conclude that ‘it would be difficult to argue that
these norms are unjust’ but that some norms might be undesirable for other reasons
like adapting workers to the demands of employers and society. I agree with Maartje
Schermer saying that it is not primarily sexism or racism making these norms in the
context of CE unjust. But I assume that an analogy to such discriminating attitudes
as sexism or racism behind such norms in the context of CE can be drawn. Calling the
discrimination on the basis of one’s concentration and alertness ability ’neuroableism’,
one could argue that there are unjust attitudes behind the norms in the context of CE.
Therefore for calling the norms in the context of CE unjust analogue to Margaret Little
in the context of norms around appearance, one has to shown that such discrimination
is taking place. I will focus on that point in section 5.4.3.
Dieter Birnbacher mentions this problem about complicity in his essay from 2006
where he argues that we have to look at the expectations of society when looking at
cognitive enhancement [122]. A successful adaption of an individual to a social norm
could be the fulfilment and confirmation of a norm without which the society as a whole
would be better off. This argument highlights the aspect that the interaction between
social norms and us goes in both directions; our behaviour influences the establishment,
maintenance or transformation of social norms and our behaviour is in turn influenced
by the social norms.
Such a questioning of some social norms rather than adapting to them has also been
raised in the quote above of Rose [121, p. 41] as well as by Claire Bambra [123]. Bambra
gives the following two examples: 1) the adaptation to shift work rather than rethinking
such work; 2) the increase of employment rates of people with a disability or chronic
illness by targeting the individual rather than changing structural barriers such as the
workplace design or the working hours [123, p. 193].
These authors support my suggestion of a critical view of the claim regarding increased
productivity by looking at the social norms behind such a claim. The authors recommend
questioning the fulfilment of certain social norms if the attitudes and actions behind
them are ‘unjust’ [52], ‘undesirable’ [53] or if the society would be better off without
these social norms [122]. In section 5.4.1, I will give reasons for assuming norms behind
the evaluation of increased productivity as desirable and will focus in section 5.4.3, under
which circumstances these norms are unjust, undesirable or without them we would be
better off.
Many authors have identified the social structure we currently live in as ’late capi-
talism’. This particular social structure has a strong influence on our understanding of
work and therefore of productivity. As stated by Tilly and Tilly in their book on ‘Work
under Capitalism’, labour markets that emerge in different social structure like e.g. state
socialism or mercantile capitalism operate in different ways because of different princi-
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ples or organization and interpersonal networks as well as different shared memories,
understandings and expectations [124, p. 138]. Furthermore, the authors conclude that
the relative salience of the goals of quality, efficiency and power depend on the task at
hand as well as on the culture being defined as the shared understandings and their rep-
resentations [124, p. 258]. In the following I want to show that these definitions of labour
markets and the influence of culture on efficiency by Tilly and Tilly combined with pre-
vious definitions lead to the conclusion that the social structure we live in can influence
our understanding of work as well as our understanding and evaluating of productivity.
As I have mentioned earlier, productivity is mostly defined as output divided by
work input. Tilly and Tilly define efficiency as large output for small inputs [124, p.
84]. Therefore efficiency is a synonym for increased productivity. The term ‘culture’
was part of the definition given above about social structure where ’socialization into
a culture is central to the maintenance of a social structure’[119]. Together with the
connection given by Tilly and Tilly that culture influences the relative salience of the
goals on quality, efficiency and power, this leads to an influence of social structure via
culture on weighting of efficiency compared to quality and power.
Tilly and Tilly, who said that labour markets emerging in different social struc-
ture operate differently, have given the connection between the social structure and
the labour markets. Taken together, the authors are therefore complied with my un-
derlining premise of the concern that the social structure we live in can influence our
understanding of work as well as our understanding and evaluating of productivity.
5.4 Lets be Critical about this Claim
If it is the case that the social structure we live in does at least in parts influence social
norms, then this could influence our evaluation of productivity. This in itself does not
ask for a critical view of the claim about evaluating increased productivity as desirable.
But when adding the premise that the attitudes and actions behind some social norms
are unjust [52] or undesirable [53] or without some social norms the society as a whole
would be better off [122, 123], the situation is different. Than it would be a necessary
condition to analyse the social norms behind such a claim more carefully if we do not
want to adapt to unjust norms or to such norms without which we would be better off.
To do such an analysis, I first want to focus on why I assume that there is a social norm
behind the claim that increased productivity is good. I then look at our understanding of
social norms concerning the body and will link this to the understanding of productivity
in late capitalism and its connection with our desire to increase the quality of life. I
focus here on late capitalism seeing it as the social structure the authors of the claim as
well as we are living in. After showing some possible influences of late capitalism on our
understanding of quality of life, I will focus in 5.4.3 on circumstances in which such a
social norm about our understanding of seeing increased productivity as desirable could
be unjust or undesirable.
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5.4.1 Social Norms
Social norms are ”common standards within a social group regarding socially acceptable
or appropriate behaviour in particular social situations, the breach of which has social
consequences. The strength of these norms varies from loose expectations to unwritten
rules” [125]. Due to the fact that different authors mentioned the valuing of increased
productivity as something desirable without giving reasons for such a claim seems to
give reasons for classifying it as ’loose expectations’. What sort of social norms could
lead to such loose expectations is discussed by Paula-Irene Villa.
As she states in her essay [126, p. 138], the lack of medical or other experts telling
us what we have to wear or which sport we should do has been replaced in the social
structure we live in by the mantra of overcoming the own imperfection. Iris Ritzmann
wrote in her essay that the norm is to be young, beautiful and in many cases male. For
being seen as normal and healthy, one has to adapt oneself to this idealized norm [105,
p. 33]. In such a social structure, I will show in the next paragraph that the usage of CE
to increase one’s productivity could be seen positively as reaching the ideal of oneself.
Peter Miller and Nikolas Rose wrote in their essay that we see ourselves in ’advanced
liberal democratic societies’ as entrepreneurs with the goal of maximizing our quality
of life by building ourselves a life style out of material goods [127]. By buying the
’commodities’ which have been attached with a ’personal’ meaning by advertisement,
this commodities will ”glow cast back upon those who purchase it, illuminating the kind
of person they are, or want to become” [127, p. 25].
The worker, according to the authors, is not anymore construed as a social creature
that wants to satisfy her or his need for security, solidarity and welfare. But we now
see us as individuals with the goal of maximizing our success and achievement by ac-
tively shaping and managing our life. When seeing ourselves as entrepreneurs, then our
personal success and achievement themselves may become synonymous with enhanced
productivity and the fostering of innovation through the active self-fulfilling impulses of
us as employees [127, p. 26].
Grit Ho¨ppner and Sigrid Schmitz give evidence for such an understanding of us as
entrepreneurs by analysing 21 journal articles between 2006 and 2011 concerning cogni-
tive enhancement [128]. The articles were published in one of the following four German
online-portals of ‘Spiegel Online’, ‘Zeit Online’, ‘sueddeutsche.de’ and ‘stern.de’. The
goal of this survey was to investigate the debate about pharmacological enhancement
in the media and focusing on gender relevant assumptions concerning terms like ‘per-
formance and success society’, personal responsibility’, ‘productive efficiency’ and ‘emo-
tionality’. Ho¨ppner and Schmitz write that CE have been described as tools to support
the ”entrepreneurial self” [114]. Ho¨ppner and Schmitz criticize that in these articles are
only seldom asked for a reflection of the social development. The authors assume that
CE can treat the symptoms, but cannot resolve the source of increased pressure for
success [128]. As seen above, success is a synonymous for increased productivity [127,
p. 26]. Grit Ho¨ppner and Sigrid Schmitz conclude that the analysed media communica-
tion one main message: For being successful and competitive, CE seems useful for both
gender to optimize oneself. Or in the words of Degele and Schmitz: The alignments
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of efficient skills of ‘capitalism compatible bodies’ [129]. But Grit Ho¨ppner and Sigrid
Schmitz state that this aspect to optimize oneself is based on a gender specific difference
where masculinity is linked to above-average productive efficacy and rational abilities,
whereas femininity is linked to average productive efficacy and short-sighted success as
well as emotional enhancement for an emotional regulation. The authors conclude such
a difference according to the frequent quotation mentioned in the publication of the sur-
vey among German employees [3] that men are more often taken CE to increase their
concentration and the capacity for remembering, whereas women are more often taken
CE that enhance mood and minimize feelings of fear. Grit Ho¨ppner and Sigrid Schmitz
criticise that such findings are not critically reflected. They conclude from their analysis
that it is stated in the media that men are using CE occasionally for keeping the ideal
level of productive efficacy whereas women need a regular use of CE to keep up on such
a level, the optimising paradigm about CE reproduces gendered capabilities and mental
states. They would most probably agree with Maartje Schermer saying that sexism is
not an underlying attitude on which norms about the use of CE are based on because
both gender are taking CE. But the reasons mentioned for such an intake are influenced
according to Grit Ho¨ppner and Sigrid Schmitz by prejudices about gendered capabilities
and mental states.
Miller, Rose, Ho¨ppner and Schmitz support our claim that in late capitalism an in-
creased productivity is seen as a personal ideal and that we want to achieve it among
other things for maximizing our success. And this goal of maximizing success is itself
linked to our desire for ’optimum personal happiness’ [127, p. 28]. Optimal personal
happiness is equivalent or at least part of the understanding of human flourishing that
is a synonym of the term ’quality of life’. Therefore, having now the line that we want
to increase our productivity for maximizing our success and achievement for increasing
our happiness. Happiness can be seen a part of human flourishing, which is a synonym
for the quality of life.
In the next section I focus on quality of life and how late capitalism could influence
our understanding of it. This will be a summary focusing on its understanding deriving
from the one of increased productivity but will also contain new aspects of an influence
of the social structure we live in.
5.4.2 Quality of Life
When looking at the international cross-culturally comparable assessment instrument
developed by the WHO in 1991 for measuring the quality of life [130], further possible
fields where the social structure we live in could influence our understanding of quality
of life can be observed. The questions of this measuring instrument being of interest
in relation to human enhancement and late capitalism are about 1) the meaningfulness
of ones life, 2) the acceptance of ones bodily appearance, 3) the opportunity for leisure
activity, 4) the satisfaction about ones capacity for work and 5) the satisfaction of oneself.
These five questions being part of the quality of life instrument are the ones I think are
important when discussion the influence of the social structure on our evaluation of
increased productivity in relation to quality of life.
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The meaningfulness of ones life is linked to our desire for a better world. One has
to be able to imagine a meaningful life to compare it to the current life one has. Such
an imagination is an important part of being able to dream of a better world. A thesis
present in the field of research on utopia from a sociological perspective is that our desires
for a better world are captured by late capitalism [131]. Zygmunt Bauman describes
happiness in our social structure of modernity as the following: Happiness as something
that is thought as an aim one has to reach individually and is seen as a series of happy
moments succeeding each other and not anymore as a steady state and therefore unlike
the utopian model of a good life [131, p. 23]. He concludes that ”the desire for a different
today has elbowed out concern with a better tomorrow” [131, p. 24]. Examples for such
an understanding of desire were given by Paula-Irene Villa of an ideal self concerning the
body [126, p. 138] and by Peter Miller and Nikolas Rose about the desire for happiness
linked to success and achievement [127]. If such an understanding of happiness is true
and is not only the case for modernity but specifically for late capitalism, then we are
not able to dream of a better world anymore. This is because our desire for a better
world has been captured by late capitalism and turned into a desire for maternal goods
as well as success and achievement.
The acceptance of ones bodily appearance, another question in the WHO questionnaire
about the quality of life, was discussed above concerning social norms and the body. As
stated by Paula-Irene Villa as well as Iris Ritzmann, we orientate ourselves towards
norms of an ideal bodily appearance. Therefore, this question related to our social
norms about the body is, according to Villa, influenced by late capitalism in which an
athletic body is used for demonstrating discipline, mobility, flexibility and autonomy
[126, p. 138]. Taking these two points about ideal norms and the influences of them by
late capitalism together, the conclusion is that late capitalism influences how we see our
bodily appearance.
The third question of interest in relation to human enhancement and late capitalism is
leisure activity. It has not in itself to do with capitalism but the term is linked to work,
CE and productivity. The data of a survey among students of the University of Zurich
[132] revealed that one of the two reasons why these students took or could imagine
taking cognitive enhancers was that ‘I could finish much of my work in less time and
would therefore have more leisure time and less tress’. This would only be true, if the
goal one has or wants to fulfil is finite. Otherwise, the goal of work would just increase
leaving the same amount of leisure time as before taking such cognitive enhancers (and
impose a social pressure for all employees to take such cognitive enhancers for reaching
the now increased goals). Looking at the increases in efficiency since industrialization
and our current working hours, I conclude that our working hours would be less by
today than they are if the working load would be more or less fix. This leads me to
the assumption that there is no steady state of working goals but that they grow with
increased efficiency and are therefore relative and not absolute.
The fourth question I want to focus on out of the measurement tool of the WHO
is about the satisfaction about ones capacity for work. As stated by various authors,
work maintains a successful capitalist economy and reinforces capitalist relations and is
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therefore promoted as a ideologically good thing as written e.g. by Claire Bambra [123,
p. 4]. One of the negative points of such a view can be seen when a person lacks paid
work (does not want to or cannot) leading to stigmatisation [123, p. 4]. Therefore the
inclusion of this question in a catalogue for evaluating our quality of life is in itself most
probably influenced by late capitalism where being able to work is seen as a good thing.
Additionally, work leads in late capitalists society to income. So at least in societies
with no or inadequate unemployment welfare, the relationship between the quality of
life and the own capacity for work is based on economic reasons.
The last question of the WHO is about how satisfied one is with oneself. The answer
to this question is in my view influenced partly by the answers one gives to the previous
discussed questions about the meaningfulness of life and the acceptance of ones bodily
appearance. Therefore, having shown that the answers to these two previous questions
are influenced by late capitalism, one can deduce a secondary influence on this question
about how satisfied one is with oneself. I am aware that many other aspects most
probably exist, which influence the answer to this question but at least some influences
derive from the social structure we live in.
Taken together, some of the questions of the WHO questionnaire on the quality of life
can be influenced by the social structure we live in as well as our evaluation of increased
productivity. This leads us to the conclusion that our understanding of quality of life is
also influenced by the system we live in.
5.4.3 Evaluation of the Social Norm about Productivity
I have elaborated the influence of late capitalism on social norms about our body in
relation to productivity and on our understanding of a flourishing life. As stated above,
such an influence in itself does not ask for a critical view of the claim about seeing
increased productivity as desirable. But when adding the premise that the attitudes
and actions behind some social norms are unjust [52] or undesirable [53], that the costs
on individuals if they are failing to live up to the norms are excessive or cruel [52], that
the system we adapt to is intolerable [121, p. 41] or that without some social norms the
society as a whole would be better off [122, 123], the situation is different. Than it would
be a necessary condition to analyse the attitudes and actions behind such a claim more
carefully. In this section, I want to analyse if this is the case in the context of being in
favour of CE because such products can increase ones productivity.
Social norms that could lead to our loose expectation of increasing productivity are, in
a nutshell, about overcoming our imperfection by imaging our ideal equal to successful
entrepreneurs [126, 127, p. 138]. It is possible that we think such an overcoming of our
imperfection and becoming successful entrepreneurs is increasing our quality of life and
that our desire for a better life is captured by such a wish.
Therefore one of the main questions is, what are the costs on individuals and their
attitudes to increase their productivity to overcome their imperfection or becoming suc-
cessful entrepreneurs? To focus on possible attitudes and costs, I will look at the ex-
ample of work. As mentioned previously by Miller and Rose, when seeing ourselves as
entrepreneurs, then our personal success and achievement is a synonym for enhanced
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productivity [127, p. 26]. Additionally, the quotes in section 5.2 about CE and the claim
of increased productivity as desirable are often discussed in reference to work. These
two reasons are why I will focus on work in the following.
The costs of not working is stigmatised e.g. [123, p. 4]. But are the costs of so-called
’neuroableism’ in relation to work as excessive, punitive, unfair or cruel as for racism
or sexism? ’Neuroableism’ was defined as the discrimination based on concentration
and alertness ability. These functions can be improved with CE according to Henry
Greely and others to increased productivity. An example for such exclusion based on
neuroableism is that being not very good in concentrating leads to a lower education
level (of course many other reasons can lead to the same output). This does often result
in taking up jobs, which are less respected in society and containing also lower wages.
The difference to exclusion according to skin colour or gender is that for at least some of
these jobs the ability of being able to concentrate is a necessary requirement for fulfilling
the job. But the question remains if we support or even increase discrimination on the
basis of neuroableism by taking CE to increase our productivity. This would be the case
if we support unjust attitudes underlying such social norms when evaluating increased
productivity positively. Taken together, the main question is: When is exclusion based
on neuroableism unjust? Or in the words of Dieter Birnbacher, when would we be better
off not focusing on increasing productivity anymore but rethinking the strong focus on
the abilities of concentration and alertness?
In the following, I will give a possible answer based on the theory of justice of John
Rawls. He stated that social and economical injustices are only acceptable if they are
for the greatest benefit of the least-advantaged members of society and if these offices
and positions are open to everyone under conditions of fair equality of opportunity [133,
p. 81]. John Rawls states that humans with the same abilities and the same willingness
should have the same chances of success [133, p. 93]. These abilities like intelligence or
physical strength are distributed in society by chance [133, p. 29] and such a natural
and unequal distribution is neither just nor unjust but a natural fact. What can be
just or unjust are the ways in which institutions act in the light of these facts [133, p.
123]. In the context of concentration and jobs would that mean that such inequalities
in wages are only just if the person being worst off in a society is better off having such
inequalities compared to not having them. And also that people of the same abilities
have equal access to CE as well as education. Otherwise the system has to be changed.
I do not want to get here into the field of various social justice theories. What I want
to point out is that exclusion on the basis of the ability of concentrating is according to
John Rawls not in itself just or unjust but it depends on how the society builds on such
abilities. The same can be applied for the claim that increased productivity is a benefit.
Only if the use of CE according to increase productivity is leading to an improvement
of the life of the persons being worst off in a society, than there is no objection based on
the theory of John Rawls. But if it is the case that some of the people belonging to the
worst-offs in a society are not as productive as others, then it could be that the pressure
on them increases to become more productive. If such pressure leads to a worsening
of the situation these people are in, than such a claim would be unjust. This view is
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similar to the one of Margaret Little focusing on the cost of the ones not fulfilling a
specific norm.
Taken together, the possible social norms influencing our positive evaluation of pro-
ductivity to overcome our imperfection or to become successful entrepreneurs could be
unjust. This would be the case if the underlying attitudes are unjust or undesirable e.g.
if such norms reinforce discrimination based on concentration and alertness ability or if
the costs for individuals not fulfilling these norms are excessive, punitive, unfair or cruel.
5.5 Conclusion
The main aim of this work was to look critically at the claim that increased productivity
is a benefit of cognitive enhancers as it has been stated in literature on CE. An increased
productivity wants to be reached by increasing concentration and alertness. Asking for
such an increase could reinforce discrimination on the basis of these abilities I have
called ’neuroableism’. If our wish of increased productivity is based on undesirable
social norms [53], we should be careful using this claim as an argument in favour of CE.
Such undesirable social norms in the context of productivity being influenced by late
capitalism could be the wish to overcome our imperfection by imaging our ideal equal
to successful entrepreneurs.
According to these possibilities of acting on unjust or undesirable social norms when
being in favour of the use of CE to increase productivity, I ask for a careful use of
this claim. There are for sure additional social norms influencing such a claim about
productivity next to overcome our imperfection or to become successful entrepreneurs.
It is important to identify, examine, question, challenge and at the end to try to subvert
or supplement these social norms if necessary. Being reflective about one’s position,
assumption and unquestioned framework behind such a claim enables us to exclude the
reinforcement of unjust social norms. This is why I ask for a critical debate about what
sort of social norms around increased productivity we want to reinforce when using the
claim about a positive evaluation of increased productivity in the discussion around CE.
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6 Conclusion
Since 2001, a number of surveys about the usage of cognitive enhancers (CE) have
been accomplished in different countries. Table 1.2 (p. 21) contains 14 surveys among
students or the general public with at least 500 participants. In this selection are also
included three surveys among physicians not asking about their usage of CE but about
their handling with requests for CE and their own attitudes about CE.
When starting my Ph.D., no data about the situation concerning the usage of CE in
Switzerland were available. We launched two surveys, one among 1765 students of the
University of Zurich (Chapter 2) and the other among 379 physicians in Switzerland
(Chapter 3). We explored attitudes and the handling of requests for CE.
The survey among students revealed that 6.2% of the participants have taken Ritalin R©,
Adderall R©or Modasomil R©at least once in their life as a healthy person. For study
purposes meaning for the preparation time or for the exam, 4.7% of the participants
have used a CE and most often Ritalin R©and more than five times in their life (almost
half of the ‘CE-users’). The knowledge about a possible use of Ritalin R©as a CE was
widespread and almost 3/4 of the participants knew of it. The most common reasons for
a usage for the CE-users were to be more concentrated (about 3/4 agreed) followed by
out of curiosity as to how it takes effect and to be more awake. Most of the CE-non-users
could not imagine a use of CE at all or rather not (almost 70%). The other 30% chose
most often the same three reasons as the CE-users but with ‘out of curiosity as to how
it takes effect’ as the most common one.
When asking about side effects, the CE-non-users categorized them more often as
rather critical or very critical for Ritalin R©compared to the CE-users. The CE-non-users
formed their opinion of the side effects most often by reading about CE in the media
whereas the CE-users by reading specialist literature. This is surprising because analyses
of the presentation of CE in the media have shown that the negative side effects are less
often mentioned compared to the positive effects of CE (see Section 1.1) [2, 4]. A possible
explanation could be that the CE-users have chosen the answers they thought are more
appropriate as e.g. having to be well informed when using such CE.
When asking the participants about reasons for taking CE and concerns about CE,
both groups chose the same three respectively two statements most often. Out of six
reasons, the three most often chosen statements were about finishing much of the work
in less time, learning more quickly and regaining lost mental vigour. The values of
agreement for the CE-users were about twice as high compared to the values for the
CE-non-users. The opposite distribution was found for the concerns. The values of
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agreements for the CE-non-users were about 1/4 to 1/3 higher than the values for the CE-
users. The two concerns out of ten concerns where the most of the participants agreed
were about possible side effects and about finding the goal to achieve more of these CE
questionable. The third most common concern for the CE-users was about that these
products represent an unnatural interference with our bodies and for the CE-non-users
about the gut feeling telling oneself to keep the hands off such products.
These results were the first ones about students in Switzerland including questions
about ethical considerations. The results of our surveys are discussed in comparisons
with other surveys about the use of CE among students or the public in the publica-
tion (p. 35) and in comparison to the other survey accomplished among students in
Switzerland [74] in section ‘2.5 Conclusion’ (p. 68).
With the data of the survey among physicians in Switzerland, we looked from a dif-
ferent angle at the use of CE. The main goal was to ask general practitioners and
psychiatrists in Switzerland about their familiarities of requests for CE and their will-
ingness to prescribe such products. Four case scenarios were presented about a student,
a single mother, a shy young woman and a scientist. The most common answer when
asked about prescribing something or not was in all four case scenarios that one would
only prescribe a drug if no therapeutic alternatives were available. Around 1/3 of the
participants who would prescribe a drug either for sure or if no therapeutic alternatives
were available chose beta blockers in the first scenario and Modasomil R©in the fourth
scenario. Around 40% of the participants who would prescribe a drug chose antidepres-
sants in the second and in the third scenario (Table 4 of ‘3.2 Publication’). When asked
if the participants do know of such request from their own work, the highest value of
agreement was found for the case scenario about the student followed by the one about
the shy women. Both scenarios were known by a bit more than half of these physicians.
About 40% of the participants have been confronted with the case scenario of the single
mother and about 1/5 with the one about the scientist. One out of 10 participants knew
all three case scenarios from their workaday life and about 2 people have not experienced
any of them. The frequency of such request were most often 1-2 times per year for case
scenario one, two and three and even less for the fourth scenario.
When asked about their personal attitudes towards CE, most of the participants were
unsure if they would count themselves among those who principally oppose CE. But also
less than 10% would embrace a consumer model (Table 6 of ‘3.2 Publication’). More
than half of the participants agree to the statement that every physician should decide
for her- or himself if she or he wants to practice CE or not (Table 8 of ‘3.2 Publication’).
This ambivalence and uncertainty regarding the opinion about the prescription of CE is
in line with surveys done in the US and in Canada and is discussed in the publication.
In sum, people requesting for CE are approaching physicians in Switzerland but not
very often. But as seen in the survey among students did more than 2/3 of the CE-
users receive the product from friends or family members and only a bit less than 1/4
from a physician. The physicians themselves did most often neither agree nor disagree
completely to the prescription of CE but rather decide on a case-to-case basis. On the
other hand revealed our survey among students that some of them are taking CE for
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study purpose but much less as it might appear in the media. These results are in line
with previous studies done in Germany and in Switzerland.
The two surveys can add knowledge to each of the three steps of ethical reflection
according to Pascal Borry and his colleagues [43] (Section ‘1.4 Ethics and Empirical
Data’). In the following, I will look at the contribution of these two surveys to each
step. Answers to the first step about describing the current situation is achieved by data
about which people do take under what circumstances CE or prescribe such products.
The second step of ethical reflection is about the assessment of the moral questions
concerning the integration of principles, norms, virtues and values when judging the use
of CE. As categorized by Martha J. Farah and her colleagues, four main categories of
arguments exist in the field of CE: Arguments about safety, about social pressure, about
distributive justice and about what it means to be a person and the value of achievement
(Section ‘1.5 Ethical Considerations’). When grouping the concerns asked about in the
survey among students according to these four categories, one gets the following four
categories: About safety are the concerns about side effects, about addiction and about
gut feelings. The concern about social pressure is the more general one about the bad
influence on society, which can also be grouped to the third group about distributive
justice next to the concern about betraying others. The concerns about what it means
to be a person and the value of achievement are the followings: About the pressure
to achieve more, about an unnatural interference, about the gut feelings (also part of
concerns about safety), about not being myself anymore, about not being able to be
proud of achievements anymore and about God’s plan. The highest value of agreement
for the 1797 students was seen for the concerns about safety and the one about an
unnatural interference of the concerns about what it means to be a person.
The ranking of the concerns are not in line with the results of the survey done by Ferenc
Biedermann [72]. He established these ten concerns according to literature, media and
open interviews. The 291 participants of a German-speaking city in Switzerland agreed
most often to the three concerns about an unnatural interference, about the gut feelings
and about not being myself anymore. Therefore these persons agreed mostly to concerns
about what it means to be a person.
When focusing on the physicians, questions about which criteria influence their de-
cision regarding the prescription of drugs and well as the evaluating of statement give
insights into their assessment of the moral questions. But these statements and criteria
cannot be grouped according to the categories of arguments in the field of CE.
The third step according to Pascal Borry and his colleagues is about the evaluation.
This step is mainly hypothetical conerning the use of CE in Switzerland, because no
specific regulations about CE have been implementend recently. In general, on can say
that this step is better accessible with qualitative interviews compared to quantitative
surveys. Still, some of our questions among students about where they received the
CE from can give some insights into aspects about safety and the possible effects of
regulations.
Taken together, the data of these two surveys can contribute to ethical reflections. A
more theoretical approach to ethical reflections are the examinations of specific argu-
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ments in the field of CE. This is what I did in the additional project within my Ph.D.
(Chapter 5). The main aim was to look critically at the claim that increased produc-
tivity is a benefit of cognitive enhancers as it has been stated in literature on CE. My
argumentation is based on arguments not being part of one of the four categories of
Martha J. Farah and her colleagues but added by a recent paper addressing the ar-
guments in the field of CE [50]. These arguments were formulated by Margaret Little,
Maartje Schermer, Nikolas Rose and Dieter Birnbacher and on social norms in relation to
human enhancement or specifically to CE. The authors assume that some social norms
might be undesirable, unjust or without them we would be better off. I drew attention
to the points that some social norms being influenced by late capitalism and on which
our evaluation of increased productivity is based could be undesirable or unjust. This
is why I ask for identifying, questioning, challenging and at the end trying to subvert
or supplement these social norms if necessary, before deciding if we want to use such a
claim about productivity in the debate around CE.
The work of this Ph.D. added empirical data about different population groups regard-
ing the use of CE. No such data existed prior to starting this research and the data are
still unique regarding questions about ethical aspects of such a use in Switzerland as well
as the data about the facilities of request of physicians and their willingness to prescribe
CE. Such data helps fostering the debate in the public sphere for which we wrote articles
in journals that are easier to access by the general public than peer-reviewed journals.
To expand the knowledge on moral actors in the field of CE, quantitative interviews
with students and physician could be conducted to find out more about their personal
attitudes concerning the use of CE as well as their view on ethical aspects about the use
of CE.
As discussed in the introduction in 1.4, the function of empirical data does not just
add knowledge to the field of normative ethics but is mandatory for understanding the
ethical actors. Such a conclusion is deriving from the social epistemology favoured by
many feminist but also other nonmainstream ethical approaches that we should turn
away from the focus on rational, disembodied and impersonal individuals towards seeing
morality as a collaborative social practice leading to relationships, responsibilities and
commitments [48]. If the social, cultural and economic situation influences the moral
judgements of individuals, than it is important that we systematically analyse in ethics
what people really do in certain situation and what their reasons for their acts and
choices are [47, p. 47]. Applied to us as researcher, this means that we ourselves are
influenced by the experiences we made. Therefore, an ethical reflection is inescapably
along a specific line of sight [47, p. 47]. It is easily possible that we as researcher miss
certain important aspects about important principles, norms, virtues and values of a
specific case in ethics because our own experiences gets somehow into our way. Only
with the help of empirical ethics, the views of others can be integrated. Such integration
is even more important because the people involved in ethical research are mostly part
of a subgroup not at all represent the people of the world.
I am fairly convinced that such integration of other views is of high importance and
will continue in the field of ethics. It is important to involve people who are in the
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specific case discussed in ethics (e.g. organ donation, terminally ill and thinking about
physician assisted suicide or being asked to donate embryos to stem cell research). This
can be achieved with various methodologies in the field of empirical ethics. On the other
hand, a higher diversity among researcher in the field of ethics is needed. How such a
process took place in the past can be seen in the example of feminist movements. Firstly,
women very similar to their background of the men who were involved in the decision
processes of a society (mostly white, well-educated, non-disabled) fought successfully for
being part of decision processes in a society. That does not mean that women with other
backgrounds were not involved in such fights at all but that it took longer for them to
be heard, by men but also by the group of white, well-educated women. In the field
of ethics being aware that our experiences influence our opinions and views on ethical
topics, it is of high importance that various views are heard. This can be reached by
asking the people being in specific situation discussed in ethics but also by having more
subgroups of people represented in the field of research in bioethics. This way, we can
decrease certain bias in ethical discussions based on our specific experiences.
115

Appendices
117

A Questionnaires
B.1 Structure of Questionnaire among Students
B.2 Questionnaire among Students
B.3 Questionnaire among Physician
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Bedenken zu CE
Titelbild
Hinweise zum Ausfüllen 
& Teil 1
Demographische Fragen 
Teil 2
Kaffee und Co &
Meditation und Co
Ritalin, Adderall, 
Modasomil: Ja/Nein
Medi-Empfehlung, 
Wann
Wofür Empfehlung
Häufigkeit I & II
Nebenwirkungen
Drogenkonsum
Alkoholkonsum
Warum
Nein
nur NEP
Teil 3
Medi-Empfehlung
Warum
Anz. Personen & 
Reaktion
Ritalin, Anabolika
IQ-Steigerung & sozialer 
Druck
Als Medi oder als CE
Herkunft
Rezept
Alter, Normalität
Prüfung: Kaffee, Ritalin
Risiko, wie Kontakt & 
Anmerkungen
nur Medi
Ja
Hinweis: Nur CE wichtig
Antwort `Beides´ 
oder x als Medi, 
y als CE
Reaktion
Bedenken zu CE (I & II)
Meinungsbildung
Endseite
Welche CE bekannt
Warum Drogenkonsum
Gründe für CE
Figure A.1.: Structure of Questionnaire among Students.
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Frageblock 1 
Frageblock 2 
Frageblock 3 
Frageblock 4 
Frageblock 5 
Frageblock 6 
Frageblock 7 
Frage 8 
Frage 9 
! Wenn angekreuzt, bitte weiter zu Frage 20. 
! Wenn angekreuzt, bitte weiter in der Reihenfolge. }
Frage 10 
! Wenn angekreuzt, bitte weiter zu Frage 20. 
! Wenn angekreuzt, bitte weiter in der Reihenfolge. 
! Wenn angekreuzt, bitte weiter in der Reihenfolge. 
Frageblock 11 
Frage 12 
Frage 13 
Frageblock 14 
Frage 15 Bitte nur für die Produkte ankreuzen, die schon mindestens einmal zur Steigerung der Konzentration oder der Wachheit genommen haben. 
Frage 16 Bitte nur für die Produkte ankreuzen, die schon mindestens einmal zur Steigerung der Konzentration oder der Wachheit genommen haben. 
Frage 17 
Frage 18 
Frage 19 
! Bitte weiter zu Frage 25. }
Frage 20 
! Bitte weiter zu Frage 22. 
Frage 21 
Frage 22 
Frage 23 
Frageblock 24 
Frage 25 
}
! Wenn Sie bei allen drei 
Produkten nur diese zwei 
Antworten angeklickt haben, 
dann bitte weiter zu Frage 27. 
Frage 26 
Frage 27 
! Bitte weiter zu Frage 29. 
Frage 28 
Frage 29 
Frage 30 
......................................................................................................................
......................................................................................................................
......................................................................................................................
......................................................................................................................
...................................................................................................................... 
Frage 31 
......................................................................................................................
......................................................................................................................
......................................................................................................................
......................................................................................................................
...................................................................................................................... 
Frage 32 
Frage 33 
Frage 34 
Frage 35 
......................................................................................................................
......................................................................................................................
......................................................................................................................
......................................................................................................................
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Institut für Biomedizinische Ethik 
 
 
 
 
 
Die Bedeutung des Neuroenhancements für praktizierende ÄrztInnen 
im Bereich Psychiatrie und Hausarztmedizin 
 
❏❏ ❏❏ ❏❏ 
Die zwei Anfangsbuchstaben 
Ihres Vornamens 
Tag Ihres 
Geburtsdatums 
Die zwei Anfangsbuchstaben 
Ihres Nachnamens 
 
 
Für das Ausfüllen des Fragebogens möchten wir uns bei Ihnen nochmals ganz herzlich 
bedanken! Ihre Anonymität bleibt in jedem Fall gewährleistet. 
 
Anmerkungen zum Ausfüllen: 
 
- Nehmen Sie sich genügend Zeit für das Lesen der Fragen. 
- Machen Sie ein Kreuz in das Feld, das am besten als Antwort passt. 
− Wenn Sie eine Antwort unmittelbar korrigieren möchten, streichen Sie den Fehler 
zweimal durch und machen Sie ein neues Kreuz. Bsp.             
− Wir bitten Sie, beim Ausfüllen des Fragebogens die vorgegebene Reihenfolge 
einzuhalten.  
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Allgemeiner Teil 
1 Demographische Angaben 
a. Geburtsjahr (JJJJ): ...................... 
  
b. Geschlecht 
1❐ männlich  
2❐ weiblich 
  
c. FMH-Titel 
1❐ Psychiatrie und Psychotherapie  
2❐ Allgemeinmedizin 
3❐ Innere Medizin 
4❐ Anderer bzw. zusätzlicher FMH Titel: 
...................................................................................................... 
5❐ Keinen FMH Titel 
 
  
d. Wie verteilen sich Ihre 
Patienten auf die 
vorgegebenen 
Alterskategorien? 
(geschätzte Angaben) 
1 18-30 Jahre: ...............%  
2 31-43 Jahre: ...............% 
3 44-56 Jahre: ...............% 
4 57-69 Jahre: ...............% 
5    >69 Jahre: ................% 
 
  
e. Wie lange sind Sie bereits als 
niedergelassene Ärztin / 
niedergelassener Arzt tätig?  
 
             Anzahl Jahre: ....................... 
  
f. Umfeld der Praxis 
1❐ eher ländlich  
2❐ eher städtisch 
 
 
       Falls FMH-Titel Psychiatrie und Psychotherapie: 
 
g. In welcher Therapierichtung 
wurden Sie ursprünglich 
ausgebildet? 
 
...................................................................................................... 
  
h. Patientengut                   
(geschätzte Angaben in %) 
1 Integrierte psychiatrisch-psychotherapeutische  
Behandlung (IPPB) ...................%  
2 Psychotherapie im engeren Sinne ......................% 
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2 Begriff Neuroenhancement (NE) 
2.1 Ist Ihnen der Begriff Neuroenhancement (NE) bekannt? 
1❐ Ja  2❐ Nein (Bitte weiter zu Frage 3) 
 
2.2 Wenn ja, woher?  
a. Aus den Medien 
1❐ Ja  2❐ Nein 
 
b. Aus der Fachliteratur 1❐ Ja  2❐ Nein 
 
c. Aus Gesprächen und Diskussionen im beruflichen 
Umfeld 
1❐ Ja  2❐ Nein 
 
d. Aus Gesprächen und Diskussionen im privaten 
Umfeld 
1❐ Ja  2❐ Nein 
 
3 Ist Ihnen der Begriff Hirndoping schon begegnet? 
1❐ Ja  2❐ Nein 
 
4 Welche spontanen Reaktionen zu der folgenden Aussage sind Ihnen am nächsten? (Mehrfachantworten 
möglich) 
In den Medien finden sich immer wieder Meldungen, dass Studenten / Studentinnen und 
Arbeitstätige insbesondere in höheren Positionen zu Medikamenten greifen, um die eigene 
Leistung zu steigern: 
 
a. Kein Wunder, dass das so läuft, wenn die Anforderungen und 
der Konkurrenzdruck stetig zunehmen. 1❐ Ja 2❐ Nein 0 ❐ Unentschieden 
 
b. Dem sollte man einen Riegel vorschieben können. 1❐ Ja 2❐ Nein 0 ❐ Unentschieden 
 
c. Jeder ist selbst verantwortlich dafür, wie er mit sich umgeht. 1❐ Ja 2❐ Nein 0 ❐ Unentschieden 
 
d. Die Menschen haben immer schon versucht, ihre Leistungs-
möglichkeiten zu verbessern, Kaffee und Red Bull gibt es ja 
schon, heute stehen halt mehr Möglichkeiten zu Verfügung. 
1❐ Ja 2❐ Nein 0 ❐ Unentschieden 
 
e. Das ist ebenso falsch wie Doping im Sport. 1❐ Ja 2❐ Nein 0 ❐ Unentschieden 
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Krankheitswert 
5 Wenn Sie bestimmen müssen, ob eine Störung mit Krankheitswert vorliegt oder nicht, welche der 
folgenden Kriterien sind für Sie dafür ausschlaggebend (Mehrfachantworten möglich):  
 
 Ja Nein Manchmal 
a. Der subjektive Leidensdruck ❐1 ❐2 ❐3  
b. Die Zuordbarkeit gemäss einem anerkannten 
Klassifikationssystem (Bspw. ICD oder DSM) 
❐1 ❐2 ❐3  
c. Insbesondere in der somatischen Medizin die 
Objektivierbarkeit mittels labormedizinischer 
bzw. bildgebender Verfahren 
❐1 ❐2 ❐3  
d. Negative Auswirkungen auf alltägliche 
Arbeitsfähigkeit 
❐1 ❐2 ❐3  
 
6 Es hat sich gezeigt, dass Ärzte / Ärztinnen verschieden damit umgehen, wenn ein Patient nach 
Medikamenten fragt, für welche keine Indikation gestellt werden kann.  
Bitte geben Sie an, welche Aussage Ihnen persönlich am meisten entspricht (nur eine Antwort ankreuzen): 
 
Wenn ich keine Indikation stellen kann, verschreibe ich auch nichts. a❐  
 
Grundsätzlich verschreibe ich nichts ohne Indikation. Ist der Leidensdruck aber 
gross und besteht beim Patienten der Wunsch nichts unversucht zu lassen, so kann 
es sein, dass ich auch etwas ohne klare Indikation verschreibe. Dies hängt jedoch 
von der Substanz, Kontraindikationen und unerwünschten Wirkungen ab. 
b❐ 
 
Ich kläre den Patienten über allfällige Risiken des gewünschten Präparates auf und 
wenn er es dann immer noch möchte, so soll er es halt mal ausprobieren.  
c❐ 
 
7 Welche der folgenden Präparate würden Sie auf Wunsch des Patienten und ohne klare Indikation 
verschreiben? 
 Ja Nein Vielleicht 
a. NSAR 
1❐ 2❐ 3❐ 
b. Benzodiazepine 
1❐ 2❐ 3❐ 
c. Antibiotika 
1❐ 2❐ 3❐ 
d. Opioide 
1❐ 2❐ 3❐ 
e. Neuroleptika 
1❐ 2❐ 3❐ 
f. Laxantien 
1❐ 2❐ 3❐ 
g. Phosphodiesterase Typ 5 -Inhibitoren (Bspw. Sildenafil 
(Viagra®) u.ä)  1❐ 2❐ 3❐ 
h. Antidepressiva 
1❐ 2❐ 3❐ 
i. Methylphenidat (Ritalin®) 
1❐ 2❐ 3❐ 
j. Modafinil (Modasomil®) 
1❐ 2❐ 3❐ 
k. Antidementiva 
1❐ 2❐ 3❐ 
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Neuroenhancement 
Unter Neuroenhancement versteht man die Verbesserung, „Optimierung“ kognitiver und emotionaler 
Fähigkeiten mittels medikamentöser Substanzen beim gesunden Menschen. Diesbezüglich werden 
hauptsächlich folgende Substanzen diskutiert, wenn auch mit unterschiedlicher klinischer Wirksamkeit: 
- Methylphenidat (Ritalin®) 
- Modafinil (Modasomil®) 
- Antidepressiva 
- Antidementiva 
Zusätzlich einige weitere Substanzen, die sich jedoch auch als mögliche Therapeutika bei Krankheiten noch 
in der Experimentalphase befinden. 
Nachfragen nach NE können in der Praxis in verschiedenen Kontexten stehen und von unterschiedlichem 
Leidensdruck begleitet sein. Im Folgenden soll dies anhand einiger Beispiele dargestellt werden.  
 
Fallbeispiele 
8 Ein Student steht vor den letzten und entscheidenden beiden Prüfungen. Besteht er sie, hat er seinen 
Abschluss und wird einen gut bezahlten Arbeitsplatz antreten können. Fällt er durch, wird er für das 
Studium nicht mehr zugelassen. Er hat vorgängig bereits Prüfungen wiederholen müssen, da er durch 
eine sehr schwierige Lebenssituation seiner Schwester selbst auch sehr belastet war und wenig Zeit und 
Kraft für das Studium gehabt hat. Nun, nach einer Zeit intensiver Prüfungsvorbereitungen, bittet er 
seinen Arzt für den „Schlussspurt“ um ein Medikament, welches sein Schlafbedürfnis etwas reduziert 
um die verbleibende Zeit noch möglichst gut nutzen zu können. 
8.1 Was würden Sie in der geschilderten Situation tun? 
 
a. Ich würde in solchen Situationen nur dann Medikamente verschreiben, 
wenn psychotherapeutische Verfahren oder Ähnliches nicht (genügend) 
helfen. 
1❐ Ja 2❐ Nein 
b. Ich würde ein Medikament wie Ritalin, Modasomil, Antidepressiva oder 
Antidementiva verschreiben. 1
❐ Ja 2❐ Nein 
c. Ich verschreibe in solchen Situationen grundsätzlich keine 
Medikamente. 1
❐ Ja 2❐ Nein 
d. Ich verschreibe in solchen Situationen keine Medikamente, verweise 
aber auf die Möglichkeit andere Kollegen aufzusuchen oder im Internet 
zu bestellen. 
1❐ Ja 2❐ Nein 
 
 
8.2 Wenn Sie in der letzten Frage Medikamente verschrieben hätten: Welche der folgenden 
Substanzen würden Sie in der geschilderten Situation verschreiben?  
 Sonst bitte weiter zu 8.3. 
 
a. Methylphenidat (Ritalin®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
c. Antidepressiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
d. Antidementiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
e. Betablocker 1❐ Ja 0❐ Vielleicht 2❐ Nein 
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8.3 Kennen Sie entsprechende Anfragen aus Ihrer Praxis? 
1❐ Ja 2❐ Nein (->bitte weiter zu Beispiel 9) 
 
8.3.1 Wie häufig sind Sie mit vergleichbaren Anfragen konfrontiert? 
❐1 
äusserst selten 
❐2 
1-2 mal jährlich 
❐3 
4-6 mal jährlich 
❐4 
monatlich 
❐5 
wöchentlich 
❐6 
täglich 
 
 
8.3.2 Haben Sie in einer solchen Situation / in solchen Situationen eines oder mehrere der folgenden 
Medikamente verschrieben? 
 
a. Methylphenidat (Ritalin®) 1❐ Ja 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 2❐ Nein 
c. Antidepressiva 1❐ Ja 2❐ Nein 
d. Antidementiva 1❐ Ja 2❐ Nein 
e. Betablocker 1❐ Ja 2❐ Nein 
 
 
 
9 Eine allein erziehende Frau von zwei schulpflichtigen Kindern pflegt seit ein paar Wochen auch ihre 
terminal erkrankte Mutter zu Hause und ist mittlerweile ziemlich müde. Doch möchte Sie die Pflege 
unbedingt selbst weiterführen können und ihre Mutter nicht in eine Institution geben müssen, für die 
kurze Zeit welche diese noch leben wird. Ihre Mutter hat sie in der sehr belastenden Zeit der Scheidung 
uneingeschränkt unterstützt und dafür möchte die Tochter ihr etwas zurückgeben und auch einen 
Wunsch erfüllen. Sie bittet ihren Arzt in dieser Situation um ein „Aufputschmittel“. 
9.1 Was würden Sie in der geschilderten Situation tun? 
 
a. Ich würde in solchen Situationen nur dann Medikamente verschreiben, 
wenn Spitex oder Ähnliches nicht (genügend) helfen. 1
❐ Ja 2❐ Nein 
b. Ich würde ein Medikament wie Ritalin, Modasomil, Antidepressiva oder 
Antidementiva verschreiben. 1
❐ Ja 2❐ Nein 
c. Ich verschreibe in solchen Situationen grundsätzlich keine 
Medikamente. 1
❐ Ja 2❐ Nein 
d. Ich verschreibe in solchen Situationen keine Medikamente, verweise 
aber auf die Möglichkeit andere Kollegen aufzusuchen oder im Internet 
zu bestellen. 
1❐ Ja 2❐ Nein 
 
 
 
9.2 Wenn Sie in der letzten Frage Medikamente verschrieben hätten: Welche der folgenden 
Substanzen würden Sie in der geschilderten Situation verschreiben?  
 Sonst bitte weiter zu 9.3.   
 
a. Methylphenidat (Ritalin®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
c. Antidepressiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
d. Antidementiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
e. Betablocker 1❐ Ja 0❐ Vielleicht 2❐ Nein 
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9.3 Kennen Sie entsprechende Anfragen aus Ihrer Praxis? 
1❐ Ja 2❐ Nein (->bitte weiter zu Beispiel 10) 
 
9.3.1 Wie häufig sind Sie mit vergleichbaren Anfragen konfrontiert? 
❐1 
äusserst selten 
❐2 
1-2 mal jährlich 
❐3 
4-6 mal jährlich 
❐4 
monatlich 
❐5 
wöchentlich 
❐6 
täglich 
 
9.3.2 Haben Sie in einer solchen Situation / in solchen Situationen eines oder mehrere der folgenden 
Medikamente verschrieben? 
 
a. Methylphenidat (Ritalin®) 1❐ Ja 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 2❐ Nein 
c. Antidepressiva 1❐ Ja 2❐ Nein 
d. Antidementiva 1❐ Ja 2❐ Nein 
e. Betablocker 1❐ Ja 2❐ Nein 
 
10 Eine 24j. Frau, welche sich als sehr schüchtern bezeichnet und im Umgang mit Männern recht unsicher 
ist, möchte ihre Hemmungen loswerden. Sie wünscht sich von ihrem Arzt ein Mittel, das ihre ängstliche 
Verkrampftheit günstig beeinflusse. Sie wolle eben auch eher so sein können wie ihre Freundinnen, die 
schon alle eine Beziehung hätten. Eine Freundin habe wegen einer sozialen Phobie ein Medikament 
bekommen, das sie nun auch gerne ausprobieren würde. 
10.1 Was würden Sie in der geschilderten Situation tun? 
 
a. Ich würde in solchen Situationen nur dann Medikamente verschreiben, 
wenn psychotherapeutische Verfahren oder Ähnliches nicht (genügend) 
helfen. 
1❐ Ja 2❐ Nein 
b. Ich würde ein Medikament wie Ritalin, Modasomil, Antidepressiva oder 
Antidementiva verschreiben. 1
❐ Ja 2❐ Nein 
c. Ich verschreibe in solchen Situationen grundsätzlich keine Medikamente. 1❐ Ja 2❐ Nein 
d. Ich verschreibe in solchen Situationen keine Medikamente, verweise aber 
auf die Möglichkeit andere Kollegen aufzusuchen oder im Internet zu 
bestellen. 
1❐ Ja 2❐ Nein 
 
 
 
10.2 Wenn Sie in der letzten Frage Medikamente verschrieben hätten: Welche der folgenden 
Substanzen würden Sie in der geschilderten Situation verschreiben?  
 Sonst bitte weiter zu 10.3.  
 
a. Methylphenidat (Ritalin®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
c. Antidepressiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
d. Antidementiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
e. Betablocker 1❐ Ja 0❐ Vielleicht 2❐ Nein 
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10.3 Kennen Sie entsprechende Anfragen aus Ihrer Praxis? 
1❐ Ja 2❐ Nein (->bitte weiter zu Beispiel 11) 
 
10.3.1 Wie häufig sind Sie mit vergleichbaren Anfragen konfrontiert? 
❐1 
äusserst selten 
❐2 
1-2 mal jährlich 
❐3 
4-6 mal jährlich 
❐4 
monatlich 
❐5 
wöchentlich 
❐6 
täglich 
 
 
10.3.2 Haben Sie in einer solchen Situation / in solchen Situationen eines oder mehrere der folgenden 
Medikamente verschrieben? 
 
a. Methylphenidat (Ritalin®) 1❐ Ja 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 2❐ Nein 
c. Antidepressiva 1❐ Ja 2❐ Nein 
d. Antidementiva 1❐ Ja 2❐ Nein 
e. Betablocker 1❐ Ja 2❐ Nein 
 
 
 
11 Ein renommierter Wissenschafter, der soeben von einer Kongressreise zurückgekehrt ist, leidet unter 
einem Jetlag und wünscht deshalb eine Verschreibung von Modafinil, da er so bald wie möglich wieder 
voll leistungsfähig sein muss. Eine wichtige Tagung steht demnächst an. Er bittet seinen Hausarzt um 
die Verschreibung eines entsprechenden "Wachmachers". 
11.1 Was würden Sie in der geschilderten Situation tun? 
 
a. Ich würde in solchen Situationen nur dann Medikamente verschreiben, 
wenn psychotherapeutische Verfahren oder Ähnliches nicht (genügend) 
helfen.  
1❐ Ja 2❐ Nein 
b. Ich würde ein Medikament wie Ritalin, Modasomil, Antidepressiva oder 
Antidementiva verschreiben. 1
❐ Ja 2❐ Nein 
c. Ich verschreibe in solchen Situationen grundsätzlich keine 
Medikamente. 1
❐ Ja 2❐ Nein 
d. Ich verschreibe in solchen Situationen keine Medikamente, verweise 
aber auf die Möglichkeit andere Kollegen aufzusuchen oder im Internet 
zu bestellen. 
1❐ Ja 2❐ Nein 
 
 
 
11.2 Wenn Sie in der letzten Frage Medikamente verschrieben hätten: Welche der folgenden 
Substanzen würden Sie in der geschilderten Situation verschreiben?  
 Sonst bitte weiter zu 11.3.  
 
a. Methylphenidat (Ritalin®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 0❐ Vielleicht 2❐ Nein 
c. Antidepressiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
d. Antidementiva 1❐ Ja 0❐ Vielleicht 2❐ Nein 
e. Betablocker 1❐ Ja 0❐ Vielleicht 2❐ Nein 
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11.3 Kennen Sie entsprechende Anfragen aus Ihrer Praxis? 
1❐ Ja 2❐ Nein (->bitte weiter zu Frage 12) 
 
11.3.1 Wie häufig sind Sie mit vergleichbaren Anfragen konfrontiert? 
❐1 
äusserst selten 
❐2 
1-2 mal jährlich 
❐3 
4-6 mal jährlich 
❐4 
monatlich 
❐5 
wöchentlich 
❐6 
täglich 
 
 
11.3.2 Haben Sie in einer solchen Situation / in solchen Situationen eines oder mehrere der 
folgenden Medikamente verschrieben? 
 
a. Methylphenidat (Ritalin®) 1❐ Ja 2❐ Nein 
b. Modafinil (Modasomil®) 1❐ Ja 2❐ Nein 
c. Antidepressiva 1❐ Ja 2❐ Nein 
d. Antidementiva 1❐ Ja 2❐ Nein 
e. Betablocker 1❐ Ja 2❐ Nein 
 
 
12 Falls Sie noch Bemerkungen zu den Fallbeispielen haben, dürfen Sie gerne einen Kommentar schreiben. 
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............................................................................................................................................................................................. 
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Persönlicher Umgang und Haltung 
13 Die folgenden Aussagen stammen aus Interviews mit klinisch tätigen Ärzten / Ärztinnen. Welche 
Kriterien oder Überlegungen sind für Sie in Fällen wie oben dargestellt für eine allfällige Verschreibung 
ausschlaggebend? Oder wenn Sie noch nie damit konfrontiert waren, welche Fälle kämen für Sie in 
Frage? (Mehrfachantworten möglich) 
 
a. Der subjektive Leidensdruck ist gross. 
1❐ Ja 2❐ Nein 
b. Eher bei einem zeitlich begrenzten Einsatz als auf unbestimmte Zeit. 
1❐ Ja 2❐ Nein 
c. Wenn Schlimmeres verhindert werden kann. 
1❐ Ja 2❐ Nein 
d. Wenn der Betroffene nichts für die Situation kann, in der er sich 
befindet. 1❐ Ja 2❐ Nein 
e. Ob das Ziel, das damit möglichst besser erreicht werden soll, 
nachvollziehbar wichtig und wertvoll ist, allenfalls auch Dritten 
zugute kommt. 
1❐ Ja 2❐ Nein 
f. Wenn klar ist, dass sich der Betroffene genug angestrengt hat, um es 
aus eigenen Kräften zu schaffen. 1❐ Ja 2❐ Nein 
 
 
14 Persönliche Haltung 
 Stimme 
zu 
Unentschieden Stimme 
nicht zu 
a) Als Arzt / Ärztin lehne ich NE ab und würde keinesfalls 
entsprechende Substanzen verschreiben. 1❐  0❐ 
 
2❐  
b) Bei NE kommt es auf die Situation an: Ich sage nicht 
grundsätzlich nein. 1❐  0❐ 
 
2❐  
c) Wenn der Anfragende über die Nebenwirkungen und Risiken 
des gewünschten Präparates aufgeklärt ist und sich dafür 
entschieden hat, dann respektiere ich die Entscheidung und 
verschreibe das Präparat. 
1❐  0❐ 
 
2❐  
 
15 Bitte bewerten Sie die folgenden Aussagen: 
 
15.1 Jeder Arzt / Ärztin sollte selber entscheiden, ob er NE praktizieren möchte oder nicht. 
❐1 völlig falsch ❐2 ziemlich falsch ❐3 unentschieden ❐4 ziemlich richtig ❐5 völlig richtig 
 
15.2 Neuroenhancement-Praktiken sind eine Realität. Da dies nun mal so ist, sollten sie zum 
Wohle des Anfragenden Teil der ärztlichen Tätigkeit werden. So kann die Beurteilung und 
Überwachung von Risiken und Nebenwirkungen gewährleistet werden. 
❐1 völlig falsch ❐2 ziemlich falsch ❐3 unentschieden ❐4 ziemlich richtig ❐5 völlig richtig 
 
 
15.3 Das Arztbild nimmt Schaden und das Vertrauen der Patienten in ihre Ärzte / Ärztinnen 
sinkt, wenn die Ärzte / Ärztinnen sich immer mehr von der eigentlichen 
Krankheitsbehandlung weg bewegen. 
❐1 völlig falsch ❐2 ziemlich falsch ❐3 unentschieden ❐4 ziemlich richtig ❐5 völlig richtig 
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Substanzen 
16 Welche der unten aufgeführten Substanzen können Ihrer Meinung nach auch bei gesunden Personen 
eine Wirkung haben und die Leistungsfähigkeit bzw. das psychische Wohlbefinden steigern? Welche 
Nebenwirkungen können sie, falls möglich, bei gesunden Personen auslösen? 
 
16.1 Antidepressiva (Mehrfachantworten möglich) 
16.1.1 Wirkung bei Gesunden   16.1.2 Nebenwirkung bei Gesunden 
a. Nein, keine Wirkung bei gesunden 
Personen ❐1 
 a. Abhängigkeit ❐1 
b. Ja, Steigerung der Konzentrationsfähigkeit ❐1  b. Nervosität/Schlafstörungen ❐1 
c. Ja, Steigerung der Wachheit ❐1  c. Arrhythmien ❐1 
d. Ja, Steigerung von Merkfähigkeit, 
Gedächtnis ❐1 
 d. Leberfunktionsstörungen ❐1 
e. Ja, Stimmungshebung ❐1  e. Wahnvorstellungen ❐1 
f. Ja, andere ❐1  f. Blutbildveränderungen ❐1 
g. Ich habe keine Erfahrung mit diesen 
Medikamenten ❐1 
 g. Weitere: ………………………. 
………………………………… ❐1 
   h. Nein, keine ❐1 
 
 
16.2 Ginkgo (Mehrfachantworten möglich) 
16.2.1 Wirkung bei Gesunden   16.2.2 Nebenwirkung bei Gesunden 
a. Nein, keine Wirkung bei gesunden 
Personen ❐1 
 a. Abhängigkeit ❐1 
b. Ja, Steigerung der Konzentrationsfähigkeit ❐1  b. Nervosität/Schlafstörungen ❐1 
c. Ja, Steigerung der Wachheit ❐1  c. Arrhythmien ❐1 
d. Ja, Steigerung von Merkfähigkeit, 
Gedächtnis ❐1 
 d. Leberfunktionsstörungen ❐1 
e. Ja, Stimmungshebung ❐1  e. Wahnvorstellungen ❐1 
f. Ja, andere ❐1  f. Blutbildveränderungen ❐1 
g. Ich habe keine Erfahrung mit diesem 
Medikament ❐1 
 g. Weitere: ……………………… 
………………………………… ❐1 
   h. Nein, keine ❐1 
 
 
16.3 Methylphenidat (Ritalin®) (Mehrfachantworten möglich) 
16.3.1 Wirkung bei Gesunden   16.3.2 Nebenwirkung bei Gesunden 
a. Nein, keine Wirkung bei gesunden 
Personen ❐1 
 a. Abhängigkeit ❐1 
b. Ja, Steigerung der Konzentrationsfähigkeit ❐1  b. Nervosität/Schlafstörungen ❐1 
c. Ja, Steigerung der Wachheit ❐1  c. Arrhythmien ❐1 
d. Ja, Steigerung von Merkfähigkeit, 
Gedächtnis ❐1 
 d. Leberfunktionsstörungen ❐1 
e. Ja, Stimmungshebung ❐1  e. Wahnvorstellungen ❐1 
f. Ja, andere ❐1  f. Blutbildveränderungen ❐1 
g. Ich habe keine Erfahrung mit diesem 
Medikament ❐1 
 g. Weitere: ……………………… 
………………………………… ❐1 
   h. Nein, keine ❐1 
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16.4 Antidementiva (Mehrfachantworten möglich) 
16.4.1 Wirkung bei Gesunden   16.4.2 Nebenwirkung bei Gesunden 
a. Nein, keine Wirkung bei gesunden 
Personen ❐1 
 a. Abhängigkeit ❐1 
b. Ja, Steigerung der Konzentrationsfähigkeit ❐1  b. Nervosität/Schlafstörungen ❐1 
c. Ja, Steigerung der Wachheit ❐1  c. Arrhythmien ❐1 
d. Ja, Steigerung von Merkfähigkeit, 
Gedächtnis ❐1 
 d. Leberfunktionsstörungen ❐1 
e. Ja, Stimmungshebung ❐1  e. Wahnvorstellungen ❐1 
f. Ja, andere ❐1  f. Blutbildveränderungen ❐1 
g. Ich habe keine Erfahrung mit diesen 
Medikamenten ❐1 
 g. Weitere: ……………………… 
………………………………… ❐1 
   h. Nein, keine ❐1 
 
 
16.5 Modafinil (Modasomil®) (Mehrfachantworten möglich) 
16.5.1 Wirkung bei Gesunden   16.5.2 Nebenwirkung bei Gesunden 
a. Nein, keine Wirkung bei gesunden 
Personen ❐1 
 a. Abhängigkeit ❐1 
b. Ja, Steigerung der Konzentrationsfähigkeit ❐1  b. Nervosität/Schlafstörungen ❐1 
c. Ja, Steigerung der Wachheit ❐1  c. Arrhythmien ❐1 
d. Ja, Steigerung von Merkfähigkeit, 
Gedächtnis ❐1 
 d. Leberfunktionsstörungen ❐1 
e. Ja, Stimmungshebung ❐1  e. Wahnvorstellungen ❐1 
f. Ja, andere ❐1  f. Blutbildveränderungen ❐1 
g. Ich habe keine Erfahrung mit diesem 
Medikament ❐1 
 g. Weitere: ……………………… 
………………………………… ❐1 
   h. Nein, keine ❐1 
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17 Falls Sie noch Bemerkungen zu den erwähnten Substanzen oder allgemein zum Thema 
Neuroenhancement sowie diesem Fragebogen haben, dürfen Sie gerne einen Kommentar schreiben. 
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Vielen Dank für Ihre Mithilfe!  
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Wissen
Über zwei Jahre haben Forscher von der University of Nebraska-Lincoln 9000 Mistkäfer von insgesamt 15 verschiedenen Arten eingefangen.  
Dabei stellten sie fest, dass die unscheinbaren Tierchen den Dung von Allesfressern im Gegensatz zu dem von Pflanzenfressern deutlich bevorzugen.
Wissen im Comic Die exotische Speisekarte der Mistkäfer
Die Neurobiologin Regula 
Ott sagt, dass während des 
Studiums mehr Männer als 
Frauen leistungsfördernde 
Wirkstoffe nehmen. 
Mit Regula Ott sprach Barbara Reye 
In Deutschland hat offenbar jeder 
fünfte Student mindestens einmal 
im vergangenen Jahr von sich aus 
leistungsfördernde Mittel wie 
 Ritalin genommen. Ist Hirndoping 
an Hochschulen so verbreitet?
Die Zahlen in der vor kurzem veröffent-
lichten Studie der Universität Mainz sind 
recht hoch. Dies könnte auch daran lie-
gen, dass die Forscher nach sehr vielen 
Produkten gefragt haben, die zur Steige-
rung der Aufmerksamkeit, Wachheit so-
wie der Stimmung genommen worden 
sind. Das Spektrum reichte von Koffein-
tabletten bis zu Kokain. Wichtig bei sol-
chen Daten ist es deshalb, die Definition 
von Hirndoping sowie von den Substan-
zen genauer anzuschauen. 
Wie sieht es in der Schweiz aus?
Im Rahmen meiner Dissertation habe 
ich 1765 Studierende an der Universität 
Zürich befragt. Allerdings war dies keine 
repräsentative Umfrage, sondern es ging 
vielmehr darum, die Nutzer mit den 
Nichtnutzern zu vergleichen. Aus den 
Ergebnissen geht hervor, dass rund 
5 Prozent schon mindestens einmal Arz-
neimittel wie Ritalin, Adderall oder Mo-
dasomil genommen haben, um als ge-
sunde Person ihre Konzentration oder 
Wachsamkeit zu steigern. Dabei kam 
unter anderem auch heraus, dass mehr 
Männer als Frauen solche Produkte nah-
men und dass sie bereits auch mehr 
 Erfahrung mit anderen Drogen hatten. 
Repräsentative Zahlen werden zurzeit 
am Schweizer Institut für Sucht- und 
 Gesundheitsforschung ausgewertet. 
Um gegen Müdigkeit anzukämpfen, 
nehmen Indios seit Jahrhunderten 
Koka oder Menschen in einigen 
Gegenden Asiens Betel. Wäre es 
nicht besser, gewisse Aufputsch-
mittel zu legalisieren, als sie auf 
dem Schwarzmarkt oder im Internet 
zu erwerben?
Im Prinzip schon, aber ich finde es wich-
tig, dass wir zuvor zwei Aspekte disku-
tieren: Erstens wissen wir heute noch zu 
wenig über Wirkung und Nebenwirkung 
von Ritalin, Adderall oder Modasomil 
bei Gesunden, sodass noch weitere Stu-
dien notwendig wären. Nur würden da-
für letztlich Gelder genutzt werden, die 
dann für die Erforschung von Medika-
menten für kranke Menschen wiederum 
fehlen würden. Zweitens sollten wir uns 
vor einer Legalisierung darüber im Kla-
ren sein, was für Ziele wir in unserer Ge-
sellschaft  erreichen wollen. 
Was heisst das?
Wir müssen uns fragen, ob wir ein leis-
tungsförderndes Produkt legalisieren 
möchten, um länger arbeiten zu können 
und dafür auch Nebenwirkungen in Kauf 
zu nehmen. Oder ob wir dies sogar als 
unsere Pflicht ansehen, um das Maxi-
mum aus uns herauszuholen. 
Wird es mal so weit kommen,  
dass Studenten nach einer  
Prüfung zum Dopingtest antreten 
müssen?
Wir sind noch lange nicht an diesem 
Punkt. Dafür zeigen die Studien zu die-
sen Stimulanzien eine zu kleine Wir-
kung. Aber wer weiss, die Liste von mög-
lichen Substanzen zur Leistungssteige-
rung ist lang und daher die Chance 
gross, dass wir eines Tages solche Wirk-
stoffe haben. Daher lohnt es sich, wenn 
wir uns als Gesellschaft bereits jetzt Ge-
danken darüber machen, wie wir mit 
solchen Produkten umgehen möchten. 
«Die Liste der 
möglichen Stoffe 
ist lang»
Small Talk
Regula Ott (28)
Die Neurobiologin 
ist Doktorandin 
am Institut für 
Biomedizinische Ethik 
der Universität Zürich 
und forscht 
zum Thema Medizin 
für Gesunde.  
 
Von Birgit Herden
Sie hatte sich auf diese ersten Monate ge-
freut, doch dann wurde die Mutterschaft 
zum Albtraum. Die neugeborene Toch-
ter schrie und schrie, das kleine Gesicht 
hochrot, alle Muskeln angespannt, der 
ganze Körper versteift. Das Kind liess 
sich einfach nicht beruhigen. Kein Stil-
len oder Wiegen, liebesvolles Zureden 
oder Streicheln half. Das Baby schien in 
unstillbarem Zorn und Schmerz gefan-
gen zu sein – unerreichbar für die Eltern. 
«Ich habe mich wie ein Häufchen Dreck 
gefühlt», erinnert sich die Mutter Ka-
rin B., die ihren Namen nicht veröffent-
lichen möchte. «Ganz offensichtlich 
brachte ich die einfachste Sache der 
Welt nicht zustande – mein Kind glück-
lich zu machen.» Das Gebrüll trieb sie 
beinahe in den Wahnsinn.
Vielleicht hätte es Katrin B. damals 
geholfen, wenn sie gewusst hätte, wie 
häufig junge Mütter unter ähnlichen Ge-
fühlen leiden: Je nach Definition legen 
5 bis 25 Prozent aller Babys das soge-
nannte «exzessive Schreien» an den Tag. 
Grob gesagt gilt ein Kind als Schreibaby, 
wenn es an drei oder mehr Tagen der 
Woche mindestens drei Stunden lang 
schreit. Nach Meinung der Fachleute 
reicht als Indikation das Gefühl der 
 Eltern, es mit dem eigenen Kind nicht 
mehr auszuhalten. Sie geraten dadurch 
meist in einen Teufelskreis. Tipps, wie 
der sich durchbrechen und das Kind 
 beruhigen lasse, gibt es zwar viele. Doch 
wie wirksam sind die einzelnen Metho-
den? Hilft überhaupt irgendetwas?
Placebo statt Fenchelsamenöl
Diese Fragen hat nun das Deutsche Ins-
titut für Medizinische Dokumentation 
und Information (Dimdi) untersuchen 
lassen. Fazit: Am besten kommen 
 psychotherapeutische Ansätze weg. 
Den meisten anderen untersuchten 
 Therapien stehen die Prüfer mindestens 
skeptisch gegenüber.
In die Bewertung sind die Ergebnisse 
von 18 Studien eingeflossen, die zum 
Teil wiederum mehrere Einzelstudien 
auswerteten. Die Mehrzahl der Untersu-
chungen stammt aus den USA und aus 
Grossbritannien. Vier der Studien befas-
sen sich mit der Wirkung pflanzlicher 
Mittel, mit denen Säuglinge im Spital be-
handelt werden, oder mit der Ernäh-
rung der Mutter, etwa wenn diese auf 
Milchprodukte verzichtet. Für eine 
Untersuchung in Russland wurden 
125 Schreibabys in zwei Gruppen aufge-
teilt. Die eine Kindergruppe erhielt Pla-
cebos, die andere eine Woche lang vier-
mal täglich eine Emulsion aus Fenchel-
samenöl. Am Ende hatte sich in der be-
handelten Gruppe bei zwei Dritteln das 
Schreien vollständig gelegt, in der Place-
bo-Gruppe war es ein knappes Viertel. 
Falsche Behandlungsansätze
Dennoch sehen die Prüfer die Ergeb-
nisse dieser Studien mit grosser Vor-
sicht. Es sei unklar, inwieweit die Spital-
atmosphäre eine Rolle spielte und ob 
sich die Resultate auf die Situation zu 
Hause übertragen lassen. Zudem beru-
hen die Behandlungsansätze auf der ver-
alteten Vorstellung, bei dem unstillba-
ren Schreien handle es sich in der Regel 
um eine sogenannte Dreimonatskolik. 
Diese Erklärung gilt medizinisch als 
überholt. «Die Eltern sollten es ruhig 
erst mit den Hausmitteln versuchen», 
sagt Dieter Korczak, ein Autor der Dim-
di-Analyse. Beliebt bei Eltern ist auch 
das blähungslösende Mittel Sab simplex. 
«Aber Dreimonatskoliken sind sicher 
nicht der wesentliche Grund für exzessi-
ves Schreien», saht Korczak.
Noch skeptischer ist der Mediziner 
bei der Bewertung chiropraktischer Be-
handlungen. Chiropraktiker oder Osteo-
pathen versuchen Schreibabys vom 
 sogenannten Kiss-Syndrom zu befreien, 
eine «Kopfgelenk-induzierte Symmetrie-
Störung», die nach Meinung mancher 
 Alternativmediziner die Ursache für das 
Schreien ist. Dass solch eine Störung 
überhaupt existiert, ist aus Sicht der evi-
denzbasierten Medizin nicht überzeu-
gend bewiesen. Auch die Dimdi-Prüfer 
kritisieren Studien als qualitativ mangel-
haft, denen zufolge die Kiss-Therapie 
wirken soll. So fehlten zum Beispiel Kon-
trollgruppen, oder die Zahl der unter-
suchten Fälle war zu klein, um daraus 
statistisch relevante Folgerungen abzu-
leiten. «Oft gab es gar keine Diagnose für 
das Syndrom», sagt Korczak. «Ich rate 
hier zur Vorsicht, denn es gibt keine 
 Behandlung ohne Nebenwirkungen.»
Positiv fiel indes die Bewertung der 
verschiedenen psychotherapeutischen 
Betreuungsangebote aus. Mehrere 
Untersuchungen zeigten, dass die Bera-
tung und Begleitung durch Kranken-
schwestern, Psychologen und Ärzte das 
Schreien der Kinder und den Stress der 
Eltern oft schon nach wenigen Tagen 
deutlich mindern können. In den meis-
ten Fällen findet man keinen organi-
schen Auslöser für das Dauergebrüll. 
Psychologen und Kinderärzte vermuten 
eine unspezifische «Regulationsstörung» 
– die Babys können auf Reize und Ein-
drücke in ihrer Umgebung nicht ange-
messen reagieren.
Suche nach dem «Engelskreis»
Wie es dazu kommen kann, ist unklar. In 
der Diskussion stehen zum Beispiel 
Stress und Ängste während der Schwan-
gerschaft, die sich auf das Ungeborene 
auswirken können, oder auch eine 
schwierige Geburt. Klar ist aber, dass 
das Dauergebrüll die Beziehung zu den 
Eltern und die Mutter-Kind-Bindung 
stark stören kann. Babys werden im Nor-
malfall von ihren Eltern fortwährend be-
ruhigt oder angeregt, und normaler-
weise fühlen sich die Eltern durch die 
Reaktionen ihres Kindes bestärkt, was 
sie in ihrem Umgang sicherer macht. Ein 
solcher «Engelskreis» aber entsteht bei 
Schreibabys oft nicht. Zudem bringen 
die Eltern häufig auch eigene Unsicher-
heiten und Ängste mit, die durch die un-
verständliche Reaktion des Kindes noch 
verstärkt werden.
Die Mehrzahl der neun ausgewerte-
ten Einzelstudien und Übersichtsarbei-
ten zur psychotherapeutischen Behand-
lung stufen die Dimdi-Prüfer als metho-
disch gut ein. Allerdings bezogen sich 
die meisten dieser Studien auf Beratun-
gen, die entweder zu Hause oder wäh-
rend eines mehrtägigen Krankenhaus-
aufenthalts stattfanden. Ambulante 
 Beratung wurde nur in fünf US-Studien 
untersucht. Sie brachte überwiegend 
gute Ergebnisse, allerdings gibt es kei-
nen direkten Vergleich mit der stationä-
ren oder häuslichen Betreuung.
Auch wenn Korczak weiteren For-
schungsbedarf sieht, lautet sein Fazit: 
«Ich würde allen Eltern mit Schreibabys 
raten, möglichst rasch eine Schreiambu-
lanz aufzusuchen, damit die Probleme 
nicht chronisch werden.» Katrin B. hat 
dies nie gemacht. «Ich wollte es selbst 
schaffen und nicht öffentliche Hilfe in 
Anspruch nehmen», sagt die junge Mut-
ter. «Damit hätte ich mich noch mehr als 
Versagerin gefühlt.»
Von alleine zur Ruhe gekommen
Um solche Vorbehalte abzubauen, sei 
eine niederschwellige Unterstützung 
notwendig, bei der schon Geburtsstatio-
nen und Hebammen Warnsignale erken-
nen und Hilfe anbieten, sagt Korczak. 
Auch beim Schlafen oder Essen kann es 
zu Problemen kommen. Das Schreien ist 
besonders gefährlich, weil es Aggressio-
nen weckt. Im schlimmsten Fall wird das 
Kind von verzweifelten Eltern geschüt-
telt, wodurch es zu Hirnblutungen kom-
men kann, die bleibende Schäden verur-
sachen oder tödlich enden können. Wel-
che Spuren die albtraumhaften ersten 
Monate bei Schreikindern und Eltern 
 ansonsten hinterlassen, darüber weiss 
man wenig. 
In den allermeisten Fällen klingt das 
Gebrüll nach dem dritten Lebensmonat 
von alleine ab. Bei der Tochter von Kat-
rin B. dauerte es ein bisschen länger. 
Doch auch dieses Kind hörte auf zu 
schreien. «Was immer damals unser 
 Problem war», sagt die Mutter, «heute ist 
meine Tochter zauberhaft.»
Zum Schreien
Neugeborene, die permanent weinen, können ihre Eltern in die Verzweiflung treiben.  
Forscher raten, mit dem Schreibaby eine Schreiambulanz aufzusuchen. 
Entgegen der verbreiteten Meinung sind Koliken meist nicht die Ursache für Schreikrämpfe von Neugeborenen. Foto: Getty Images
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Bioethik – Kombination vieler
Gedankengänge
Immer mehr Universitäten in Europa bieten eine fundierte Ausbildung an
Viele moderne Technologien
stellen uns heute vor neue
ethische Fragen. Bioethiker mit
einer Grundausbildung in einem
klassischen Studiengang sollen
helfen, Antworten zu finden.
Stephanie Lahrtz
Bioethik ist ganz offenbar chic. Immer
mehr Universitäten im deutschsprachi-
gen Raum, aber auch anderswo in
Europa bieten in letzter Zeit struktu-
rierte Kurse statt nur vereinzelter Vor-
lesungen für Biologen, Mediziner oder
Juristen an. Als erste Hochschule in der
Schweiz hat die Universität Zürich
2009 ein dreijähriges Programm für
Doktoranden ins Leben gerufen, an-
gesiedelt am Institut für biomedizini-
sche Ethik. In Deutschland war die
Universität Tübingen mit 1991 gestar-
teten Doktorandenkursen am Inter-
disziplinären Zentrum für Ethik in den
Wissenschaften Vorreiter und zugleich
viele Jahre auch Einzelkämpfer. Un-
sere von neuen Technologien geprägte
Welt stelle die Gesellschaft eben auch
vor neue ethische Fragen, die neue
Qualifikationen erforderten, argumen-
tieren die Befürworter der Bioethik-
Ausbildungsgänge. Moderne Spitzen-
forschung und Spitzenmedizin seien
heute ohne eine hochqualifizierte Ethik
nicht mehr denkbar.
Vorreiter USA
Ein Blick auf die Angebote guter und
vor allem sehr guter amerikanischer wie
auch kanadischer Universitäten zeigt,
dass Bioethik-Kurse, sei es für Bache-
lor-Studenten, Master-Abschlüsse oder
auch als Programm für Doktoranden,
dort seit vielen Jahren gang und gäbe
sind. Ursachen dafür gibt es laut Exper-
ten viele. So habe der technische Fort-
schritt in Amerika weit früher begon-
nen und verlaufe oft auch schneller. So-
mit seien dort auch viel früher Fragen
nach möglichen Problemen aufgekom-
men. Zudem habe man in den USA auf-
grund einer liberaleren Tradition bereits
in den 1970er Jahren viel über die
Rechte von Patienten beispielsweise bei
der Teilnahme an klinischen Studien
debattiert, ergänzt Roland Kipke vom
Ethikzentrum in Tübingen.
Auch seien Programme in Bioethik
immer sehr interdisziplinär angelegt, er-
läutert Effy Vayena, Koordinatorin des
PhD-Programms «Biomedical Ethics
and Law» an der Universität Zürich.
«Diese Interdisziplinarität hat man in
den USA viel früher als in Europa an
den Universitäten gepflegt, und man tut
sich dort nach wie vor leichter damit.»
Nun helfe dabei hierzulande auch die
neue Struktur der Studiengänge gemäss
dem Bologna-Prozess. Denn Kurse mit
interdisziplinären Themen seien nun
besser ins Studium integrierbar. Ge-
mäss den Programmbeschreibungen
von beidseits des Atlantiks umfasst Bio-
ethik weit mehr als die landläufig damit
verbundenen Fragen, ob menschliche
embryonale Stammzellen von der For-
schung verwendet werden dürfen oder
ab wann man Organe Sterbender für
Transplantationen freigeben darf. So
beschäftige sich eine Doktorarbeit da-
mit, ob es ethisch vertretbar sei, klini-
sche Studien mit neuen Medikamenten
statt in Europa in Entwicklungsländern
durchzuführen, weil es dort billiger und
einfacher sei, erzählt Vayena.
Interesse für mehrere Fächer
RegulaOtt, eine der ZürcherDoktoran-
dinnen, geht der Frage nach, ob es der
Gesellschaft gegenüber fair sei, soge-
nannte Neuroenhancer, also Substan-
zen zur Verbesserung der Gehirnleis-
tung, im Studium einzusetzen. Und Jürg
Streuli, Assistenzarzt in der Kinder- und
Jugendmedizin, erforscht am Beispiel
der Intersexualität, bis zu welchem
Mass Eltern und Fachpersonen grund-
legendeMerkmale eines Kindes bestim-
men sollen und dürfen. Sowohl Streuli
als auchOtt erzählen, dass sie sich schon
während ihres jeweiligen Studiums be-
ziehungsweise ihrer Arbeit im Spital
immer wieder gefragt hätten, warum
man etwas mache und ob es gut sei, so
zu handeln. Beide wollen durch eine tie-
fergehende Beschäftigung mit grund-
legenden Wertvorstellungen neue
Denkweisen und somit auch Lösungs-
ansätze für Fragen in der alltäglichen
Arbeit erhalten.
Dieses Interesse für mehrere Fächer
sowie für die Kombination philosophi-
scher Analysen und empirischer Stu-
dien ist nicht nur in Zürich eine der
Voraussetzungen für die Zulassung
zum jeweiligen Programm.Mittlerweile
habe man deutlich mehr Anfragen als
Studienplätze, erzählt Vayena. Denn in
Zürich wie auch anderswo werden in
der Regel nur zwischen fünf und zehn
Teilnehmer zugelassen. Dies hat zum
einen mit den jeweils begrenzten
Ressourcen der Ethik-Institute zu tun.
Zum anderen wissen auch die Pro-
grammverantwortlichen, dass insge-
samt nur wenige Fachkräfte mit um-
fassender Ausbildung in Bioethik be-
nötigt werden. Erfahrungen aus den
USA und Kanada zeigen, dass Dok-
toranden mit solchen Qualifikationen
neben der Arbeit an Universitäten
auch in Ethik-Komitees, in Behörden,
Medien, aber auch bei Nichtregierungs-
organisationen tätig sind. Doch insge-
samt ist der Jobmarkt zwar vielfältig,
aber überschaubar.
Kein Feigenblatt werden
Fraglich ist nun, ob Bioethik-Program-
memehr als eineModeerscheinung sind
– oder ein Ausweg für Mediziner und
Biologen, die sich nicht im Labor und
im OP-Saal die Hände dreckig machen
wollen, wie manchmal gelästert wird.
Brigitte von Rechenberg, Tierärztin in
der Forschung an der Universität Zü-
rich, seit vielen JahrenMitglied in diver-
sen Ethik-Komitees und Präsidentin der
kantonalen Tierversuchskommission
gibt zu bedenken, dass fundierte Kom-
petenz in einem medizinischen oder
biologischen Fach gerade auch in Ethik-
Komitees von grosser, wenn nicht sogar
von grösserer Bedeutung sei als das
alleinige Nachdenken über Moral. Ethi-
sche Entscheidungen müssten letztlich
auf der Grundlage von Fachwissen ge-
troffen werden. Streuli warnt davor,
dass ein überstrapazierter Ethikbegriff
ohne die nötigen Kompetenzen zu ei-
nem Feigenblatt verkommen könnte
und so problematische Entscheidungen
eher decke als kritisch hinterfrage.
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